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     The work presented here demonstrates two unique approaches in the application of 
LC/MS for the analysis of drugs and endogenous compounds in biofluids. First, the use 
of basic aqueous mobile phases in conjunction with both methanol and acetonitrile by 
LC/MS operating in electrospray positive ionization mode was investigated. Second, the 
design and development of a prototype ceramic micro-fluidic device (CMFD) and 
optimized MS source was carried out. The CMFD was packed with sub 2 µm bridged 
ethyl hybrid (BEH) chromatographic particles that could withstand operating pressures 
of up to 12,000 psi. The MS source was built to operate in both positive and negative 
electrospray ionization mode with the operating flow rates corresponding to the 300 um 
i.d. of the CMFD.  
     The results generated from studies utilizing the addition of a base, such as 
ammonium hydroxide to modify the aqueous mobile phase, showed significant benefits 
for LC/MS/MS based bioanalytical assays when analyzed with electrospray positive 
ionization mode.  Increases in the signal-to-noise values were observed for twenty-two 
out of twenty-four of the probe pharmaceuticals tested. Increase in the chromatographic 
retention of poorly retained compounds was also observed however, this increase in 
analyte retention did not occur for many highly polar compounds that eluted in the 
column void when chromatographed with the basic mobile phase conditions. The effect 
of the pH of the mobile phase further showed that the phospholipid fraction, present in 
protein precipitated plasma, was only slightly affected by the change in mobile phase 




mobile phases and results in an increased number of ions detected overall for 
metabonomic studies.  Further it was observed that by changing the pH to a basic 
system it was possible to resolve compounds that had previously co-eluted on traditional 
acidic reversed-phase LC/MS.   
     A 0.3 x 100 mm i.d. CMFD and compatible MS source was successfully designed 
for the analysis of biological samples. The device showed average chromatographic 
efficiencies of 9038 plates compared to 10219 plates for standard silica capillary 
columns. Gradient performance utilizing a diverse mix of compounds yielded a peak 
capacity of 55 as the average peak widths for all analytes was 0.11 minutes for a 6 
minute separation. Resolution of the probe pharmaceutical alprazolam and associated 
hydroxylated metabolite was maintained between 1.2 and 1.5 for four different devices. 
Testing of the device with plasma samples prepared by protein precipitation resulted in 
over 1000 injections being carried out over approximately a one week period. The 
system was however unable to withstand the high pH (10.5) utilized in the previous  
study but could operate with a mobile phase pH of 10. The resulting MS source built to 
operate under these conditions and with the flow rates required to operate the 0.3 x 100 
mm CMFD yielded signal to noise increase in the range of 8.3 to 38.6 for the molecules 
tested.  
     The CMFD/MS system was successful in the analysis of biofluid samples in both 
ESI + and ESI – ionization modes and was shown to allow for the analysis of small 
sample injection volumes from plasma prepared by protein precipitation, and dried 
blood spots.    This device was successfully utilized for the profiling of metabolites from 
the beta blocker drug, propranolol. Further separation of complex biofluid samples 
derived from axenic rats and bile from dogs again illustrated the separation and 
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kV                                           Kilovolt 
L                                              Length 
LC                                           Liquid chromatography 




LC/MS                                    Liquid chromatography coupled to mass spectrometry 
LOD                                        Limit of detection 
LLOQ                                     Lower limit of quantification 
LC/UV                                   Liquid chromatography coupled with ultra violet detection 
M                                           Mass 
MALDI                                  Matrix assisted laser desorption ionization 
MALLS                                  Multiple angle laser light scattering 
MeOH Methanol 
mg                                    Milligram 
min Minute 
mL Milliliter 
mm                                         Millimeter 
MRM                                     Multiple reaction monitoring 
MS                                         Mass spectrometry 
m/z                                         Mass/charge ratio 
n                                             Number of replicates 
N                                             Efficiency  
NaOH  Sodium hydroxide  






NMR                                      Nuclear magnetic resonance 
Pc                                             Peak capacity 
PCA                                       Principal compnent analysis 
PCB                                        Printed cercuit board 
PD                                          Phamacokinetics 
pg                                           Picogram 
PK                                          Pharmacokinetics 
psi                                          Pressure per square inch 
Pw Peak width  
Q                                            Single quadrupole  
QQQ                                      Triple quadrupole 
Q-Tof                                      Quadrupole time of flight mass spectometer 
R                                             Resolution (mass spectometer) 
RCF                                        Relative centrifugal force 
RI                                           Refractive index 
RP        Reversed-phase 
Rs Resolution 
R2                                                                 Coefficient of determination  
s Second 
SIR                                         Single ion recording 
SPE  Solid phase extraction  
SRM                                       Selected reaction monitoring 
tg                                                                   Gradient time 
Tmax                                      Time where Cmax is observed 




t0 Void time 
tR Retention time 
t ½                                                                Drug half life      
u Linear velocity  
µL                                          Microliter 
µm                                          Micrometer 
UPLC                                     Ultra performance liquid chromatography 
US FDA                                 United States Federal Drug Administration 
UV Ultraviolet 
V Applied voltage 
Vo                                                             Volume of mobile phase pumped for an unretained analyte               
                                                to reach the detector 
VR                                                                Volume of mobile phase pumped for a retained analyte to      
                                                reach the detector 
 
w                                            Chromatographic peak width 
α Selectivity 
˚C Degree Celsius 
ΔM                                         Delta M is the difference of two neighboring m/z values 
%                                            Percent 
















Knowledge is of two kinds. We know a subject ourselves, or we know where we can 











1.1 Bioanalytical aspects of pharmaceutical drug development  
 
 
     The primary function of any bioanalytical department working within the 
pharmaceutical industry is to carry out identification, and quantification of biomarkers, 
candidate drug compounds and their related metabolites in biological fluids. This 
activity is critical to the successful development of new medicines since the majority of 
new chemical compounds that are synthesized by medicinal chemists never become 
suitable drug compounds [1].  Reasons for failure vary and can be contributed to safety, 
efficacy, cost of goods, formulation, bioavailability (F), pharmacokinetics (PK), and 
toxicology [2, 3].  Of the previously listed reasons for failure, efficacy, toxicity, and 
unacceptable pharmacokinetics are the three main causes for clinical failure of drug 
compounds [4, 5].   Even when a new medicine is approved by regulatory agencies, 
issues can arise regarding drug product safety due to idiosyncratic toxicity or 
unexpected drug-drug interactions [6-9]. Furthermore, the formation of toxic 
metabolites by the liver can inhibit enzymes that can change the rate or metabolism of 
other compounds [10, 11]. Because of these facts and the enormous cost of producing a 
drug to treat a particular disease from concept through to commercialization, it is critical 
to have the correct clinical study design and analytical techniques to obtain precise and 
accurate data that can be used by the clinicians and drug development teams to 
successfully navigate a drug candidate through the drug discovery/development  
process. Figure 1.1.1 illustrates the time it can take to deliver a drug to market and the 
number of compounds that may be screened or tested for potential use as therapy for a 
designated disease cure. Here one can observe  that it can take up to 16 years to produce 




drug compounds in order to correctly identify the best compound that has the desired 
pharmacodynamics (PD), PK, and low toxicity required. Figure 1.1.2 Illustrates the cost 
that can be associated with the drug discovery process.  
 
       
 












Figure 1.1.2 Cost associated with the development of a new drug compound from 
discovery to commercialization phase. 
 
     As can be seen the costs that are associated with the drug development process are as 
of 2012 estimated to be between 4-11 billion US dollars [13].    Therefore due to the 
data shown in Figures 1.1.1 and 1.1.2 it is imperative that drug characteristics such as 
PK, toxicity, and PD of a candidate drug molecule are well understood so that resources 
and investment costs are not wasted on drug candidates that may prove to have poor 
characteristics. Therefore due to the important nature of correctly defining or acquiring 
high quality, precise and accurate data on critical drug characteristics they will be 



























1.1.1 Pharmacokinetics  
     Pharmacokinetics (PK) is a branch of pharmacology focused on the determination of 
the fate of substances administered to a living organism. These substances of interest 
can include pharmaceutical drugs, hormones, nutrients, and toxins. PK is often studied 
in conjunction with pharmacodynamics (PD), which is defined as the effect of a 
substance to a living organism. PK also includes the study of the mechanisms of 
absorption, distribution, metabolism, and excretion (ADME) of an administered 
pharmaceutical drug and determines the rate at which any drug action begins and 
duration of the effect. The study of PK is an important step in the drug discovery 
process as it determines the effective dose at which a drug is to be administered to a 
patient population. Inhaled therapeutics and low dose new chemical entities (NCE) 
present one of the most significant analytical challenges due to their low systemic 
concentration. Standard curves and internal standards are used for quantification of 
usually a single pharmaceutical extracted from a patient sample. The samples represent 
different time points as a pharmaceutical is administered and then metabolized or 
cleared from the body. Data collected from the different time points is plotted and a PK 
curve is produced. Figure 1.1.3 illustrates a generic PK curve. Typical useful 
measurements that are derived from this plot are: the maximum drug concentration 
present in the sample (CMax), the time it takes to reach the maximum drug concentration 





Figure 1.1.3 Generic PK curve for oral administered drug.  
 
1.1.2 Drug metabolism 
 
  As previously described the metabolism or biotransformation of a drug can influence 
the PD or toxicity, and therefore safety exhibited by the drug once it is administered into 
an organism The overall response of the organism to metabolize a drug is based on the 
fact that any drug molecule is usually xenobiotic in nature and an organism’s response 
to the drug, once detected, is to eliminate from the body as soon as possible. Drug 
metabolism is generally divided into two areas: Phase I (functionalisation reactions) and 
Phase II (conjugation reactions). A list of these reactions is shown in Table 1.1.1 
     Phase I metabolism includes a number of chemical reactions that modify the drug 
molecule in order that it may be eliminated by the body directly, or conjugated with 
another molecule, such as a sugar, and then eliminated from the body. Phase I reactions 



























groups. The process whereby another molecule is conjugated with these functional 
groups produced by one of the Phase I reactions is termed Phase II.  Table 1.1.1 lists the 



















Amino acid conjugation 
Isomerisation 
 






      Table 1.1.1 Common phase I and phase II metabolites found in mammals. 
 
     Because drug metabolism and drug metabolites can cause a myriad of problems from 
lack of efficacy, and toxicity, to cases of inhibition and induction of p450 enzymes it is 
an important area of investigation for any new drug compound. Due to the potential 
issues drug metabolites can cause, the United States Food and Drug Agency (FDA) 
incorporated the Metabolites in Safety Testing or MIST guidelines in February of 2008. 
This document gives recommendations to the pharmaceutical industry on when the 
characterization of drug metabolites should be carried out. This document indicates that 




and those metabolites having a systematic exposure in humans of greater than 10 % of 
parent drug at steady state must be considered for additional safety testing [14].  
1.1.3 Biomarkers 
 
     The determinations of biomarkers can aid in the indication of predisposed risk or the 
state of a disease. Biomarkers can further be utilized in determining toxicity or the PD 
of a drug and are therefore a useful tool in drug development [15]. Recently the US 
FDA has encouraged the incorporation of biomarkers in drug development and use in 
clinical diagnostics and has issued a guidance regarding the use of biomarkers [16]. One 
reason for this approach is the belief that this tactic will aid in the alleviation of 
stagnation of drug development and lead to innovation in the development of new drug 
compounds and personalized medicine [17]. Biomarkers can include molecules such as: 
mRNAs, proteins, metabolites, and electrolytes [18]. 
     One method utilized in the discovery of biomarkers are shotgun or so called –omics 
approaches such as metabonomics. Metabonomics has been defined as “The 
Quantitative measurement of time-related multiparametric metabolic responses of 
multicellular systems to pathophysiological stimuli or genetic modification” [19, 20]. 
Metabonomic studies are usually carried out by the analysis of mammalian biofluids 
such as urine, plasma, or bile. The analytical techniques often employed in 
metabonomic studies include NMR, GC/MS, and LC/MS [21-23]. The complex data 
produced from these analytical techniques is then interrogated by mathematical 
techniques or algorithms such as principal component analysis (PCA). It is here during 
this process that the algorithms during PCA analysis identify analytes that may be 





1.2 High-Performance Liquid Chromatography 
 
     High-performance liquid chromatography is a form of column chromatography used 
in biochemistry and analytical chemistry in order to separate, identify, purify, and 
quantify compounds. It is utilized in many application areas including: clinical, 
pharmaceutical, environmental and agricultural [24-26]. It has been noted that 
approximately one million liquid chromatographic analyses are carried out daily [25].  It 
is one of the most powerful techniques in analytical chemistry due to the compatibility 
of the technique with a wide range of samples with varying chemical properties, 
polarities, and structures.   
 
1.2.1 Origins of Chromatography 
 
     The general acceptance is that liquid chromatography was defined in the early 1900s 
by Mikhail S. Tswett and his work is considered the start of chromatographic analysis. 
His work focused on separating compounds extracted from plants using a solvent, in a 
column packed with particles. Tswett filled an open glass column with particles, poured 
his sample into the column and allowed it to pass into the particle bed. This was 
followed by a different solvent. As the sample passed through the column by gravity, 
different colour bands could be seen separating due to the fact that some components 
were moving faster than others. He related these different coloured bands to different 
compounds contained in the sample. The compounds that were more strongly attracted 
to the particles slowed down, while other compounds more strongly attracted to the 




chroma, meaning colour, and graph, meaning writing [24, 27, 28]. Chromatography 
changed little after Tswett's work until the mid-20th century where Martin and Synge 
developed partition chromatography to separate chemicals with only slight differences 
in partition coefficients between two liquid solvents. After unsuccessful experiments 
with complex countercurrent extraction machines, Martin had the idea of using silica gel 
in columns to hold water stationary while an organic solvent flows through the column. 
The preparation of the silica gel was tedious so they instead utilized filter paper as the 
inert support. Martin and Synge demonstrated the potential of the methods by separating 
amino acids. In a series of publications beginning in 1941, they described increasingly 
powerful methods of separating amino acids and other organic chemicals. Further they 
described the concepts of the height equivalent to a theoretical plate (HETP) and band 
spreading in these early publications [29] . 
     Martin, in collaboration with Anthony T. James, went on to develop gas 
chromatography beginning in 1949 and published on the subject in 1952. During his 
lecture for the Nobel Prize in Chemistry (shared with Synge, for their earlier 
chromatography work) Martin announced the successful separation of a wide variety of 
natural compounds by gas chromatography [30, 31].  
     The major components of a modern high-performance liquid chromatography system 
are shown below in Figure 1.2.1. The system consists of (A) containers for mobile 
phase, (B) a pump to move solvent through the system, (C) an autosampler to inject 
sample onto the system, (D) column and temperature control device, (E) detector to 
measure analytes in the separation, (F) waste container to collect the used mobile phase 














       
     The pump is the major part of the chromatography system. Its purpose is to deliver 
mobile phase through the chromatographic system in a precise manner. The pump is 
comprised of check valves, flow controllers, and transducers in order to ensure the 
delivery of mobile phase in a reproducible manner with minimal baseline noise. Modern 
pump assemblies also contain degassing features and a means to mix mobile phases for 
gradient type separations.  
      The autosampler provides a means to inject sample from the container in which the 
sample is stored, usually a glass vial or microtiter plate, onto the chromatographic 
system. The sample is injected onto the system utilizing a 6 port valve. The valve works 
in two positions: load, where the sample is introduced into the sample loop, and inject, 
where sample is placed into the flow path of the system and then onto the head of the 
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column. The autosampler is usually equipped with a means of temperature control so 
that thermally labile samples will not decompose during the course of an analytical run. 
It is imperative that the autosampler injects sample volumes reproducibly as 
inconsistencies will influence the accurate and precise measurement of analytes during 
quantification.  
     The column is the heart of the chromatographic system. The column provides a 
means for separation of analytes from one another. The selectivity, efficiency, capacity, 
and resolution of a separation can all be affected by the type and performance of the 
packing or stationary phase material contained within the column hardware. The 
packing material consists of particles in µm diameter dimension. The particles can be 
porous, non-porous or a combination or both, so called pellicular particles. Silica-based 
packings are the most common type, mainly because silica is easy to obtain and to 
derivatize. Chromatographic columns are usually kept in a column heater/cooler device 
that maintains the temperature of the column while separations are being carried out. 
Ensuring constant column temperature is important due to the fact that selectivity can be 
influenced by temperature [28]. If one is running a routine or validated analysis, the 
retention times of analytes must be reproducible if they are to meet established criteria.  
     Detectors are a key component, as the analytes that are separated by chromatography 
must be qualitatively and/or quantitatively measured in order to realize any meaningful 
results [32]. The detector produces an electrical signal that is proportional to the mass or 
concentration of a sample and is interpreted by the data handling system. Detectors are 
often categorized by the physical or chemical means by which they operate. Some 
detectors are very selective in their response while others tend to be more universal. 
There are many different types of detectors available that are readily coupled with high-




(UV/Vis), refractive index (RI), electrochemical (EC), evaporative light scattering 
(ELS), fluorescence, and mass spectrometry (MS). (7)  The performance of a detector is 
based on sensitivity, noise and baseline stability. The most common type of detector 
used is UV-based whether tunable UV or photodiode array type [33].  
 
1.2.3 Separation in a Chromatographic System 
 
     Separation of analytes or components in a chromatographic system is carried out on 
the column. The basic mechanism for separation is the difference in affinities an analyte 
has for the stationary phase or packing material and the mobile phase. The higher the 
degree of affinity an analyte has for the stationary phase the longer it will stay on the 
column. The higher the affinity an analyte has for mobile phase the faster it will elute 

























     To illustrate this, a dye is injected onto a chromatographic column, Figure 1.2.2, the 
dye being a mixture of individual components. Each of the individual components in 
the dye is different and therefore has varying chemical and structural properties that 
influence their affinity for the stationary and mobile phases. We see that the dye is 
separated into three discreet bands: blue, red, and yellow. The yellow band has the 
highest affinity of the dye components for the mobile phase, and therefore elutes from 
the chromatographic column first. This is in contrast to the blue band which has the 








from the column. The red component exhibits properties that are in between the yellow 
and blue components. 
      What an analyst operating a modern chromatographic system observes during this 
process is shown in Figure 1.2.3. Here we see that as the individual dye components are 
eluted from the column there are measured by a detector. This data is collected by a 
computer and observed on a computer screen. Below we see that the yellow component 
eluted first from the column is seen on the left of the computer screen as a triangular or 
“peak” shape. Later eluting peaks will be seen to the right of the yellow peak as 


















1.2.4 Modes of Chromatography 
 
     A variety of chromatographic techniques exist. The key modes of chromatography 
are reversed-phase, normal-phase, ion-exchange, size-exclusion, and affinity with each 
mode of chromatography being categorized by a specific mechanism of retention and 
operation [25].  There are advantages and disadvantages to each of the different modes. 
Further, each mode is applied depending on the type of sample or analyte and the 
desired result one is seeking [26].  
 
1.2.5  Reversed-phase Chromatography  
 
      Reversed-phase chromatography is the most popular chromatographic technique; in 
fact approximately 70 to 80% of all LC separations are carried out by reversed-phase 
[34].  This is due to the relative ease of use, compatibility with analytes, reproducible 
retention times, and fast equilibration [34]. The retention mechanism of reversed-phase 
is as follows: The surface of the stationary phase is non-polar. This hydrophobic surface 
interacts with the hydrophobic part of the analyte. The larger or stronger the 
hydrophobic interactions are of an analyte, the longer it will be retained by reversed-
phase. Converse to this are analytes with polar functional groups, and these analytes will 
be less retained.  
      Stationary phases are typically long chain hydrocarbons, usually C8 or C18 in length 
chemically attached to a base particle. The most popular reversed-phase columns are 
made from silica-based particles with different functional groups bonded to them. There 




providing different selectivities. The mobile phase is polar and usually a mixture of 
water or buffer with a miscible organic solvent such as methanol or acetonitrile. 
     The applications of reversed-phase LC are vast. As stated earlier a majority of small 
molecule separations are carried out by reversed-phase. Peptides and oligonucleotides 
are also readily separated by reversed-phase, as well as large biopolymers such as 
proteins. The advantage of reversed-phase chromatography is it is so widely applicable, 
as many compounds can be separated with few technical problems [34].  
 
1.3 Mathematical Description of the Chromatographic Process 
 
 
     Over the last one hundred years many scientists have investigated the 
chromatographic process. Martin and Synge, van Deemter, Knox and Guiochon, [34, 
35] and others developed numerous mathematical equations to describe and compare the 
chromatographic process and parameters. Due to the previously stated fact that 70-80 
percent of all chromatographic separations are accomplished by reversed-phase, the 
following section will describe the mathematical measurements and theory behind 
reversed-phase separations. The values for capacity, retention, selectivity, resolution, 
linear velocity, efficiency and peak capacity are explained in the following section. The 
plate and rate theory will also be discussed. These measurements can become useful in 






1.3.1 Capacity factor 
 
 
     In order to achieve effective chromatographic separations, chromatographic columns 
must have the ability to retain and separate sample analytes. The capacity factor, k is a 
measure of the strength of interaction of the analyte with the column packing material. 
The capacity factor for a given separation is defined by the following equation: [25, 32, 
35, 36]. 
 
Equation 1.3.1 Definition of capacity factor. 
 
     Whereby tR is the time taken for the analyte to reach the detector and to  is the time 
for unretained analytes to reach the detector. The same value for k can be determined by 
volume instead of time. VR represent the volume of solution pumped for an analyte to 
reach the detector and V0 is the volume of solvent pumped whereby unretained analytes 
reach the detector. 
     The capacity factor is mostly dependant on the type of packing material in the 
column [25]. However, the capacity factor can be influenced by the strength of the 
mobile phase. As a rule, a calculated capacity factor of between 2 and 5 represents an 
acceptable balance between the length in time of the analysis and the resolution of the 
analysis. A capacity factor that lies outside the 2 to 5 region may lead to insufficient 
resolution from unretained analytes in the void volume (V0), if  < 2, or an analysis time 
that is too long,  > 5.  
VR - V0
k =









     The selectivity of a chromatographic separation is the measure of the difference in 
retention time or volume for two given analytes in a separation. Selectivity is defined by 
the symbol α and is described in the following equation: [25, 32, 34-36] 
 
 
Equation 1.3.2 Definition of selectivity. 
 
     The selectivity of a separation can be a function of the column packing material. It 
can also be influenced by the composition and pH of the mobile phase as well as the 
separation temperature.   Selectivity values can range from values of as little as 1 to very 
large values. Values of 1 represent no difference in the selectivity between analytes in a 
separation and therefore no separation between analytes will occur. One of the easiest 
ways to affect the selectivity of a separation is to modify the mobile phase. This can 


















1.3.3 Resolution      
 
 
     The resolution in a chromatographic separation is utilized in order to define the 
degree of separation between analytes in the chromatogram. The three previously 
discussed concepts of capacity, selectivity, and efficiency all have a role in the 
resolution of a separation. This can be seen in the following formula: [25, 34-36] 
 
   
Equation 1.3.3 Definition of resolution. 
 
N (efficiency, described later in Chapter 1) is controlled by physical and mechanical 
factors while selectivity and capacity are influenced by chemical factors.  
The resolution between two peaks in a separation can be measured by utilizing the 




Equation1.3.4 Calculation of chromatographic resolution of two adjacent peaks. 
Where ∆tR  is the difference in the retention time between two adjacent peaks and wt1 
and wt2 are the widths of the peaks. The width of the peak can be measured at different 
Rs = 
∆tR




points. Common peak widths utilized to calculate chromatographic resolution are at 4.4, 
13.4 and 50 percent peak height. 
 
1.3.4 Linear Velocity 
 
     The linear velocity of the mobile phase passing through the column is an important 
parameter to consider and is represented by the symbol µ. The linear velocity 
determines how long an analysis will take and also the backpressure on the 




















1.3.5 Efficiency, plate count 
 
     Efficiency or plate count is a measure of the peak broadening as a function of 
retention time. The origin of this measure of chromatographic separation is based on the 
distillation theory in gas chromatography. In this theory, a column of fixed length is 
occupied by a theoretical plate. This fixed length represented the height equivalent to a 
theoretical plate. The efficiency or plate count of a separation can therefore be 
determined by the formula: [25, 32, 34-36] 
 
 
Equation 1.3.5 Definition of efficiency. 
 
In this equation N represents the efficiency or plate count. L represents the length of a 
column and H is the height equivalent of a theoretical plate. This equation can further be 




Equation 1.3.6 Calculation of efficiency. 
 











      In this derivation of the efficiency formula tR represents the retention time of the 
analyte and WP represents the width of the peak at a certain height. The position where 
WP is measured dictates the value for the factor f. For example a common WP taken for 
the measurement of efficiency is at 13.4 % of the peak height. Here the value of the 
factor f is 16.00. It should be noted that the efficiency or plate count of a separation can 
only be applied to isocratic separations and not to gradient separations. Two major 
theories are often utilized to describe column efficiency. The simplest of these is the 
plate theory. The second is the rate theory developed by van Deemter and others which 
takes into consideration different causes of peak broadening that affect column 
efficiency [25, 35].  
 
1.3.6 Peak Capacity 
 
     In isocratic mode peak capacity (Pc) describes the number of analytes that can 
theoretically be separated as peaks with a given resolution in a given analysis time. 
 









Peak capacity increases with column efficiency, but the major factor influencing peak 
capacity is the capacity factor of the last eluting peak. Therefore, any aspect of the 
4Rs





chromatographic system that might limit the value of kmax for the last peak will also 
limit the peak capacity [34].  
When using a gradient elution, peak capacity can be calculated by the following 





Equation 1.3.8 Calculation of peak capacity in gradient mode. 
   
 
1.3.7 Plate Theory 
 
     The plate theory and expressions derived from the theory are generally applied to 
different types of column chromatography. In the plate theory it is assumed that the 
analyte passing through the column is in equilibrium with both the mobile and 
stationary phases [25]. However equilibrium of the analyte between the two phases 
never actually happens and furthermore the plate theory does not address the effects of 
band broadening on the chromatographic separation. The plate theory also does not 
consider particle size, loading, mobile phase viscosity, and flow rate. In the plate theory 
the chromatographic column is divided into a number of sections termed “plates”. The 
greater the number of plates or theoretical plates (N) the higher the column efficiency. 
The smaller or thinner each plate is, the more plates can be fit into a column. This is 
expressed mathematically as: [25, 34, 35] 
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Equation 1.3.9 Definition of HETP. 
 
Where H is the height equivalent to a theoretical plate or HETP, L is the length of the 
column, and N is the column efficiency. Therefore from the equation we can see that a 
column with a very high N will have a small H. The plate theory was developed from 
distillation theory and applied to chromatography by Martin and Synge in 1941. The 
work they did established the plate concept as an approach for the mathematical 
explanation of  the chromatographic process [35]. 
 
1.3.8 The Rate Theory  
 
     Because the plate theory does not take into consideration factors that can cause band 
broadening in a column, other theories have been developed to explain the 
chromatographic process. Some of the theories that have addressed the contribution of 
band broadening during the chromatographic process are:  the Gidding equation, the 
Knox equation, and the van Deemter equation [35].  
     The most popular of the rate theories is the van Deemter. The most general form of 









            
     Equation 1.3.10 Definition of van Deemter equation.  
 
Where H represents the efficiency of the column and µ represent the linear velocity of 
the mobile phase. The A term is independent of the linear velocity and is related to the 
size and the distribution of the inter-particle channels within the packed bed of the 
column. The B term is inversely proportional to the linear velocity and describes 
diffusion in the axial direction. Last the C term, which is directly proportional to the 
linear velocity and describes mass transfer from the flowing mobile phase to the particle 
and back again. A typical van Deemter plot can be seen in Figure 1.3.2. 
 
Figure 1.3.1 van Deemter Plot showing contribution of A, B, and C terms on HETP. 
Figure courtesy of Waters Corporation 




     The three terms or dispersion mechanisms of the van Deemter curve are affected in 
different ways by the flow rate of the mobile phase.  To reduce dispersion due to 
longitudinal diffusion a high flow rate can be used, whereas a low flow rate is required 
to reduce dispersion from mass transfer.  The van Deemter equation represented in a 
graphical format demonstrates the contribution to overall HETP by the three dispersion 
mechanisms.  The point at which the total dispersion from the three effects produces 
minimum dispersion gives the optimum linear velocity and flow rate of the mobile 
phase. This represents the flow rates required if one is to achieve maximum benefit [34, 
37].  
 
1.3.9 Band Spreading 
 
     Two sources of band spreading exist; they are the contributions from the column and 
external contributions or extra column effects. Both of these will affect the N of a 
separation [38]. Contributions from the column include: end fittings, column volume, 
packed bed uniformity and particle size. Extra-column dispersion may arise from the 
volumes of the injection valve, the detector cell, the tubing between the injector and 
column, the tubing between column and detector, as well as the connecting fittings.  
These extra-column volumes should be kept to a minimum as they affect separation by 
causing band broadening and tailing.  In addition, the diameter and total length of tubing 
between the injector and detector has been shown to be crucial to resolution with narrow 
diameter columns such as columns with less than 2.1mm i.d. and 3μm diameter particles 





1.3.10 Effect in the reduction of particle size on van Deemter equation 
 
     Reduction in particle size (dp) is a means of increasing chromatographic 
performance. This can mathematically be illustrated in the van Deemter equation. The 
van Deemter equation can be rewritten in the following way to illustrate the effect of 
particle size on H. 
 
 
Equation 1.3.11 Modified van Deemter to illustrate effect of particle size. 
 
     In the above equation we can see that only the A and C term are affected by the 
particle size of the stationary phase in the chromatographic column. The A term is 
affected by particle size in the following way: large particles or irregular particles 
packed into a column will lead to a larger interstitial volume between the particles. The 
effect of this is a broader band or peak resulting in a less efficient column due to the 
large value of the A term. Smaller particles or spherical particles will pack within the 
column in a tighter configuration. This tighter packing of the particles reduces the 
interstitial volume between the particles and results in a narrow band or peak and a 
column with greater efficiency due to the smaller A term.  
      The C term, or mass transfer, is affected by particle size in the following way: 
Larger particles have a greater distance, through the pores, which analytes in the mobile 







phase must travel in order to interact with the stationary phase. Smaller diameter 
particles have a shorter distance through the pores which analytes must travel in order to 
interact with the stationary phase. This shorter distance associated with smaller particles 
reduces the C term, which reduces band broadening resulting in sharper 
chromatographic peaks.  
 
 
Figure 1.3.2 Effect of particle size on van Deemter curve. Figure courtesy of Waters 
Corporation.  
 





Figure 1.3.2 illustrates the effect of reducing the chromatographic particle size on the 
van Deemter curve. The plot illustrates three main points. First, as you decrease the 
particle size H is reduced, increasing chromatographic efficiency. Second, as the 
particle size is decreased, the optimal linear velocity whereby H is at its lowest value 
increases. Third, the optimal flow rate where H is at its lowest value has a much wider 
operating range for small particles compared to  larger particles. In practical terms the 
effect of smaller particles is: First, a higher flow rate must be utilized in order to gain 
the maximum benefit for the use of smaller particles. Second, we can shorten the 
analysis time by moving to smaller particles due to the wide operating range of optimal 
linear velocity. However, although reduction in particle size does have the effect of 
lowering H and therefore increasing chromatographic performance, it increases the 
pressure at which the chromatographic system must operate.  
 
1.3.11 Effect of the Reduction in Particle Size on Back Pressure 
 
 
    System pressure increases inversely with the square of the chromatographic particle 
size, however, the relationship between particle size and back pressure is inversely 
proportional to the third power of the particle size at the optimal flow rate.  [39]. The 
increase is system pressure as a function of particle size is shown in Figure 1.3.3 
Standard HPLC instrumentation has an upper back pressure limit of 6000 psi. Due to the 
greater pressure generated by the 1.7 µm columns, instrumentation must be capable of 
operating at these higher pressures. This must include the fittings, pumps, injector valve 
and seals. The instrumentation must also have minimal volume if the narrow 






Figure  1.3.3 System pressure versus  chromatographic particle size utilizing  2.1  x  50 
mm columns and optimal linear velocities for each particle size. Conditions: column 
temperature = 40 °C, mobile phase = 50/50 H2O/CH3CN,  LC system = Waters 
ACQUITY UPLC. 
 
1.4 Mass Spectrometry 
 
     A Mass Spectrometer (MS) is an analytical instrument that measures the masses of 
individual molecules which have been converted into gas-phase ions. Ions are separated, 
detected and measured by their mass-to-charge ratio (m/z). The m/z ratio is by 
definition the mass of the ion (m) divided by the number of charges (z) that the ion 
carries. MS is an important analytical technique that can provide very selective and 
sensitive detection. The technique can provide information on the molecular weight, 
composition, and quantification of an analyte. Scientists from various disciplines within 



























industry scientists involved in the process of drug discovery and development rely on 
the specificity, dynamic range, and sensitivity of MS.  
 
1.4.1 Origins of Mass Spectrometry  
 
Eugen Goldstein in 1886 observed rays under low pressure travelled away from the 
anode and through channels in a perforated cathode, opposite to the direction of 
negatively charged cathode rays. Goldstein called these positively charged anode rays 
"Kanalstrahlen"; the standard translation of this term into English is "canal rays". Later 
Wilhelm Wien found that the influence of electric or magnetic fields deflected the canal 
rays and, in 1899, constructed a device whereby parallel electric and magnetic fields 
separated the positive rays according to their charge-to-mass ratio. Wien found that the 
charge-to-mass ratio depended on the nature of the gas in the discharge tube [40, 41]. 
The English scientist J.J. Thomson later improved on the work of Wien by reducing the 
pressure to create the first mass spectrograph, at the time referred to as a parabola 
spectrograph. The word spectrograph relates to the terms spectr-um and phot-ograph-ic 
plate [42]. The early devices that measured the m/z ratio of ions were referred to as 
mass spectrographs and recorded the mass spectra on photographic plates [43, 44]. 
Thomson is considered the founder of MS and he obtained, for the first time, mass 
spectra of many elements and compounds such as neon, oxygen, nitrogen, carbon 
dioxide and others. Later Thomson’s student Francis Aston made many accurate mass 
measurements with his velocity focusing instrument. He found the atomic weight of 




in contrast to the atomic weight of 35.4 which chlorine has previously been known by 
[45].  
 
1.4.2 Principles of Mass Spectrometry  
 
There are three basic steps in the analysis of molecules by MS. The first step is the 
production of gas phase ions from the sample molecules. This step in the process may 
involve the removal of electrons or protons, and is referred to as the ionization process. 
The second step is the separation of the ions by a mass analyzer based on the ions mass-
to-charge ratio (m/z). Here at this step the trajectory or motion of charged ions through 
the mass analyzer are manipulated via the application of electric or magnetic fields in 
order to successfully separate, accumulate, or fragment dependant on their m/z ratio and 
direct or not direct the ions introduced into the mass analyzer to the detector. The third 
step is the detection step whereby the ions that reach the detector component are 
measured, the signal amplified, and a mass spectrum is displayed.  
 
1.4.3 Components of a Mass Spectrometer 
 
The mass spectrometer is comprised of six basic elements: First, a means to introduce 
sample into the MS. The second, is a source, whereby ionization of sample occurs. 
Third, the mass analyzer, which separates ions based on their mass-to-charge ratio. 




a useful output. Fifth,  a computer system to process data. Figure 1.4.1 below illustrates 
the basic components of a modern MS system. Last a vacuum system.  
 
 
Figure 1.4.1 Components of a mass spectrometer. 
 
     There are many different methods in which a sample can be introduced into the MS. 
These methods can involve direct introduction by a probe, plate, a syringe, a liquid or 
gas chromatographic system. The sample then must undergo a process whereby the 
sample is converted into a gaseous state and ionized. There are numerous methods that 
can produce ions that are then separated in the mass analyzer. Ionization techniques 
include: electron impact, (EI) chemical ionization, (CI) fast ion bombardment, (FAB) 
matrix-assisted laser desorption ionization (MALDI), atmospheric pressure chemical 
ionization, (APCI), and electrospray ionization (ESI). Of the ionization techniques 
listed, ESI is most utilized for bioanalytical studies due to the ability of the technique to 
ionize analytes over a wide polarity range and the fact that the parent ion is often left 
intact during the ionization process. The mass analyzer is the heart of the MS system 




Mass analyzers can include: quadrupoles, ion traps, time-of flight, ion cyclotron 
resonance, and magnetic sector types. Mass analyzers can also exist as a combination of 
mass analyzers such as a quadrupole time-of-flight or Q-ToF. The three main attributes 
of a mass analyzer are the ion transmission, the resolution, and the mass limit. The mass 
analyzer is under vacuum in order to ensure proper transmission of ions through the 
mass analyzer to the detector without interference from the atmosphere. The detector 
component of the MS provides a means to convert the signal from the MS into useful 
data that can then be utilized by the analyst. Detectors utilized by mass spectrometers 
can be micro-channel plates, electron multiplier, or photomultiplier. A data system is 
required in order to record, process, store and display the data in a form that can be 
interpreted by the user. A vacuum system is the last component of the MS system. It is 
utilized in order to remove atoms or molecules from specific components of the MS 
system. Pumping systems can require the ability to maintain a pressure of 10-4 to 
10-8 Torr and are usually oil-based rotary and turbo-molecular pumping systems that are 
electrically driven.  
 
1.4.4 Electrospray Ionization Mode 
 
    Electrospray ionization (ESI) is an ionization technique that is carried out at 
atmospheric pressure and therefore is referred to as an atmospheric pressure ionization 
(API) technique. It is the most successful interface for LC/MS applications [40]. The 
concept of electrospray was founded by Malcom Dole in 1968 [40]. However, the 
successful development of the technique for LC/MS is credited to John Fenn. The 
mechanism of ESI is a debated topic however it is generally believed to follow a process 




phase ions are then introduced into the mass analyzer component of the MS system for 
separation, fragmentation, or accumulation. Figure 1.4.2 below illustrates this process.  
     
 
 
Figure 1.4.2  Electrospray ionization process. Figure courtesy of Waters Corporation 
     As we see in Figure 1.4.2, ions present in solution are introduced into the MS source 
via a steel capillary to which a voltage has been applied. The application of voltage and 
nebulizer gas produces a fine spray or plume. A counter electrode attracts the ions 
toward the sample cone and into the mass analyzer. Over the distance whereby the ions 
travel into the mass analyzer the droplets containing the ions are evaporated and 
undergo a process of fission. The end result of this process is a gas phase ion that can be 
introduced into the mass analyzer [40, 41]. ESI can be performed in either positive or 
negative modes and the chemical composition of the analyte will predict whether 




moieties in their composition will prefer electrospray positive ionization mode (ESI+) 
and compounds with acidic moieties in their composition will prefer electrospray 
negative ionization mode (ESI-).  
     ESI is referred to as a soft ionization technique. This is due to the fact that a 
molecule introduced into the MS source operating in ESI mode is often left intact as the 
protonated molecular ion in positive ionization or as the deprotonated anion in negative 
ionization mode. This is in contrast to other ionization techniques such as electron 
ionization where the molecule is often fragmented. The value of this intrinsic feature on 
this mode of ionization is that information of the molecular weight can be readily 
obtained and can be useful in properly identifying components and their structure. An 
example of this would be attempting to identify all of the associated metabolites of a 
new pharmaceutical compound. The ability to detect intact mass of the pharmaceutical 
or the conjugated pharmaceutical can lead to insight on how a pharmaceutical 
compound is metabolized, an important aspect in drug development.  
 
1.4.5 Quadrupole and Time-of-flight Mass Analyzer Principles 
 
    Quadrupole and time-of-flight based mass analyzer MS instruments represent two 
very common types of MS instrument that are currently used by bioanalytical scientists 
in order to perform both quantification and qualitative analyses. This is based on the fact 
that the attributes of these two types of mass analyzer i.e. mass range, resolution, 
sensitivity, duty cycle, dynamic range, and speed are sufficient to perform LC/MS/MS 




    The quadrupole mass analyser was developed in parallel with the quadrupole ion trap 
by Wolfgang Paul [46]. A quadrupole mass analyser consists of four parallel rods, with 
opposite rods connected electrically, (Figure 1.4.3) that have fixed DC and alternating 
RF potentials applied to them. Ions produced in the source of the instrument are then 
focused and passed along the middle of the quadrupoles. Their motion will depend on 
the electric fields so that only ions of a particular m/z will have a stable trajectory and 
thus pass to the detector. Specific combinations of the potentials and frequency will 
result in specific ions having a stable trajectory through the quadrupole to the detector. 
All other m/z values will have unstable trajectories and will hit the quadrupoles and not 




Figure 1.4.3 Separation of ions in a quadrupole mass analyzer. Figure courtesy of 
Waters Corporation. 
     Quadrupole mass spectrometers generally have two configurations in the modern 
laboratory, either single (Q) or tandem configurations (QQQ). The tandem configuration 













commonly used in conjunction with LC for use as a simple high-throughput screening 
system.  
     Time-of-flight (TOF) MS was first described by Stephens in 1946 [48].  Later Wiley 
and McLaren produced the design of a linear TOF mass analyzer that became the first 
commercially available instrument [41] .  TOF MS is a method in which an ion's m/z 
ratio is determined by measurement of time. Here ions are accelerated through the mass 
analyzer by an electric field of known strength. This acceleration results in an ion 
having the same kinetic energy as any other ions being separated at the same point in 
time [49]. The time taken for an ion to reach the detector at a known distance is 
measured and will depend on the m/z ratio of the ion. Therefore ions that have a larger 
m/z ratio will reach the detector after ions that have a smaller m/z value. This process is 
illustrated in Figure 1.4.4 below. 
 
 
Figure 1.4.4 Separation in a time of flight mass analyzer. 








     Important attributes of this type of MS are the increased resolution of the instrument 
compared to the quadrupole MS previously described. Figure 1.4.5 below shows a 
comparison of the resolution of a TOF MS compared with that of a quadrupole MS. 
 
 
Figure 1.4.5 Resolution (FWHM) using a time of flight versus quadrupole mass 
analyzer. Figure courtesy of Waters Corporation. 
     The advantage of this increase in resolution is that it enables for the identification of 
analytes with much greater mass accuracy. This can be of great importance in DMPK 
work where on may be carrying out experiments in order to correctly identify and 
elucidate the structure of a drug metabolite or potential biomarker [50]. The resolution 














Equation 1.4.1 Calculation of resolving power of a mass analyzer. 
Where R is the resolution of a MS, M is the average m/z value for a detected ion, and 
delta M is the difference of two neighbouring m/z values measured at half height 
(FWHM). The larger the resolution of the MS indicates better separation of the spectral 
peaks and is similar to the convention used with chromatographic separations. An 
example of this is shown in Figure 1.4.5. Here we observe the typical resolution of a 
quadrupole MS compared with that of a TOF MS of resolution 10,000. Typical 
resolution for a quadrupole MS is 1000, as is termed a unit mass resolution instrument 
due to the fact that it can resolve m/z of unit mass i.e. m/z 215 versus 216.  
     Along with resolution the mass accuracy of a mass spectrometer is a key parameter 
in the performance of the mass spectrometer and is of particular importance when 
performing structural elucidation of compounds. An example of this would be in the 
identification of drug metabolites.  The mass accuracy is measured by dividing the mass 
error by the exact or calculated mass and multiplying by 106  and  is  expressed in parts 






mass error = exact mass-accurate mass 
ppm = (mass error/exact mass) x 106 
Equation 1.4.2 Calculation of the mass accuracy of a mass spectrometer. 
 
 
1.5  Bioanalytical LC/MS and the drive for improvement  
 
 
     As previously stated, bioanalytical methods must effectively determine a drug’s PK 
profile and any associated metabolites that would be produced once administered to a 
patient.  Further the quantitative measurement of biomarkers can indicate the PD or 
toxicity related to a new drug compound is essential. The analytical technique of 
LC/MS is often utilized for this purpose. The primary reason for the use of LC/MS is 
due to the fact that all determinations of analytes in bioanalysis are carried out in the 
presence of biological matrix. All biological matrices including: blood, plasma, urine, 
bile, or cerebrospinal fluids (CSF) are complex mixtures of multiple analytes that all 
contain multiple chromophores.  Because of this it is quite difficult to develop a very 
sensitive and selective methods whereby one can perform quantification of a target 
analyte by utilizing LC with UV detection. 
      Figure 1.5.1 illustrates this point. Here we observe the separation of a mix of 
pharmaceutical probe compounds spiked into rat plasma that has been precipitated with 
acetonitrile and analyzed by LC/UV and by LC/MS. In this example the UV detector 
was set at 254 nm and the MS was operating in selected reaction monitoring (SRM) 
mode. From this comparison of the two analytical techniques it is observed that the 




the sensitivity of current LC/MS/MS instrumentation that analyte levels of pg/mL can 
be determined regularly [51-53]. 
 
 
Figure 1.5.1 Separation of pharmaceutical compounds spiked into rat plasma by LC/UV 
and by LC/MS.   Analytes separated are: lidocaine, alprazolam, warfarin, tolbutamide, 
clopidogrel  (in order peaks 1-5).     











    The use of a tandem quadrupole mass spectrometer in combination with liquid 
chromatography is often the most utilized configuration for quantification methods [54-
56]. However, the identification of drug metabolites and relevant biomarkers is 
frequently carried out by time-of-flight or trap type mass analyzers. The reason for this 
is the inherent higher mass resolution and accurate mass measure characteristics of these 
mass analyzers which enables for easier structural elucidation and determination of the 
chemical composition of compounds such as metabolites or potential biomarkers. 
      Despite the current sensitivity and ability of LC/MS/MS to extract relevant data 
from complex biological samples, there still exists the need for improvement of the 
technique. The reasons for this increased need in LC/MS sensitivity can be categorized 
into two main areas: i) low circulating drug levels resulting from low exposure drug 
compounds, such as inhaled medications, and ii) low volume of sample available, such 
as from serially bled mice or new sample formats such as dried blood spot samples 
(DBS) provides new sensitivity challenges that must be addressed [57-59]. 
     The sensitivity of bioanalytical LC/MS/MS can be increased by utilizing a variety of 
different techniques. These techniques are listed in Table 1.5.1.  There exist three areas 
whereby the sensitivity of a bioanalytical LC/MS method can be influenced: i) sample 









Sample pre-treatment Chromatography Mass Spectrometry 
Concentration Increase injection volume Acquisition mode 
Protein-precipitation Longer column length Mass analyzer 
Liquid-liquid extraction Increase selectivity Ionization  
Lipid depletion devices Sub 2 µm particles Selected ion for detection 
Solid liquid extraction Pellicular particles  
Solid-phase  extraction Reduction of column i.d.  
 2 dimensional LC  
 
Table 1.5.1 Parameters of a Bioanalytical LC/MS method that can influence sensitivity.  
     The first part of a bioanalytical LC/MS method that can be addressed in order to 
increase the sensitivity of a method is sample pre-treatment. Sample pre-treatment 
methods fall into two main areas: sample concentration or sample separation. The first 
of these, sample concentration, is carried out by reduction of the sample volume by 
reduction or removal of the liquid component and can be accomplished by dry down or 
microelution SPE methods. This process results in an increase in analyte concentration. 
In the case whereby the whole of the liquid component of the sample is removed, 
reconstitution of the sample into a smaller than original volume, must be carried out 
prior to injection onto the LC/MS system. 
     Sample pre-treatment methods can also include methods where removal or 
purification of the target analyte from the endogenous biological sample components is 
a desirable option. Methods that utilize precipitation, liquid-liquid and solid phase 
extraction are often implemented for this purpose [60, 61]. There are two main reasons 
for implementation of a pre-treatment strategy. The first is to put the sample into a 
format that is ready to inject onto a LC system, The second is that  removal of the target 
analyte from other biological endogenous materials present in the sample reduces the 
probability of a process referred to as ion suppression.[62, 63]. Ion suppression is part of 




process occurs when analytes of interest co-elute with endogenous components from the 
biological sample or matrix and are introduced into the source of the MS simultaneously 
and can lead to erroneous results [62, 64, 65]. The importance of ion suppression in 
bioanalytical assays carried out by LC/MS/MS is well recognized by the US FDA who 
have included requirements for the calculation of matrix-derived ion suppression in 
assay development and validation.   
     In addition to sample pretreatment, different chromatographic method parameters 
can influence the sensitivity of LC/MS based analysis either by influencing 
chromatographic peak shape or resolution of target analytes from matrix components in 
order to reduce matrix effects. The first of these is the injection volume, one of the 
simplest methods to increase sensitivity of a LC/MS based assay is to inject more 
sample onto the LC system. This is of course predicated on the fact that there exists 
enough sample to accomplish this. Column length can also be considered, as an increase 
in the column length can provide for increased separation efficiency thereby resolving 
components and minimizing any chance of matrix effects.  Selectivity changes produced 
by either mobile phase composition or column stationary phase can also be manipulated 
in order to increase the resolution of a separation.  Furthermore, a change in 
chromatographic particle properties, such as utilizing a smaller particle, can produce 
sharper chromatographic peaks thus increasing resolution from matrix component 
present in biofluids [66, 67].        
     Reduction of column i.d. has been explored in the past as a means to increase 
sensitivity in bioanalytical LC/MS [68-70]. With this technique analytes can be eluted 
from a column in a smaller elution volume thus increasing the concentration introduced 
into the detector resulting in a greater signal being produced. A further advantage of this 




with this is the reduction in overall solvent consumption compared to standard 2.1 mm 
i.d. columns utilized by most LC/MS methods.  
     Recently the use of 2-dimensional chromatography has been explored for use in 
increasing sensitivity in bioanalytical LC/MS [71]. This technique relies on the increase 
in resolution not offered by single column LC/MS therefore resulting in a reduction in 
the possible event of co-elution of the analyte of interest with endogenous matrix 
components resulting in matrix effects. Two main configurations that are utilized for 
this approach are the trap and elute and heart-cut configurations. In both of these cases 
increased resolution of the target analyte from the matrix components is accomplished 
prior to MS detection.  The use of this technique also offers a means whereby the MS 
source is kept cleaner through the use of the required valves and diversion of flow from 
the MS to waste during the high organic column wash step usually incorporated into any 
bioanalytical method in order to wash the column clean of any highly hydrophobic 
compounds present in the sample that may be bound to the column during analysis. 
      Mass spectrometric detection parameters that can be manipulated for increased 
assay sensitivity are based on four areas: The type of acquisition mode, the mass 
analyzer, ionization of the analyte under investigation, and the selected m/z used for 
detection. The first of these, the acquisition mode, can be changed dependent on the 
type of mass analyzer being used during the analysis. For a tandem quadrupole MS, the 
acquisition modes that are typically available are full scan, product scan, precursor scan, 
neutral loss, selected ion monitoring (SIM), and selected reaction monitoring (SRM) 
sometimes, by several instrument manufacturers, referred to as multiple reaction 
monitoring (MRM). The most sensitive of these is SRM mode which is most commonly 
used for quantification studies due to the fact that it is the most sensitive. This mode is 




available. The type of mass analyzer can also influence sensitivity, and as stated earlier 
tandem quadrupole mass analyzers operating in SRM mode are very sensitive due to the 
selectivity of the instrument operating in this mode. TOF instruments unlike tandem 
quadrupole instruments cannot operate in SRM mode of acquisition simply due to the 
components that this type of mass analyzer is fabricated from. This instrument therefore 
is operated mainly in a full scan type of acquisition thus detecting all of the ions present 
in an analysis producing a very non-selective analysis. Therefore they are not as 
sensitive as the tandem quadrupole instruments when operating in SRM mode.  
     The ionization of the analyte under investigation can be controlled by the ionization 
technique used. There are many types of ionization techniques however for the purposes 
of bioanalysis, most are carried out using electrospray ionization, however, atmospheric 
pressure chemical ionization (APCI) is sometimes used [72, 73]. With electrospray 
ionization parameters such as capillary and cone voltages as well as desolvation 
temperatures must all be optimized in order to realize the best sensitivity that can be 
offered by the technique. In addition to these software controllable parameters, 
manipulation of ionization can be accomplished through modification of the mobile 
phase. Most often formic acid is added to the mobile phase and either acetonitrile or 
methanol used as the strong eluent during analysis with ESI in the positive mode 
LC/MS/MS [74-76].   
     The m/z that is being monitored during an analysis can also influence sensitivity. 
Often a different m/z can be monitored that may lead to increase in sensitivity. 
Typically when developing an SRM method multiple fragment ions of choice can be 
evaluated to assess which is the best to use. This approach will almost always be limited 
to SRM mode of acquisition and the fragment ions as most small molecule drugs only 




     In the work presented here, the use of conventional and non-conventional mobile 
phase additives and compositions was explored in conjunction with a prototype ceramic 
microfluidic device for use in bioanalytical studies. The prototype ceramic microfluidic 
device was packed with sub 2 µm bridged ethyl hybrid chromatographic particles and 
operated with pressures of up to 10,000 psi. This liquid chromatography approach was 
coupled to MS detection with either a tandem quadrupole operating in SRM mode or Q-
TOF operating in full scan mode. Both instruments were operated in the electrospray 
positive ionization mode. The aims of this work was to investigate the effect of these 
techniques on chromatographic performance, assay sensitivity and ability to extract 
increased information gathered during the analysis of small molecules derived from or 
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Success comes to the man who so works that his efforts will bring the most and the best 
results-not to the man who simply works hard. - Agriculture for Beginners Burkette, 










     As described in Chapter 1 several LC/MS parameters can be adjusted in order to 
increase the MS response and signal-to-noise of a compound being analyzed. One 
approach that can be taken is to improve the ionization efficiency of the compound. 
Ionization efficiency can be increased by proper adjustment of desolvation temperature, 
desolvation gas flows, capillary and cone voltage settings on the MS. All of these 
parameters influence the ability of an analyte to exist in a charged gaseous state, 
required for introduction into the MS. Another approach to increasing the ionization of a 
compound is to remove or separate it from compounds that co-elute and interfere with 
the ionization process as previously mentioned in section 1.6. 
     The addition of formic or acetic acid to the LC mobile phase is commonly utilized to 
increase ionization with positive-ion ESI MS [1-4]. The fundamental rational for the 
acidification of the mobile phase is that most pharmaceuticals or analytes that are basic 
are analyzed in ESI positive mode because when exposed to an acidic environment they 
exist in a protonated state readily promoting the gas phase ionized state [5] see Figure 
2.1.1. Here lidocaine, a basic pharmaceutical compound with a pKa value of 










Figure 2.1.1 Lidocaine in neutral (a) and charged state (b). 
 
     However the vast majority of pharmaceutical LC/MS analysis being performed with 
acidic based mobile phases, early work by Leclercq et al. in 2005 and that by Farkas et 
al. in 2008 had illustrated some benefit of using high pH mobile phases for the analysis 
of basic pharmaceutical compounds in simple solvent matrices under positive ionization 
ESI mode[6, 7]. These two investigations showed that it was possible to use basic 
instead of the widely utilized acidic mobile phases for ESI positive mode without 
detriment to the MS signal. Secondly, in many cases the MS signal for basic compounds 
was greater when analyzed under basic mobile phase versus acidic mobile phase 
compositions. Thirdly, these basic mobile phases produced some advantage to the 
improvement in serial UV detection and chromatographic peak shape. 
     One of the major reasons for not considering the use of high pH mobile phases was 
the widespread usage of silica based LC columns which have an upper operating range 
of pH 7.5-8. At greater pH these types of LC columns begin to dissolve and collapse. 
The use of high pH mobile phases for LC/MS was enabled by developments in 
stationary phases such as hybrid organo-silica stationary phases which have an 






the main advantages of using high pH mobile phases is the decrease in chromatographic 
peak tailing associated with basic compounds that can occur when analyzed with acidic 
mobile phases. This peak tailing is normally associated with chemical interaction 
between the basic analyte and active groups on the surface of the silica stationary phase 
but can also be as a result of mass overload [10]. This decrease in chromatographic peak 
tailing therefore can lead to narrower, more symmetrical peak shape that can result in an 
increase in the signal-to-noise during analysis. 
     As a result of these pH related observations and need for improved performance and 
sensitivity of bioanalytical assays, the use of basic mobile phases for use in LC/MS 
based bioanalytical assays was investigated. The data presented in this chapter compares 
the MS response of twenty-four probe pharmaceutical compounds spiked into protein 
precipitated plasma and into solvent when analysed using pH 2.5 or pH 10.5 aqueous 
mobile phases. The probe pharmaceuticals chosen varied in pKa, molecular weight, 
hydrophobicity, and functional groups (Table 2.1.1). The signal-to-noise, peak area, 
peak width, and retention time were calculated for each probe compound. The influence 
of the organic eluents acetonitrile and methanol was evaluated with the acidic and basic 
aqueous mobile phase components, since these two organic solvents are the most 
commonly used. The effect of the acidic and basic mobile phase on the choline-
containing lipid fraction, a major matrix component present in the protein-precipitated 
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2.2 Methods and Materials 
 
2.2.1 Chemicals and Materials 
 
    Methanol and acetonitrile were obtained from Fisher Scientific (Waltham, MA USA). 
Formic acid, dimethyl sulfoxide and ammonium hydroxide were obtained from Sigma – 
Aldrich Chemicals (St Louis, MO, USA). Rat plasma was purchased from Equitech-Bio 
(Kerrville,TX, USA) and stored frozen at -20 ˚C prior to use. Purified  water was 
generated in house using a Millipore water system. Authentic standards for 
acetaminophen, antipyrine, atenolol, budesonide, cyclobenzaprine, danazol, 
dextromethorphan, diclofenac, erythromycin, fluconazole, lidocaine, loperamide, 
nefazodone, nortriptyline, oxycodone, omeprazole, propranolol, ranitidine, sitamaquine 
terfenadine, venlafaxine, verapamil were purchased from (Sigma-Aldrich St. Louis, 
MO. USA). Sample standard for alprazolam was purchased from Cerilliant (Round 
Rock, TX, USA). Fluticasone propionate and salmeterol was obtained from Toronto 
Research Chemicals (North York ON, Canada). 
2.2.2 Sample Preparation 
 
     The standard compounds were dissolved in methanol, with the exception of 
fluticasone, which was dissolved in dimethyl sulfoxide, to produce 1 mg/mL solutions. 
The resulting solutions were then diluted with aqueous methanol: water (5:95 v/v) to 
provide a series of spiking solutions. The standard solutions were then spiked into rat 
plasma or into aqueous methanol: water (5:95 v/v). The solvent composition was kept at 
less than five percent in the plasma samples. Samples were then protein-precipitated by 




Sample mixtures were then vortex mixed for one minute and centrifuged at 13,000 RCF  
for 5 minutes. The supernatant was then removed and diluted with water using 1:5 
protein-precipitated sample: water in order to match the initial generic gradient 
conditions utilized in the study. Samples prepared in order to investigate the 
phospholipid component present in the rat plasma, were prepared utilizing the same 
previously described protein-precipitation method. 
2.2.3 Liquid Chromatography 
 
     A 5 µL injection of each sample was injected onto an ACQUITY® Ultra Performance 
LC® separations module (Waters Corporation, MA, USA). Chromatography was 
performed on a 2.1 x 50 mm 1.7 µm ACQUITY BEH C18 column. Mobile phase A 
consisted of water with formic acid (0.1%v/v) or water with ammonium hydroxide 
(0.1 % v/v). Mobile phase B consisted of methanol or acetonitrile. The column was 
maintained at 45 ˚C and eluted under linear gradient conditions from 5 to 95 percent B 
over 2.5 minutes at a flow rate of 0.6 mL/min. 
2.2.4 Mass Spectrometry 
 
     Mass spectrometry was performed on a Waters Xevo™ TQ mass spectrometer 
(Waters, Manchester, UK) equipped with an electrospray interface. Settings were as 
follows:  source temperature = 150 ˚C, desolvation temperature = 600 ˚C, desolvation 
gas flow rate = 1000 L/h, and cone gas flow = 40 L/h. Cone and collision energies were 
optimized for each compound. Argon was utilized as the collision gas. The mass 
spectrometer was operated in SRM, SRM with precursor ion scan or SRM with full scan 
MS mode. Table 2.2.1 lists the transitions and conditions utilized for each of the 





    
Compound Name Cone (V) 
Collision 
Energy (eV) SRM (m/z) 
    Alprazolam 40 25 309.2 > 281.0 
Antipyrine 36 26 189.3 > 106.3 
Atenolol 30 24 267.2 > 144.9 
Budesonide 16 12 431.3 > 323.1 
Cyclobenzaprine 28 38 276.2 > 215.2 
Danazol 30 24 338.3 > 148.0 
Dextromethorphan 40 38 272.3 > 171.0 
Diclofenac 16 32 296.1 > 214.1 
Erythromycin 28 32 716.8 > 158.1 
Fluconazole 28 16 307.2 > 220.0 
Fluticasone 18 20 501.2 > 293.3 
Lidocaine 22 26 235.2 > 86.1 
Loperamide 28 28 477.3 > 266.1 
Nefazodone 48 34 470.3 > 246.1 
Nortriptyline 24 14 262.2 > 233.0 
Oxycodone 28 30 316.2 > 241.1 
Omeprazole 16 10 345.9 > 198.1 
Propranolol 25 20 260.1 > 183.1 
Ranitidine 22 24 315.2 > 130.1 
Salmeterol 28 24 416.5 > 232.2 
Sitamaquine 30 21 344.3 > 271.2 
Terfenadine 22 26 472.4 > 436.3 
Venlafaxine 8 28 278.3 > 121.1 
Verapamil 38 30 455.3 > 165.0 
 
   
 
 
Table 2.2.1 SRM transitions and MS conditions utilized for each compound. 









2.3 Results and Discussion 
 
2.3.1 Comparison of acidic and basic mobile phase pH on probe pharmaceuticals 
 
     The benefits of high pH mobile phases in reversed-phase chromatography are known 
for compounds containing basic moieties. Analyzing these compounds at a pH level 
above their pKa can allow the compounds to be chromatographed as neutrals. This 
results in longer retention times as well as more symmetrical peak shapes. As previously 
stated, Farkas and Peng were the first to report a thorough investigation of the use of 
high pH for the analysis of over 45 basic drug substances in 2008. 
     The data presented here highlights the benefits of high pH mobile phase for the 
LC/MS/MS analysis of pharmaceutical compounds that ionize under electrospray 
positive ion mode. These compounds tested were selected due to their variation in 
chemical structure, polarity and lipophilicity. Six consecutive, replicate injections were 
carried out for each compound under the acidic and basic mobile phase conditions. The 
effect of the mobile phase pH in combination with organic modifier on endogenous 
molecules, such as phospholipids, present in biological matrix was also investigated as 
well as the contribution of each of the mobile phase component to the overall  
background noise detected by the mass spectrometer. 
     The effect of utilizing a high pH mobile phase is shown in Figure 2.3.1. The data 
displayed here shows the effect of mobile phase pH on the LC/MS/MS analysis of 
omeprazole spiked into 95/5 (H2O/CH3OH). The data from Figure 2.3.1 shows roughly 
a two-fold increase in response when omeprazole was analyzed with the basic mobile 
phase compared to the traditional acidic mobile phase. This experiment was then 




protein precipitation. From Figure 2.3.2 we observe again the same approximate two-
fold increase in response that was observed when omeprazole was spiked into solvent. 
These results indicate that the endogenous matrix components present in the protein-
precipitated rat plasma are not contributing to the increased response observed under the 
basic mobile phase conditions i.e. matrix effects are not the cause for the increase in MS 
response. 
 
Figure 2.3.1 Analysis of omeprazole spiked into 95/5 (H2O/CH3OH) by LC/MS under 
ESI+ ionization mode with either acidic or basic modified mobile phase. The 
chromatograms are scaled to the largest response. Chromatographic conditions: flow 
rate = 0.6 mL/min, gradient elution = 5-95 B/2.5 minutes, column temperature = 40 °C, 
injection volume = 5 µL, column = Waters ACQUITY BEH 1.7 µm C18. 
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Figure 2.3.2 Analysis of omeprazole spiked into rat plasma by LC/MS under ESI+ 
ionization mode with either acidic or basic modified mobile phase. The chromatograms 
are scaled to the largest response. 
  Previously reported studies have suggested that the increase in response of compounds 
analyzed under basic mobile phase conditions may be due to an increase in retention 
time and therefore elution in a higher concentration of organic modifier [7]. However in 
this example, the retention time for omeprazole was decreased by 0.16 minutes when 
analyzed with the basic mobile phase and the response was greater than when analyzed 
with traditional acidic conditions. This result suggests that the increase in analyte 
response may not be due to a later elution time and higher organic solvent composition 
of the peak. A similar result was also observed for diclofenac analyzed under the acidic 
and basic conditions as again the higher pH mobile phase produced a reduced retention 
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time and increased MS response compared to the acidic mobile phase analysis where 
diclofenac was retained on the column for a longer time and yet produced a much 
smaller MS response compared with the basic analysis. 
     An increase in MS response was also observed even when the retention time did not 
change with the change in mobile phase pH. This is illustrated in Figure 2.3.3. Here 
fluticasone propionate  was analyzed in the same manner as the previous omeprazole 
example. 
 
Figure 2.3.3 Analysis of fluticasone propionate under acidic and basic mobile phase 
conditions. The chromatograms are scaled to the largest response. 
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However, in this case, the retention time for fluticasone propionate was identical under 
both acidic and basic modified mobile phase conditions. Thus the organic solvent 
composition of the analyte peak entering the mass spectrometer is identical. This result 
was observed for five of the twenty-four compounds, (approximately twenty percent) 
tested during this study. These compounds were: alprazolam, antipyrine, danazol, 
fluconazole, and fluticasone propionate. This data again indicates that the increase in 
MS response  with the basic mobile phase may not be due to chromatographic peak 
elution in a higher organic solvent composition. 
     A significant increase in analyte retention times was observed for the more polar 
compounds when analyzed with the basic versus acidic mobile phase. An example of 
this retention time shift is illustrated with the analysis of the H2-receptor antagonist, 
ranitidine, as shown in Figure 2.3.4. 
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In this example, a retention time increase of 0.31 minutes was observed, producing an 
increase in the gradient retention factor from 1.0 to 2.2. This observed increase in 
retention time under basic conditions for polar compounds has significant benefit in 
bioanalytical assays. By increasing analyte retention there is greater opportunity to 
separate the analyte from matrix interferences eluting near the void volume of the 
column and improve assay robustness. These matrix interferences could potentially lead 
to the incorrect measurement of the drug in a biofluid sample, leading to erroneous 
results due to ion suppression as discussed in Chapter 1. Table 2.3.1 list the gradient 
retention factor (kg)  for all of the twenty four probe pharmaceutical tested in this study. 
kg was calculated in the same manner as capacity factor.  
 
Compound 
n = 6 
(minutes) ACID/CH3CN ACID/CH3OH BASE/CH3CN BASE/CH3OH 
      
      Alprazolam AVG 3.92 5.50 3.96 5.54 
 
ST DEV 0.00 0.00 0.00 0.00 
 
%RSD 0.00 0.00 0.00 0.00 
      Antipyrine AVG 2.13 3.31 2.06 3.35 
 
ST DEV 0.02 0.02 0.03 0.04 
 
%RSD 0.93 0.47 1.56 1.26 
      Atenolol AVG 1.08 1.72 2.15 4.01 
 
ST DEV 0.02 0.02 0.00 0.06 
 
%RSD 1.80 1.16 0.00 1.44 
      Budesonide AVG 4.76 6.98 4.74 6.99 
 
ST DEV 0.02 0.02 0.02 0.02 
 
%RSD 0.42 0.30 0.42 0.28 
      Cyclobenzaprine AVG 4.20 7.05 
  
 
ST DEV 0.04 0.05 
  
 
%RSD 0.90 0.66 
  
      Danazol AVG 5.77 7.04 5.77 7.05 
 
ST DEV 0.00 0.00 0.02 0.00 
 
%RSD 0.00 0.00 0.28 0.00 
      





n = 6 
(minutes) ACID/CH3CN ACID/CH3OH BASE/CH3CN BASE/CH3OH 
      
      Dextromethorphan AVG 4.08 5.53 6.39 7.49 
 
ST DEV 0.04 0.02 0.02 0.02 
 
%RSD 1.10 0.36 0.25 0.21 
      Diclofenac AVG 5.22 8.94 2.88 6.17 
 
ST DEV 0.03 0.08 0.02 0.02 
 
%RSD 0.55 0.89 0.55 0.32 
      Erythromycin AVG 4.87 6.54 5.69 7.06 
 
ST DEV 0.03 0.02 0.00 0.02 
 
%RSD 0.66 0.37 0.00 0.28 
      Fluconazole AVG 2.19 3.46 2.20 3.46 
 
ST DEV 0.00 0.02 0.02 0.00 
 
%RSD 0.00 0.45 0.71 0.00 
      Fluticasone AVG 5.74 6.63 5.74 6.63 
 
ST DEV 0.02 0.02 0.02 0.02 
 
%RSD 0.35 0.30 0.35 0.30 
      Lidocaine AVG 2.50 3.35 5.17 6.31 
 
ST DEV 0.00 0.02 0.02 0.00 
 
%RSD 0.00 0.47 0.38 0.00 
      Loperamide AVG 5.06 5.77 5.94 7.08 
 
ST DEV 0.02 0.00 0.02 0.00 
 
%RSD 0.39 0.00 0.33 0.00 
      Nefazodone AVG 5.53 6.85 6.08 7.62 
 
ST DEV 0.03 0.02 0.00 0.00 
 
%RSD 0.52 0.23 0.00 0.00 
      Nortriptyline AVG 4.09 5.67 6.58 7.29 
 
ST DEV 0.02 0.02 0.00 0.02 
 
%RSD 0.51 0.35 0.00 0.29 
      Oxycodone AVG 2.04 2.39 4.27 5.33 
 
ST DEV 0.00 0.02 0.00 0.05 
 
%RSD 0.00 0.66 0.00 0.88 
      Omeprazole AVG 2.92 4.62 2.15 4.04 
 
ST DEV 0.00 0.02 0.00 0.00 
 







     





n = 6 
(minutes) ACID/CH3CN ACID/CH3OH BASE/CH3CN BASE/CH3OH 
      
      
      Propranolol AVG 3.60 5.44 5.08 6.83 
 
ST DEV 0.02 0.02 0.00 0.02 
 
%RSD 0.55 0.39 0.00 0.29 
      Ranitadine AVG 1.09 1.50 2.26 3.42 
 
ST DEV 0.02 0.00 0.02 0.00 
 
%RSD 1.82 0.00 0.69 0.00 
      Salmeterol AVG 5.23 7.01 5.35 7.19 
 
ST DEV 0.03 0.03 0.00 0.00 
 
%RSD 0.66 0.41 0.00 0.00 
      Sitamaquine AVG 5.22 6.42 6.02 8.35 
 
ST DEV 0.06 0.03 0.11 0.00 
 
%RSD 1.08 0.45 1.75 0.00 
      Terfenadine AVG 5.52 8.38 7.71 8.12 
 
ST DEV 0.06 0.10 0.02 0.00 
 
%RSD 1.06 1.20 0.27 0.00 
      Venlafaxine AVG 3.60 4.85 5.65 6.73 
 
ST DEV 0.02 0.02 0.00 0.00 
 
%RSD 0.55 0.32 0.00 0.00 
      Verapamil AVG 3.89 4.90 6.05 6.81 
 
ST DEV 0.02 0.02 0.02 0.00 
 
%RSD 0.40 0.41 0.33 0.00 
 
 
      Table 2.3.1 Probe pharmaceutical gradient retention factors analyzed under acidic and 





2.3.2 Effect on Peak Area 
 
The chromatographic peak area is a measure of the sensitivity or response of the LC/MS 
system. The data displayed in Figure 2.3.5 shows the average peak area values 
 
Figure 2.3.5 Bar graph illustrating the effect of mobile phase pH with CH3CN as the 
organic modifier on the area count for the probe pharmaceuticals tested. 
for the twenty-four probe pharmaceutical compounds that were spiked into plasma and 
analyzed under basic and acidic conditions with acetonitrile as the strong eluent. The 
results obtained for the basic mobile phase analysis were normalized against the peak 































areas obtained with standard acidic conditions. One can see from Figure 2.3.5 that of 
the twenty four compounds tested, twenty-one compounds had greater average peak 
area counts when run with the basic mobile phase, the exceptions being budesonide, 
cyclobenzaprine and salmeterol, which showed no increase in their average peak area 
The increases in peak area ranged from 1.2 to 9.6 fold with propranolol and 
dextromethorphan having respectively the lowest and highest increases in peak areas. 
     The experimental procedure was then repeated utilizing methanol as the organic 
eluent. The data from this experiment is shown in Figure 2.3.6. In this figure one can 
observe that twenty out of twenty-four compounds showed an increase in average peak 
area count when analyzed with the basic mobile phase. Three of the compounds gave 
similar results as the previous experiment when acetonitrile was used as the strong 
eluent. These compounds were: budesonide, cyclobenzaprine and salmeterol. 
Terfenadine, which exhibited a higher area count when analyzed with base and 
acetonitrile, showed a decrease in peak area when analyzed with base and methanol 







Figure 2.3.6 Bar graph illustrating the effect of mobile phase pH with CH3OH as the 





































2.3.3 Impact on Signal-to-Noise 
 
     Whereas an increase in area response or count may indicate an increase in the 
detection capability of the LC/MS system towards the compounds analyzed using a 
basic mobile phase, it is the signal-to-noise measurement which is the most important 
measurement as this is the parameter which determines the lower limit of quantification 
of an assay[11, 12]. Figure 2.3.7 shows the average signal-to-noise values for the test 
compounds spiked into plasma, and run with acetonitrile as the organic modifier under 
acidic and basic conditions. The signal-to-noise was calculated using the peak-to-peak 
algorithm within the operating system, MassLynx software version 4.1. The data 
obtained under the basic mobile phase conditions is normalized against the signal-to-
noise values for the acidic mobile phase analyses in the same manner as was performed 
with the area count measurements. 
     From Figure 2.3.7, the number of compounds showing an increase in the average 
signal-to-noise analyzed when using the basic/acetonitrile mobile phase was seventeen 










Figure 2.3.7 Bar graph illustrating the effect of mobile phase pH with CH3CN as the 




































Figure 2.3.8 Bar graph illustrating the effect of mobile phase pH with CH3OH as the 
organic modifier on the signal-to-noise for probe pharmaceuticals tested at a 
concentration of 1 ng/mL. 
     The signal-to-noise measurements when employing methanol showed twenty-two 
out of twenty-four had increased signal to noise values compared with the acidic mobile 
phase (Figure 2.3.8). The signal-to-noise values were more scattered compared to that 
of the peak area data. The chromatographic peak area data when analyzed with either 
acetonitrile or methanol as the organic mobile phase gave the same general trend for 































increases in area counts for the test compounds when the pH of the mobile phase was 
altered. The only exception to this trend was terfenadine. This can be contrasted with 
the signal-to-noise data where the trend is not as obvious. For example, the highest and 
lowest signal-to-noise responses with base and acetonitrile as the mobile phase were 
terfenadine and verapamil respectively. Whereas with the basic methanol mobile phase 
combination the compounds that exhibited the highest and lowest signal-to-noise values 
were diclofenac and salmeterol. It was also noted that the basic mobile phases produced 
greater signal-to-noise values for twenty-two out of twenty-four compounds tested when 
compared to traditional acidic mobile phases irrespective of the organic modifier. This 
result indicates that the organic modifier as well as the mobile phase pH needs to be 
considered when optimizing for assay sensitivity. One possible explanation for the 
variance in the signal to noise data may be due to interferences present in the mobile 
phase, sample, or sample diluents. These interferences may lead to higher background 
or matrix suppression [12, 13] . 
 
2.3.4 Effect on Peak Width 
 
     Chromatographic peak widths have a direct effect on the signal-to-noise, as the 
narrower or sharper a chromatographic peak, the greater is the peak height resulting in 
improved signal-to-noise values. The chromatographic peak widths for the test 
compounds were measured at ten percent peak height. Figure 2.3.9 and Figure 2.3.10 
show the resulting average peak width measurements using the four mobile phase 
combinations of the study. From the graph one can observe that eight of the twenty-four 
compounds tested had narrower peak widths with the basic/acetonitrile mobile phase 




widths with the basic/methanol mobile phase combination compared to the standard 
acidic conditions. The entire test compounds that had decreased peak widths with the 
ammonium hydroxide modified mobile phase also had a corresponding increase in 
signal-to-noise values. Therefore the narrower peak shape observed with the basic 
mobile phase did contribute to the improved signal-to-noise values obtained. 
 
Figure 2.3.9 Bar graph illustrating the effect of mobile phase pH with CH3CN as the 
organic modifier on the chromatographic peak width for probe pharmaceuticals tested. 
 



































Figure 2.3.10 Bar graph illustrating the effect of mobile phase pH with CH3OH as the 




































2.3.5 Effect on choline-containing lipids 
 
     The minimization of matrix interferences can be as important as increasing the signal 
to noise for a bioanalytical LC/MS assay, as it adds directly to the assay robustness. 
Sources of matrix interferences can be due to concomitant medications, metabolites, as 
well as other endogenous compounds and can inhibit or enhance MS response through a 
process referred to as ion suppression / ion enhancement as previously stated in Chapter 
1 [14-16]. One of the most common endogenous matrix components that has been 
indicated as a source of potential problems in blood derived matrices are the 
glycerophosphocholine-containing phospholipids (GPChos) [17-19]. Therefore, the 
effect of changing mobile phase pH and organic mobile phase on the retention time of 
GPChos was investigated during this study. Figure 2.3.11 illustrates the profile for the 
GPChos in protein-precipitated rat plasma acquired by precursor ion scan of m/z 184, in 
positive ion electrospray with each of the four mobile phase conditions. 
     Here we can observe that the retention time of the major choline-containing 
phospholipids present remained only slightly affected when the pH of the mobile phase 
was changed from an acidic to basic conditions. This is in contrast to the effect that the 
organic modifier had on these GPChos components. Changing the organic modifier 
from acetonitrile to methanol resulted in a significant increase in the retention time as 
well as the overall MS response for the GPChos. Therefore if one is to consider 
developing a bioanalytical assay using a basic mobile phase one must consider the effect 
that the mobile phase pH will have on the compound under analysis. If the retention 
time of the analyte under basic conditions is later than that with a standard acidic 
modified mobile phase, special consideration to matrix effects must be investigated as 




as the GPCho profiles can differ not only between different species such as rat and 




Figure 2.3.11 Profile of GPChos in protein-precipitated rat plasma acquired by 


























































Figure 2.3.12 Profile of GPChos in protein-precipitated rat plasma acquired by 
precursor ion scan of m/z 184, in positive ion electrospray for different species. 
     While it is not clear from these experiments as to why an increase in signal-to-noise 
is possible with the basic mobile phases, there is a definite correlation between the use 
of basic mobile phase and an increase in the MS response of the probe pharmaceuticals 
tested in this study with the MS operating in electrospray positive ionization mode. 
However, as stated earlier, the increase in MS response is unlikely to be due to 
increased retention time with the basic mobile phase and subsequent elution of the 
chromatographic peak in a higher organic content. Also some of the compounds that 
showed increased MS response had reduced retention time. Furthermore the 




for a portion of the test compounds indicates that the use of a basic mobile phase in 
bioanalysis would be beneficial compared to traditional acidic mobile phases. The 
results from this study are similar to results observed by Delatour and Leclercq, who 
showed the potential for incorporating high pH mobile phases for use in pharmaceutical 
analysis by LC/MS/MS in 2005 [21]. They postulated different mechanisms to try to 
explain the observed MS response while using basic mobile phases. These mechanisms 
were based on the ionization process and included: gas-phase proton transfer from the 
ammonium ion to the compound undergoing analysis or collision-induced dissociation 
of the analyte-ammonium ion to the protonated analyte form and surface enrichment of 
protons in the surface layer of droplets from which ions are desorbed. An investigation 
across different MS instrument platforms may contribute information in order to 
evaluate whether the results shown here are also observed over a wide range of MS 
instruments that vary in source architecture. The observation that methanol gave an 
increased response for many of the compounds over that of acetonitrile may be 
explained by the fact that, depending on the nature of the probe pharmaceutical under 
investigation, the organic modifier can enhance or suppress the signal observed by the 
MS [22]. The increase in GPCho response when methanol was utilized may be due to 










     The data presented here has indicated that the addition of a base, such as ammonium 
hydroxide, to modify the aqueous mobile phase, has significant benefits for LC/MS/MS 
based bioanalytical assays under electrospray positive ionization mode. An increase in 
the signal-to-noise was observed for twenty-two out of twenty-four of the probe 
pharmaceuticals tested indicating the importance of mobile phase pH optimization when 
developing an LC/MS/MS based assay. An increase in the chromatographic retention of 
poorly retained compounds was also observed. The increase in the MS response was not 
necessarily related to the later elution of the analyte in a higher organic composition 
under basic conditions. The results demonstrated that seven out of the twenty-four 
(approximately thirty percent) of the probe pharmaceuticals tested eluted earlier, or with 
the same retention time, compared to acidic mobile phase, produced a greater signal-to-
noise when analyzed with the basic conditions. The effect of the pH of the mobile phase 
further showed that the phospholipid fraction present in protein precipitated rat plasma 
was slightly affected by the change in mobile phase pH. However, the basic modified 
aqueous mobile phase in combination with methanol yielded the highest response for 
the choline-containing lipid fraction of the prepared plasma sample. The results of these 
studies indicate that basic mobile phases may be an effective option in order to increase 
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    The use of both acidic ( pH 2.5) and basic (pH 10.5) pH aqueous mobile phases for 
positive ESI LC/MS analysis  was extensively explored in Chapter 2 for a variety of 
pharmaceutical drug compounds varying in molecular weight, structure, pKa, and 
hydrophobicity. Significant gains in chromatographic peak area, retention time, and 
signal to noise were all observed during the study when analyzed under the basic mobile 
phase conditions. Also observed was a reduction in the peak width and the influence of 
mobile phase modification on endogenous analytes within plasma samples.  
     One of the compounds included in the study was the small molecule drug 
alprazolam. Alprazolam (Figure 3.1.1) is a short acting benzodiazepine used for the 
treatment of moderate to severe anxiety disorders, panic attacks, and as an adjunctive 
treatment for anxiety associated with clinical depression. Alprazolam is readily 
absorbed from the gastrointestinal tract with the peak plasma concentration achieved in 
1-2 hours. Most of the drug is bound to plasma protein, mainly serum albumin. 
Alprazolam is hydroxylated in the liver to hydroxyl alprazolam, which is also 
pharmacologically active. Some of the drug is also excreted in the dosed form. The 
compound is typically dosed at 1-3 mg/day resulting in a Cmax of 8-37 ng/mL with a 
typical half-life of 12 hours [1, 2]. 
     In this chapter, the development and partial validation of a LC/MS/MS bioanalytical 
assay for alprazolam in rat plasma was carried out over a dynamic range of 
0.01-10 ng/mL utilizing basic mobile phases with positive ESI LC/MS. Both accuracy 




with respect to the mobile phase pH and organic modifier was further evaluated as well 
as the robustness of the assay over a 96 hour period.  
 
 
Figure 3.1.1 Chemical structure of alprazolam, deuterated alprazolam, and the hydroxyl-










3.2 Materials and Methods 
 
3.2.1 Chemicals and Materials  
 
     Methanol and acetonitrile were obtained from Fisher Scientific (Waltham, MA 
USA), Formic acid and ammonium hydroxide were obtained from Sigma – Aldrich 
Chemicals (St Louis, MO, USA). Rat plasma was purchased from Equitech-Bio 
(Kerrville,TX, USA) and stored frozen at -20 ˚C prior to use. Purified water was 
generated in house using a MilliQ water system from Millipore (MA, USA). 
Alprazolam (1.0 mg/mL in methanol), d5-alprazolam (internal standard) and the 
hydroxyl-alprazolam metabolite was purchased from Cerilliant (Round Rock, TX, 
USA). 
3.2.2 Sample Preparation 
 
      The alprazolam solution (1 mg/mL) was volumetrically diluted in methanol : water 
(5:95 v/v) to produce series of spiking standards. Calibrants were prepared by spiking 
alprazolam from the spiking standards into control rat plasma over the range 0.01-10 
ng/mL and QC samples at concentrations of 0.025, 0.25, 0.625, 2.50 and 6.25 ng/mL. 
The plasma samples were then prepared for analysis by protein precipitation by taking 
0.375 mL of the alprazolam spiked plasma and adding 0.75 mL of acetonitrile. The 
samples were vortex-mixed for 1 minute and centrifuged at 13,000 RCF for 5 minutes. 






3.2.3 Liquid Chromatography 
 
     A 20 µL injection of each sample was injected onto an ACQUITY® Ultra 
Performance LC® separations module (UPLC) and onto an Alliance HPLC separations 
module (Waters Corporation, MA, USA). UPLC method development was performed 
on four columns: 2.1 x 50 mm 1.7 µm ACQUITY BEH C18, 2.1 x 50 mm 1.7 µm 
ACQUITY BEH C8, 2.1 x 50 mm 1.8 µm ACQUITY HSS T3 C18, and 2.1 x 50 mm 
1.7 µm ACQUITY BEH RP Shield C18. HPLC was performed on a 2.1 x 50 mm 5 µm 
XBridge C18. Mobile phase A consisted of water with formic acid (0.1 % v/v) or water 
with ammonium hydroxide (0.1 % v/v). Mobile phase B consisted of methanol or 
acetonitrile. The column was maintained at 45 ˚C and eluted under linear gradient 
conditions from 5 to 95 percent B. UPLC was run at a flow rate of 0.6 mL/min while the 
HPLC was run at 0.2 mL/min.  
3.2.4 Mass Spectrometry 
 
     Mass spectrometry was performed on a Waters Xevo™ TQ mass spectrometer 
(Waters, Manchester, UK) equipped with an electrospray interface. Settings were as 
follows:  capillary voltage = 1 kV, source temperature = 150 ˚C, desolvation 
temperature = 600 ˚C, desolvation gas flow rate = 1200 L/Hr, and cone gas flow = 
40 L/Hr. The mass spectrometer was operated in SRM mode. Table 3.1.1 illustrates the 







Compound SRM m/z Cone (V) Collision Energy (eV) 
Alprazolam 309.2 > 281.0 40 25 
Alprazolam D5 314.2 > 286.1 40 25 
Alprazolam OH 325.0 > 297.0 40 25 
 
Table 3.1.1 SRM transitions and MS conditions utilized for each compound. 
3.2.5 Validation Protocol 
     The assay was validated using the procedures outlined in the US FDA Guidance for 
Industry Bioanalytical Method Validation [3]. The calibrants (concentration range 
0.01 – 10 ng/mL) and five QC levels (covering the range of 0.025 to 6.25 ng/mL) were 
analysed by LC/MS/MS. The ratio of organic to plasma was never more than 5 % 
organic when creating the plasma spiked samples.  
3.3 Results and Discussion 
 
3.3.1 Development of a sub-2 µm LC method versus the standard HPLC method 
     The development of a LC/MS/MS method requires the selection and optimization of 
the mass spectrometry and chromatography conditions.  Alprazolam is a benzodiazepine 
class of compound having an elemental composition of C17H13ClN4, giving a 
monoisotopic molecular mass of 308.0829. Alprazolam was found to give the best 
response in positive ion mode using electrospray ionization mode. The cone voltage, 
collision energy and most selective and sensitive fragment ion were optimised using 
both manual and automatic tuning. The best fragment transition in terms of specificity 
and sensitivity was determined to be m/z 309.2 > 281.0 using a cone voltage of 40 V 





     The chromatographic conditions were developed using a reversed-phase 
chromatography system, using sub 2 µm particle LC. Previous work by many authors 
has illustrated the benefits of these sub 2 µm particle LC materials [4-6]. Most 
importantly this extra resolution allows for greater confidence in resolution of the 
analyte of interest from the endogenous components in the sample and from the 
metabolites of the dosed candidate pharmaceutical. The LC/MS chromatographic 
method for alprazolam in rat plasma was developed to address the following major 
factors; resolution of the analyte from endogenous components in plasma, resolution 









Figure 3.3.1 Increase in the resolution of analytes separated under sub 2 µm  UPLC 
conditions  compared to standard 5 µm HPLC.   Both separations carried out under 
gradient conditions and at optimum linear velocity ( sub 2 µm = 0.6 mL/min and  5 µm 
= 0.2 mL/min) Equivelent column volumes  of mobile phase were calculated and 
reflected in the total run time of the analysis ie the HPLC analysis run time was 3 X 
longer.   
 
      
 





    The data in Figure 3.3.1 shows an expanded view of the resolution between 
alprazolam and the hydroxyl metabolite acquired utilizing sub 2 µm LC and traditional 
HPLC. The resolution value measured at peak base produced by the sub 2 µm LC 
separation was 1.5 compared with only partial resolution value of 0.7, for the HPLC 
separation. This result is of particular importance due to the fact that some drug 
metabolites such as N-oxides and glucuronides, if unresolved from their parent drug, 
may decompose in the source of the mass spectrometer back to the parent drug structure 
[7]. This can result in the over estimation of parent drug concentration and the 
subsequent erroneous pharmacokinetic plots.  
     Chromatographic peak widths were also measured at peak base, for alprazolam, 
hydroxyl alprazolam and deuterated alprazolam separated under each chromatographic 
condition are displayed in Figure 3.3.2. The data in this figure show that peak widths 
obtained under HPLC conditions are in the order of three times larger than when the 
same analytes are separated under sub 2 µm LC conditions. The narrower peaks 
generated from the sub 2 µm LC separation gave a peak capacity, measured at peak 
base, in 1.5 minutes, of 29.3. This value is 16 percent higher than the peak capacity for 
the HPLC separation, measured in the same manner, in 5 minutes, of 24.6. This result 
indicates that a greater number of analytes can be separated in less time with the sub-2 
µm LC separation compared to the conventional HPLC separation. The increase in the 
peak capacity produced by the sub 2 µm LC can be of particular importance in the 
reduction of co-elution of target analytes from endogenous components present in 
biofluid matrices. As stated in Chapter 1, co-elution of target analytes with matrix 












Figure 3.3.2 Comparison of peak widths using sub 2 µm LC and HPLC conditions.  
 
     The observed narrow chromatographic peak widths observed for the 2 µm LC 
separation enables greater peak height to be obtained, therefore increasing the signal of 
an analyte. This has the effect of lowering the limits of quantification and detection of 
analytes. Figure 3.3.3 shows the increase in peak height for equal injection volume of 
the analytes on both the sub 2 µm LC and HPLC systems. A 4.5 fold increase in signal 
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Figure 3.3.3 Comparison in sensitivity of analytes under sub 2 µm LC and HPLC       
 conditions. 
 
     The retention of alprazolam and its resolution from hydroxyl-alprazolam was 
evaluated on various organo-silica hybrid materials including: BEH C8, BEH C18, and 
polar embedded C18 column (BEH RP C18) as well as a high strength silica C18 column 
(HSS T3), Figure 3.3.4. The chromatography was performed using 2.1 x 50 mm 
columns to facilitate short analysis times and hence rapid evaluation. A generic 5-95 % 
gradient over 2 minutes was utilized with mobile phase A comprised of 0.1 % v/v 
formic acid in water and mobile phase B comprised of acetonitrile. The data generated 
showed that the silica-based C18 column gave the greatest retention and resolution of the 
compound and metabolite.  





  Figure 3.3.4 Comparison of the separation of alprazolam and hydroxyl- alprazolam on 
(A) BEH C8, (B) BEH C18, (C) BEH Shield RP18, and (D) HSS T3. 
The BEH C8 gave good resolution between alprazolam and hydroxyl-alprazolam as well 
as better peak shape for the metabolite compared to the BEH C18. Although the BEH RP 
C18 gave sufficient resolution between the alprazolam and hydroxyl-alprazolam as well 
as good peak shape for both analytes it was not chosen due to potential bleed issues that 
could cause potential matrix effects in the MS detector. Therefore the best columns to 
progress the method development process were the organo-silica hybrid BEH C8 and the 

















3.3.2 Optimization of mobile phase composition 
     As previously stated in Chapter 2, the acidity or alkalinity of the mobile phase will 
change the ionization state of the analytes, e.g. acids will be in their ionic form with 
high pH mobile phases whereas they will be neutral at acidic pH. This change in 
ionization state will directly affect the chromatography; in reversed phase mode neutral 
compounds will be retained longer and generate less peak tailing. Thus operation at a 
pH where the analytes are in their neutral form is preferred from a chromatographic 
point of view, whereas from an MS point of view it is typically beneficial to have the 
analyte in a charged state as it will enhance the sensitivity. A comparison of MS 
sensitivity for alprazolam utilizing the two different pH values (< 3 and >10 pH units) 
was carried out and the data is shown in Figure 3.3.5. The data displayed in this figure, 
was obtained for alprazolam analyzed with positive mode electrospray ionization. The 
data shows a 5 fold increase in sensitivity with the basic mobile phase compared with 
the traditional acidic mobile phase was obtained for alprazolam analyzed with positive 






Figure 3.3.5 Comparison of MS peak response for alprazolam in basic (top) and acidic 
(bottom) mobile phases. 
 
     The initial chromatographic evaluation of alprazolam was performed using 
acetonitrile as the organic modifier and the effect of changing the organic modifier to 
methanol on the retention time and MS detector response is displayed in Figure 3.3.6.  
The data acquired showed that, when using methanol, the retention time of alprazolam 
was increased from 1.28 minutes to 1.63 minutes, and the signal response increased by a 
factor of 2.5.   
Ammonium Hydroxide pH 10.0







Figure 3.3.6 Comparison of MS peak response for alprazolam using 
basic/methanol (top) and basic/acetonitrile (bottom) mobile phases. 
     As the sensitivity was substantially greater with the aqueous high basic pH/ methanol 
mobile phase, this was therefore selected for further studies.  This selection meant that 
the high strength silica column (HSS T3) could not be used as it is not chemically stable 
at this high pH. However the chemical stability of the organo-silica hybrid BEH C8 
column allows this column to be operated at high pH and thus this column was selected 
for this analysis. 
 
3.3.3 Partial method validation 
 
     Using protein precipitation as the sample preparation technique the basic mobile 
phase assay was shown to be linear (using a weighting factor of 1/x) over the range of 







subjected to partial validation over the concentration range. The calculated 
concentration RSD of 6 replicate analysis of the QC samples at levels 0.025, 0.250, 
0.625, 2.50 and 6.25 ng/mL is displayed in Table 3.3.1.        
 
 





(ng/mL) Accuracy  Precison 
QC 1 0.025 0.023 8.00 3.01 
QC 2 0.25 0.24 4.00 5.29 
QC 3 0.63 0.60 4.76 2.09 
QC 4 2.50 2.40 4.00 2.46 
QC 5 6.25 6.11 2.24 2.00 
 
Table 3.3.1 QC accuracy and precision data for alprazolam assay run with basic mobile 








3.3.4 Sub 2 µm LC method robustness evaluation  
 
     Assay robustness is an issue for methods that are to be utilized for routine analysis. 
This is the case for many bioanalytical methods. These methods must be able to 
quantify drug molecules from thousands of samples during clinical trials. Column 
plugging can result in system overpressure and poor peak shape due to build-up on the 
inlet frit. Protein precipitated plasma represents one of the most problematic biological 
samples due to the limited sample cleanup the methods offer. It is however, one of the 
most utilized methods for sample preparation of plasma due to the ease to perform, 
speed, and low cost of the technique.  
 
 
Figure 3.3.8 Chromatographic comparison between first injection and last injection 




The use of sub 2 µm chromatographic particles required the incorporation of smaller 
porosity frits compared to those utilized with conventional HPLC columns and therefore 
could be the site of blockage. Therefore a robustness test was carried out utilizing a 
protein-precipitated plasma sample spiked with alprazolam.  
 
Figure 3.3.8 shows the alprazolam peak at the first injection and after 4 days (96 hours) 
of continuous analytical runs. Here we can see that after this length of time the 
chromatographic performance is maintained for the sub 2 µm LC separation as the 
retention time and peak width for the analyte is unchanged.  
 
 
Figure 3.3.9 Comparison of system back pressure comparison between first injection 






Figure 3.3.9 shows the pressure trace at the start and end of the column lifetime 
experiment. The pressure trace and the end of the experiment shows no increase 
compared to the pressure trace at the beginning. This would indicate that the inlet frit or 








      The data shown here demonstrates the advantages of narrow bore columns packed 
with sub 2 µm particles run on a low volume, high pressure system under gradient 
conditions over that of 5 µm particles run using a conventional HPLC system. Greater 
resolution between alprazolam and the associated hydroxyl metabolite was observed. 
Reduction in analysis time and gains in sensitivity were also obtained with the sub 2 µm 
LC assay. A comparison of a basic aqueous mobile phase showed a fivefold increase in 
the MS response for alprazolam compared to the traditional acidic aqueous mobile 
phase used with positive ion mode ESI MS. In addition to the increase in sensitivity that 
the base modified aqueous mobile phase produced, methanol provided a further increase 
in the MS signal for alprazolam. These conditions were then utilized to produce a 
simple, sensitive and specific LC/MS assay for alprazolam in rat plasma. The limit of 
quantification using protein precipitation was determined to 0.01 ng/mL. The precision 
of the protein precipitation assay was determined to be less than 6 % and below 
calculated via multiple QC sample levels. The assay was shown to be linear  over a 
range of 0.01 to 10 ng/mL. The system and column were also shown to be robust as it 
ran continuously over 4 days and 1000 injections of protein precipitated plasma samples 
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 Chapter 4 
Investigation of Basic and Acidic LC Mobile phases with Positive 
Mode ESI Mass Spectrometry in Biomarker Discovery  
 
This chapter is based on the following publication:  
 
Investigation of Basic Mobile Phases with Positive ESI LC/MS for Metabonomics 
Studies 
 
Paul D Rainville, Norman W Smith, David Cowan, Jeremy K Nicholson, J P Shockcor, 
St John Skilton and Robert S Plumb  




Every addition to true knowledge is an addition  








     Metabonomics has been defined as “Quantitative measurement of multivariate 
metabolic responses of multicellular systems to pathophysiological stimuli or genetic 
modification”  and has been primarily utilized to provide information for the wide-
spread understanding of global metabolic regulation and biological system failure [1]. 
Initial work in the area of metabonomics was focused upon understanding the 
mechanisms of drug toxicity in mammalian system [2-5].    
     The main aim of these studies was to collate information on biomarkers of  
nephrotoxicity, and  hepatotoxicity. This information was subsequently used to build 
statistical models to monitor early safety assessment studies as a means to eliminate 
potentially undesirable compounds earlier in the drug development process [6-8]. As 
part of these early studies it was clear that the use of spectroscopic and spectrometric 
profiling of biological fluids could yield data that could result in the ability to 
discriminate between gender, age, and diurnal variations [9, 10].   
     As a result of these promising early studies more elaborate studies where undertaken 
such as the Consortium on Metabolism and Toxicology (COMET I&II) to understand 
and build statistical models of toxicity [11, 12]. These promising initial studies resulted 
in a dramatic increase in the interest and use of the metabonomic approach to 
investigate disease models and dietary effects [13-16]. More recently the use of data 
from high resolution NMR and MS has aided decision making in both surgical and 




     Much of the initial metabonomics research employed either NMR or GC-MS as the 
primary platforms to acquire analytical data [19-21]. Although NMR and LC/NMR are 
used in drug metabolism studies, LC/MS is by far the dominant analytical platform for 
the acquisition of qualitative and quantitative in drug metabolism and pharmacokinetics 
(DMPK) studies because of the inherent sensitivity, speed and throughput of the 
technique. The application of LC/MS to metabonomics studies has provided 
complementary data to that obtained by NMR, often producing assays of greater 
sensitivity [22-24].   
     The vast majority of the LC/MS metabonomics methodologies employed the use of 
formic acid based organo-aqueous gradient approaches [25-27], primarily due to the fact 
that it is  most common mobile phase combination used in LC/MS when the ionization 
mode utilized is positive ESI. This could have been further compounded by the dearth 
of chromatographic stationary phases that were chemically and mechanically stable in 
basic pH environments prior to the late 1990s. In Chapter 3,  the sensitivity benefits of 
using basic pH mobile phases for the analysis of the benzodiazepine drug alprazolam 
analyzed under positive ESI mode [28], and in Chapter 2 a subsequent larger 
bioanalytical study for a significant number of compounds varying in structure, 
molecular weight, pKa, and hydrophobicity [29]. 
     In this study, the first known investigation into the utilization of basic pH mobile 
phase with reversed-phase chromatography coupled with positive ESI LC/MS for  
metabonomic analysis is presented. Urine samples from rats treated with the model 
hepatotoxin, hydrazine, were utilized to determine the benefit derived from this non-
traditional mobile phase combination for positive ESI LC/MS. Chromatographic 
resolution, analyte response and retention were all compared to that obtained when 




additional goal of this study was to compare the differences in the detection of analytes 
between the traditional acidic mobile phase LC/MS analysis with the non-traditional 
basic mobile phase LC/MS analysis. Furthermore due to the great interest in retention 
and subsequent detection of highly polar analytes that elute in the void volume of an 
LC/MS/MS analysis, part of the study was to evaluate the effectiveness of high pH 
mobile phases to better retain the polar components that elute in the chromatographic 
void when using traditional acidic based mobile phases. 




4.2 Materials and Methods 
 
4.2.1 Chemicals and Materials 
 
     Optima grade acetonitrile (HPLC grade) was purchased from Fisher Scientific 
(Hampton, NH, USA), formic acid (spectroscopic grade) and 0.1 M ammonium 
hydroxide solution were purchased from Sigma/Aldrich (MO, USA). Purified water was 
generated purified in-house using a MilliQ system Millipore (MA, USA).   
 
4.2.2 Animal Studies 
 
     Rat urine samples were obtained from a study of hydrazine toxicity conducted as part 
of a major toxicology project[30]. All animal experiments were conducted according to 
appropriate national guidelines. In this study, male Sprague-Dawley rats were randomly 
allocated to groups control, low and high-dose (n = 10 per group). Here we only 
consider the control and high-dose groups. The high-dose group received hydrazine 
hydrochloride in 0.9 % saline administered orally at 90 mg/kg. Dose vehicles alone 
were administered to matched control animals. Rats were housed in individual 
metabolic cages under controlled temperature, humidity, and light cycles. Urine samples 
were collected at times from -16 h pre-dosing to 168 h post-dosing. Data for the high-
dose group were obtained from 58 samples, of which 20 corresponded to pre-dose time 
points (showing no toxic response) and 38 for time points known to demonstrate a high 








     The separations were performed on a 2.1 x 100 mm ACQUITY UPLC 1.7 µm BEH 
C18 column using an ACQUITY Ultra Performance LC Chromatography™ (UPLC) 
System (Waters® Corporation, MA, USA). The column was maintained at 40 ºC and 
eluted with a linear acetonitrile – aqueous gradient over 10 minutes at 500 µL/min, 
starting at 5 % acetonitrile and rising to 95 % over the course of the gradient. The 
aqueous mobile phase was either 0.1 % v/v formic acid or 0.1 % v/v ammonium 
hydroxide. The column eluent was directed to the mass spectrometer for analysis. 
 
4.2.4 Mass Spectrometry 
 
     Mass spectrometry was performed on a Waters® Micromass® Xevo™ G2 QTof  
mass spectrometer (Waters Micromass, Manchester, UK) operated in positive ESI mode 
with “W-Optics” , the collision cell was set to alternate between a collision energy of 5 
eV and 25 eV every 60 mSec with a 20 mSec inter scan delay. The instrument was 
operated with Lockspray™ frequency of 11 with a scans to average set to 5. Leucine 






4.2.5 Statistical Analysis 
 
     Data were analysed using the MarkerLynx XS™ applications manager (Waters, 
UK); this application manager integrates peaks in the LC/MS data by using automated 
ApexTrack™ peak detection algorithm. The LC/MS data were peak-detected and noise-
reduced in both the LC and MS domains such that only true analytical peaks were 
further processed by the software (e.g., noise spikes are rejected). A list of the 
intensities of the peaks detected was then generated for the first sample, using the 
retention time (RT) and m/z data pairs as the identifier for each peak. An arbitrary 
number is then assigned to each of these RT-m/z pairs in order of elution, 
(1,2,3,4,….etc). This process was repeated for each run. Once this was completed the 
data from each LC/MS analysis in the batch were then sorted such that the correct peak 
intensity data for each RT-m/z pair was aligned in the final data table. The resulting 3 
dimensional data, peak number (RT – m/z pair), sample name, and ion intensity were 
analysed by Principal Components Analysis (PCA). The PCA was performed in the 












4.3 Results and Discussion 
 
4.3.1 Basic pH mobile phase with positive electrospray MS  
 
     The benefits of basic pH mobile phases in reversed-phase chromatography are well 
known for compounds containing basic groups. Operation at a pH above the pKa of 
these compounds allows them to be chromatographed as neutral species, resulting in 
greater retention, and more symmetrical peak shapes. Further, the use of basic pH helps 
to overcome the effect of peak tailing.   
     The routine application of basic pH mobile phase was made possible by the 
development of organo-silica based stationary phases in the late 1990s [31]. These new 
phases relied on the incorporation of a methyl group into the core silica structure, 
reducing phase dissolution and allowing operation in the range 9-10 pH units. More 
recently the development of a bridged-ethyl silica hybrid stationary phase has resulted 
in greater phase stability allowing continual operation at pH 10-11 [32] . 
     As mentioned in Chapter 2, Delatour and Leclercq showed the potential for 
incorporating basic pH mobile phases for use in pharmaceutical analysis by positive ESI 
mode LC/MS in 2005 [33]. Following in 2008, Farkas and Peng reported the first 
in-depth study utilizing basic pH mobile phases for the analysis of over forty basic drug 
substances analyzed with positive ESI mode LC/MS. In this work, the authors reported 







4.3.2 Application to metabonomic study 
 
     Plasma and urine contain a significant proportion of basic compounds [35], so the 
ability to improve retention and separation of these compounds in reversed-phase 
LC/MS would be of significant benefit. Greater separation of analytes from the 
components eluting in the void of the column is also likely to reduce ion suppression 
and improved assay reproducibility. This is critical in metabonomics studies as any 
variation in analyte response could be interpreted as the result of a toxicological or 
disease state response. The use of other forms of chromatography such as hydrophilic 
interaction liquid chromatography (HILIC) has yielded promising results in this 
area[35]. However, this form of chromatography is less effective than reversed-phase at 
dealing with the broad range of analyte polarities present in biological fluids.   
     The data displayed in Figure 4.3.1 illustrates two chromatograms obtained for the 
analysis of control rat urine, using either acidic or basic mobile phase. In these two 
examples, the gradient duration, organic solvent and gradient steepness has been kept 
constant. The top chromatogram represents the acidic mobile phase separation and the 
bottom that obtained from a basic mobile phase separation. A qualitative review of the 
data shows that there is a significant difference in the elution profile across the whole of 





Figure 4.3.1 Positive ESI LC/MS chromatogram of control rat urine using an acidic 
(top chromatogram) and basic mobile phase (bottom chromatogram). 
 
 
     The use of the basic mobile phase not only increased analyte retention but also 
improved analyte sensitivity and peak resolution. The data displayed in Figure 4.3.2 
illustrates the increased analyte response obtained from the two ions detected within the 






Figure 4.3.2 Influence of basic mobile phase pH on urinary analyte with m/z 150.077.  
The top chromatogram is the separation with the acidic mobile phase and the bottom 
chromatogram that obtained from the basic mobile phase. The two chromatograms axes 
are linked for intensity. The peak eluting with a retention time of 3.00 minutes in the 
basic separation shows a response almost 50 % greater than the same analyte in the 
acidic separation, where it elutes with a retention time of 1.82 minutes.   
     The same phenomenon is also observed for the smaller peak in the two 
chromatograms eluting with a retention time of 2.08 and 0.81 min in the basic and 
acidic mobile phase systems respectively. Due to the fact that many analytes in 
biological fluids are basic in nature, upon exposure to an acidic mobile phase these 
analytes will be present in a charged state. This charged state will in effect make the 
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analyte more polar and therefore less likely to retain on a reversed-phase column. 
However, when basic analytes are exposed to a basic mobile phase, they exist in a 
neutral state and are more likely to be retained by reversed-phase.  
     The use of a basic mobile phase also, in some cases, provided enhanced resolution. 
This fact is illustrated in Figure 4.3.3. In this example the single peak eluting with a 
retention time of 10.96 minutes in the acidic system (top chromatogram) is resolved into 
two discrete peaks eluting at 9.72 and 10.03 minutes in the basic system. The accurate 
mass of the two peaks detected, m/z = 358.269 was subjected to a search on multiple 
databases but did not return any potential compounds. The data shown in Figure 4.3.3 
clearly illustrates that the spectra  
Figure 4.3.3 Increase in chromatographic resolution of analytes analyzed with basic pH 
mobile phase.  
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 from the two discrete peaks from the basic separation were significantly cleaner 
whereas the spectra obtained from the acidic separation was less informative. The extra 
resolution is a result of extra selectivity imparted onto the separation system as a result 
of employing a basic pH mobile phase. This improved resolution can be beneficial not 
only in metabonomic studies but also in metabolite identification studies especially in 
the light of the recent Metabolites in Safety Testing (MIST) guidelines which emphasize 
the need to study toxic species [36].   
 
4.3.3  Model toxin study samples 
 
     The effect of utilizing basic mobile phase combinations in an LC/MS based 
metabonomics study was investigated using urine samples obtained from a toxicology 
study with a model toxin, hydrazine, dosed to rats. The analysis of these samples was 
previously reported by Crockford et al.[30] In that paper the authors describe the use of 
a high resolution chromatography, accurate mass QTof MS system combined with 
advanced correlation statistical analysis to obtain structural, as well as higher level 
biological, information relating to changes in metabolic pathway activity and 
connectivity.   
     For the present study we have reanalyzed a subset of these samples using both the 
acidic and basic aqueous-organic reversed-phase chromatography systems. Again as 
with the previous control urine, the samples were analysed using high-resolution sub 
2 µm porous particle LC/MS with QTof detection in positive ion mode. The data 
displayed in Figure 4.3.4 illustrates the separations obtained from the LC/MS analysis 




pre-dose. The top chromatogram illustrates the data obtained from the acidic separation 
and the bottom chromatogram that obtained from the basic LC/MS analysis.   




Figure 4.3.4 Positive ESI LC/MS chromatogram of rat urine following the oral 
administration of hydrazine at 60 mg/kg, using an acidic (top chromatogram) and basic 






      The samples were analysed by the PCA method and using the OPLS class model 
described by Shockcor et al.[20] The data shown in Figure 4.3.5 shows the PCA plots 
for the analysis of the 0 hr and 48 Hr samples using either the acid mobile phase (Fig. 
4.3.5a) or basic mobile phase (Fig. 4.3.5b).  The statistical analysis of the two data sets 
showed that both systems clearly separated the 0 Hr samples from the 48 Hr samples 




Figure 4.3.5a Principal components analysis of positive ion LC/MS analysis of rat urine 







Figure 4.3.5b Principal components analysis of positive ion LC/MS analysis of rat 




      However it is clear from the data analysis, that the ions showing the greatest 
contribution to the variance in the data were different between the two chromatographic 
systems, irrespective of the actual retention time. The data displayed in Table 4.3.1 list 
the top ten ions contributing to variation in the data for both the 0 hr and 48 hr samples. 








pH 2.5, 0 Hr  
Mobile phase 
pH 2.5, 48 Hr  
Mobile phase 
pH 10, 0 Hr  
Mobile phase 
pH 10, 48 Hr  
m/z  m/z   m/z m/z  
287.863 431.688 284.948 309.044 
162.660 295.731 215.744 267.815 
144.131 160.858 182.489 234.191 
144.044 141.272 167.834 211.589 
139.497 129.423 163.578 156.260 
117.805 123.879 160.262 143.760 
117.787 113.722 160.199 140.175 
114.180 109.387 111.560 137.354 
104.861 100.739 110.745 131.268 
287.863 431.688 106.291 309.044 
 
Table 4.3.1 Comparison of the LC/MS marker ions detected with acidic and basic 
mobile phase in the analysis of hydrazine dosed rats. 
 
This point can be further illustrated graphically in Figure 4.3.6. In this data we can see 
the acid and basic separations as well as a trend plot one of the ions. From the data we 
can see that with the acid separation the ion m/z = 962.3001 is not detected but is well 
detected in the basic separation. 
 






Figure 4.3.6 Positive ion LC/MS analysis of rat urine using acidic and basic mobile 
phases and trend plot for the marker ion detected eluting at 7.44 min, m/z = 962.3001. 
 
      The data displayed in Table 4.3.2 compares the retention time and signal intensity 
obtained for a select set of extracted signals (ions) previously identified in the work of 
Crockford et al. on hydrazine toxicity as well as selected other commonly reported 
marker of toxicity compounds, in both the acidic and basic mobile phases. As can be 
seen from the data, the retention time was increased for some of the marker ions under 
basic conditions and the signal intensity increased for fifty percent of ions under basic 
conditions (all measurements were made under the same positive ESI conditions). Not 
unsurprisingly the acidic compounds such as hippuric acid and pantothenic acid were 
retained to a greater extent under acidic conditions, however even when the retention 
(kg) did not increase under basic conditions the signal response often did. For example, 
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biomarker candidate m/z 170.06 had a reduced retention time under basic conditions but 
the signal intensity increased by a factor of 5. 
 
   
Signal intensity kg 
 
Compound m/z Acid Base Acid Base 
1 Biomarker candidate 127.04 1 0.5 1.7 4.2 
2 Biomarker candidate 149.04 1 ND* 1.7 ND* 
3 Biomarker candidate 156.03 1 0.7 0.1 0.3 
4 Biomarker candidate 156.06 1 0.4 0.9 0.3 
5 Biomarker candidate 170.06 1 5.0 8.5 7.7 
6 Pantothenic acid 220.12 1 1.1 6.0 4.8 
7 Hippuric acid 180.06 1 1.5 7.5 3.6 
8 
Hydrazine toxicity 
marker 402.1 1 2.7 7.0 6.3 
9 
Hydrazine toxicity 
marker 265.05 1 2.9 0.3 0.3 
10 
Hydrazine toxicity 
marker 218.11 1 0.2 10.6 4.7 
       
 
 Not Detected* 
     
        
Table 4.3.2 Comparison of the retention (kg) of reported biomarkers of toxicity 






4.3.4 Effect of basic mobile phase pH on poorly retained compounds 
 
     As mentioned previously, it is of great interest to retain highly polar analytes that 
elute early near or in the void volume of an LC/MS/MS analysis. Therefore part of the 
study was to evaluate the effectiveness of utilizing high pH mobile phases to better 
retain the polar components that elute early in the chromatographic run when using 
traditional acidic mobile phases. Due to the fact that many analytes in biological fluids 
are basic in nature, upon exposure to an acidic mobile phase, these analytes will be 
present in a charged state. This charged state will in effect make the analyte more polar 
and therefore less likely to retain on a reversed-phase column.  
 
 
Figure 4.3.7 Summed MS spectra of first two minutes of human urine separated by 
LC/MS with traditional acidic mobile phase modifier.  
Urine 1:100
m/z




















Figure 4.3.8 Extracted Ion Chromatogram (XIC) of top five m/z detected in first two 
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Figure 4.3.9 XIC of top five m/z detected in first two minute separation of human urine 
by LC/MS with basic mobile phase modifier.  
 
     However, when basic analytes are exposed to a basic mobile phase, they exist in a 
neutral state and may be more likely to be retained by a reversed-phase system. The data 
displayed in Figure 4.3.1 showed significant increase in retention for the analyte with 
m/z 150.077. These observations lead to the targeted analysis of the analytes eluting in 
the void time of the column. Figure 4.3.7 showed the summed MS spectra for the first 
two minutes of the LC/MS separation of human urine carried out with traditional acidic 
mobile phase. An analysis of the top five most abundant ions was then carried out to 
determine the applicability of utilizing basic mobile phase to increase the retention of 
analytes eluting in the void under traditional acidic mobile phase conditions. As can be 
seen in comparing the XIC for the top five abundant ions in Figures 4.3.8 and 4.3.9 
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     The application of basic mobile phases coupled with positive ESI LC/MS to the 
analysis of biological samples in metabonomic studies shows great promise. It provides 
complementary data to that obtained with traditional acidic based mobile phases and 
results in an increased number of ions detected overall. For many analytes, the use of a 
basic mobile phase increases analyte retention and results in enhanced response in the 
mass spectrometer. This increase in analyte retention did not occur with many highly 
polar compounds that eluted in the column void when chromatographed with the basic 
mobile phase conditions. During this study, it was also noted that by changing the pH to 
a basic system it was possible to resolve compounds that had previously co-eluted on an 
acidic reversed-phase system. The analysis of a real sample set of urines from control 
rats and rats dosed with hydrazine revealed that both the acidic and basic system were 
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Development of a Ceramic Microfluidic Separations LC/MS Platform 
for DMPK and Biomarker Discovery Studies 
 
This chapter is based on the following publication: 
 
 Microfluidic LC–MS for analysis of small-volume biofluid samples: where we have 
been and where we need to go 
Paul D. Rainville 





Many things difficult to design prove easy to performance 






     The use of micro-bore i.d. chromatographic columns is not a new concept, as the 
separation and detection of analytes by micro-column liquid chromatography can be 
traced as far back as the late 1960s by Horvath and contributors [1]. These researchers 
used 1.0 mm i.d. columns packed with pellicular ion exchange sorbents to separate 
nucleotides.  During the mid 1970s, Novotny, Scott and Ishii were all working on 
various aspects of micro-column separations from the miniaturization of LC systems to 
the development of columns [2-4]. These early researchers identified that by reducing 
the i.d. of a chromatographic column, benefits could be realized in sensitivity, reduction 
in the consumption of mobile phases, and the use of smaller sample volumes. The work 
performed by these various researchers during this period is considered to be the 
foundation and premier references for micro-column separations. 
           The coupling of  LC to MS was first accomplished by Victor Talrose and 
followed by MacLaffety and others [5] Some of these early LC/MS interfaces were 
composed of wires or belts whereby the liquid from the chromatographic columns was 
directed, subsequently evaporated, and the sample then introduced into the MS [3, 6]. 
This approach was common with the early MS interfaces which had a limited capability 
to cope with the water content utilized by reversed-phase chromatography, and the 
inadequacies of the vacuum pumping systems made it impossible to introduce the entire 
LC eluent into the MS.        
     Prior to the development of interfaces that could introduce LC column effluent 
directly into a MS, individual chromatographic peaks had to be trapped or isolated, 
concentrated and then introduced into the MS via a probe [3]. This could become a very 




analytes from a complex sample since multiple fractions would need to be collected and 
processed.  
     Therefore a more efficient approach for this type of analysis would be the direct 
linking of the liquid chromatography system with the MS. This process of coupling 
these two powerful analytical techniques however was impeded for a period of time by 
the unavailability of vacuum systems and interfaces that were capable of coping with 
the LC column effluent.   
      The use of capillary columns as a means to overcome some of the potential issues of 
direct on-line sampling was noted by many researchers including Novotny  [7, 8]. This 
idea was introduced as the reduced flow rates required for these columns was much 
smaller compared to conventional columns using flow rates in the range of 0.5 – 2 
mL/min. This therefore  made it more amenable for direct on-line coupling with MS [9]. 
This utilization of micro-scale columns coupled with MS was further investigated and 
utilized by researchers such as J. Henion, and others to solve real analytical 
problems.[10, 11] Throughout the 1980s there were many advances with respect to how 
the LC effluent could be directly introduced into the MS and in the development of 
ionization source [12, 13] . Further in the late 1990s and into the early 2000s much work 
was done in the development of 2.1 mm i.d. columns as a means to directly couple LC 
with MS.  Prior to this the use of 4.6 mm i.d. columns were utilized. Due to the required 
flow rates of 1.4 mL/min or higher, and the inability of MS sources to cope with this 
volume of liquid the flow had to be split before introduction into the MS.  Current 
LC/MS systems with ESI sources are now fully capable of handling flow rates of up to 




      The implementation and wide-spread use of nano and capillary scale LC with MS 
detection occurred during the last decade and was a result of the explosion of work in 
the field of proteomics. Here, 75 -150 µm i.d. columns coupled with MS became the 
workhorse for exploring and identifying the protein component in living organisms [14, 
15]. The primary reason for the use of micro-scale columns for this type of 
chromatography was that the sample size available for the analysis was greatly limited, 
and the increased sensitivity offered by the technique was both necessary and enabling. 
     During the late 1990s, Fraser, Dear et. al. described the first uses of commercial 
capillary LC/MS systems for use in DMPK studies [16, 17]. This work highlighted the 
benefits of utilizing capillary LC coupled with mass spectrometry for both qualitative 
and quantitative bioanalysis. The authors showed the quantification of drugs present in 
biofluid using a minimal sample volume (1 µL of extracted plasma). This technique was 
further utilized to detect low level metabolites in complex biofluids [18].  
    Of the benefits previously listed earlier in this introduction, increased sensitivity has 
the greatest impact in DMPK and biomarker studies.  This increase in sensitivity could 
mean the difference in detecting a critical, low level, metabolite or correctly defining the 
pharmacokinetic (PK) parameters of a dosed medicine. Although interesting, the 
reduced consumption of mobile phases is purely an economic benefit, but could allow 
for the use of costly, exotic mobile phases such as deuterated acetonitrile or methanol, 
as well as chiral additives. The ability to address very small samples has great 
importance in the bioanalytical field.  It can facilitate the analysis of serial sampling 
from tail bled animals. Small sample volumes allows for the use of expensive animal 
models such as genetically engineered mice, where an individual animal can cost 
thousands of dollars. In this case, one does not wish to quickly sacrifice the animal for 




inherent cost associated with the animals. An added benefit of smaller sample volumes 
may be observed in the clinic where fewer traumas will be inflicted during the course of 
a study. With less trauma inflicted, the metabolic profile and body functions will more 
closely resemble the actual healthy or disease state of the subject rather than a stressed 
state. It may also lead to better patient recruitment. 
     Although microfluidics and capillary scale formats are currently utilized in the 
bioanalytical community, they are still not as widely accepted as their larger i.d. column 
counterparts. There are a few reasons for this. First, it is difficult to make dispersion-
free fluidic connections using this scale of chromatography. The cutting and making of 
connections with glass capillary tubing requires an experienced analyst in order to get 
the best possible connection, often requiring both patience and time. Second, smaller i.d. 
columns and tubing can plug easier when sampling complex biofluids, which makes the 
columns less robust. Third, the speed in which analysis can be carried out. The use of 
smaller i.d. columns equates to a lower flow rate being employed and therefore longer 
time to overcome system volumes from injection to detection. Finally the development 
of MS sources that can effectively operate with the coupled LC to exploit optimal 
performance of the MS.  
            In an attempt to overcome these problems and to simplify the operation of 
nano/capillary LC/MS many researchers have investigated the use of fully integrated 
microfluidic devices, often described as “chips” as a means to increase sensitivity and 
reduce sample consumption. [19] Many of these early chip-based separations were 
performed by researchers such as Ramsey with electrophoretic separations [20, 21].  
However the concept quickly migrated from electrophoresis to devices aimed to 
improve the spray/tip connection such as the nanomate™ [22, 23] to LC-based 




[24].  Most of the work directed with these devices has been focused on protein, 
peptides and proteomic based research [24-26], however there has also been work 
carried out with small molecule drugs [27]. 
     In this chapter the development of a 300 µm i.d. ceramic microfluidic device packed 
with sub 2 µm alkyl-bonded porous hybrid – silica particles for the analysis of small 
molecules and peptide analytes in solvent and biological samples is discussed.  This 
chapter will demonstrate the chromatographic performance, robustness, and sensitivity 
benefits, of such a device. The chapter will further describe the development of a closed 
ESI MS  source capable of working at a wide range of capillary voltages  and within the 
operating flow rates of the separations device. Finally the performance of this device 





5.2 Materials and Methods 
 
5.2.1 Chemicals and Materials  
 
     Acetaminophen, antipyrine, atenolol, danazol, desmopressin, dextromethorphan, 
diphenhydramine, erythromycin, fluconazol, propanolol, pentamidine, metoptolol, 
nefazadone, and ammonium acetate (LC/MS grade)  were  purchased from Sigma 
Chemical Co. (St. Louis, MO., USA). Their structures are shown in Table 5.2.1 
Acetonitrile, ammonium hydroxide, formic acid, and methanol were all purchased from 
Thermo Fisher Scientific (Pittsburgh, PA, USA). Alprazolam, and the hydroxyl 
metabolite were obtained from Cerilliant (Round Rock, TX, USA). Salmeterol was 
purchased from Toronto Research (Toronto, Canada) Rat plasma was obtained from 
Equitech-Bio (Kerrville, TX, USA). Water was obtained from an in-house milli Q 
filtration system. 
 
Number Compound Structure Class Indication 
1 Acetaminophen 
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5.2.2 Preparation of gradient test mix 
 
     Atenolol, pentamidine, metoprolol, antipyrine, dextromethorphan, diphenhydramine, 
erythromycin, and danazol were dissolved in methanol at a concentration of 1 mg/mL to 
make stock solutions. The individual analytes were then combined and diluted with a 
solution of 95:5 warter:methanol to produce a dilution series from 0.1 ng/mL to 1000 
ng/mL. 
5.2.3 Preparation of alprazolam test mix 
 
     Alprazolam, and  hydroxyl-alprazolam metabolite were dissolved in 50:50 methanol: 
water and further diluted with 95:5 water:methanol to produce spiking standards. The 
spiking standards were then diluted in rat plasma to produce a dilution series. A simple 
protein crash was then performed using a 2:1, acetonitrile:plasma mix. The samples 
were vortex mixed and then centrifuged at 13,000 RCF for 10 minutes. The supernatant 
was then removed and diluted 50:50 with H2O. 
5.2.4 Preparation of prototype MS source desolvation gas/temperature test 
 
     Acetaminophen, dextromethorphan, fluconazole, and verapamil were dissolved in 
methanol at a concentration of 1 mg/mL. The samples were then diluted with a solution 
of 50:50 methanol: water with 0.1 % formic acid (v/v) to a concentration of 50 ng.mL. 
All compounds were infused at their optimal capillary and cone voltages at 10 µL/min. 
5.2.5 Preparation of standards for LC platform comparison 
 
     Alprazolam, hydroxyl alprazolam, fluconazole, and nefazodone were dissolved in 




95:5 (water:acetonitrile) to make a concentration series from 0.01 ng.mL to 1000 
ng/mL. Desmopressin was dissolved in 95:5 (water with 0.1%formic acid:acetonitrile). 
Samples were then diluted with the same solution to make a concentration series 
from1000 ng/mL to 0.1 ng/mL. 
5.2.6 300 µm i.d. Chromatography 
 
     Chromatography was carried out on a modified nanoACQUITY™ UPLC system 
(Waters Corporation, Milford, MA, USA) equipped with a prototype ceramic 
microfluidic device (CMFD) with a 0.3 mm x 100 mm channel packed with 1.7 µm 
BEH C18. The CMFD was thermostatically controlled at 45 ˚C. Control of device 
temperature was accomplished via the use of insulating material and an electrical heater 
controlled via resistance adjustment. The mobile phase consisted of A: 0.1% formic 
acid, or 0.1 % ammonium hydroxide, or 10 mM ammonium acetate, adjusted to pH 3.0 
or 10.0 and B: acetonitrile. The analytes were eluted under a linear gradient from 5 – 95 
% B at a flow rate of 10 – 12  µL/min on the UPLC system The column effluent from 
the system was routed into a Xevo TQ mass spectrometer operated in electrospray 
positive ionization mode and in SRM mode acquisition.  
5.2.7 Analytical Scale Chromatography 
 
      1 µL of each sample was injected onto an ACQUITY® Ultra Performance LC® 
separations module (Waters Corporation, MA, USA). Chromatography was performed 
on a 2.1 x 50 mm 1.7 µm ACQUITY BEH C18 column. Mobile phase A consisted of 
water with formic acid (0.1% v/v) while mobile phase B consisted of  acetonitrile. The 
column was maintained at 45 ˚C and eluted under linear gradient conditions from 5 to 





5.2.8 Mass Spectrometry  
 
     Mass spectrometry was performed on a Waters Xevo™ TQ mass spectrometer 
(Waters Corporation, Manchester, UK) equipped with a traditional high flow source 
modified with a narrow bore (75 µm) steel capillary and a prototype modified 
electrospray interface. Capillary, cone and collision energies were optimized for each 
compound.  The mass spectrometer was operated in SRM mode. Table 5.2.2 lists the 
transitions and conditions utilized for each of the compounds analyzed in this work. 
Desolvation gas flow and temperature were also optimized. 
 
Compound Name Cone (V) Collision Energy (eV) SRM 
    Alprazolam 40 25 309.2 > 281.0 
Alprazolam OH 40 25 325.0 > 297.0 
Antipyrine 36 26 189.3 > 106.3 
Atenolol 30 24 267.2 > 144.9 
Danazol 30 24 338.3 > 148.0 
Desmopressin 18 16 535.5 > 328.2 
Dextromethorphan 40 38 272.3 > 171.0 
Diphenhydramine 14 12 256.3 > 167.1 
Erythromycin 28 32 716.8 > 158.1 
Fluconazole 28 16 307.2 > 220.0 
Nefazodone 48 34 470.3 > 246.1 
Metoprolol 24 14 262.2 > 233.0 
Pentamidine 40 38 341.3 > 120.0 
 






5.2.9 Converting a nanoACQUITY UPLC system for non proteomics based 
application work 
 
     The Waters nanoACQUITY UPLC system as designed by K. Fadgen et. al. was 
designed as proteomics based nano to micro-bore scale LC system to interface with MS, 
primarily, Q-TOF based mass analyzers. In order to optimize the system for drug 
metabolism and bioanalytical work several attributes of the system had to be addressed 
in order for the system to accommodate the sub 2 µm chromatographic particle CMFD. 
     The first of these was to extend the upper limit of the operating pressure range of the 
system. This was achieved through the use of an algorithm that enables the system to 
operate above the previous upper pressure limit of 5000 psi up to a limit of 15,000 psi.  
In addition to this change, tubing(s), and flow sensors needed to be replaced with higher 
pressure tolerant variants.   
     In addition to enabling the increased upper operating pressure limits of the LC 
system the removal of system pressure ramping was also addressed. The use of pressure 
ramps for standard proteomic applications is based on the fact that in most proteomic 
analysis a two dimensional chromatographic plumbing configuration aims first of all to 
decrease sample loading time and then provide increased resolving power by increasing 
chromatographic selectivity and the means to efficiently separate complex proteomic 
samples. The pressure ramps were originally instituted in an order to remove any issues 
with flow sensor compensation created by the pressure differences related to column 
lengths, i.d.s or particle size or any further configuration of these combinations. 
Therefore this ramping capability was removed from the software to provide for the 




     The last major modification that was carried out was the installation of fittings and 
tubings that could withstand high pH, i.e. mobile phase pH values greater than eight. 
The impetus for the desire to make these changes in the LC system in order to operate at 
higher pH levels was shown previously in Chapters 2 through 4. This modification was 
accomplished through the use of highly polished silica-capillary tubing. This highly 
polished silica-capillary tubing impedes dissolution of the silica material by limiting the 
exposure of the basic solution to the silica tubing surface by decreasing the surface area 















5.3 Results and Discussion 
 
5.3.1 Construction of the CMFD 
 
     High-temperature co-fired ceramics (HTCC) technology has been widely used in the 
production of multilayered electronic circuits.  Unlike common printed circuit board 
(PCB) technology the HTCC fabrication process enables passive electronic components 
to be embedded with multiple layers on ceramic material resulting in a high density 
complex board in a very small scale.  This same principle has been implemented to 
create a microfluidic device.  Instead of using a multi-layered technique to embed 
electronic components, fluidic channels are created within the device.  Thereafter the 
device was packed with chromatography media at high pressure creating a compact 
efficient chromatographic column. 
     The manufacturing process begins with a raw material called “green” tape it is 
referred to as “green” because of its virgin quality as it has not been manipulated in 
manufacturing process(s). Figure 5.3.1 shows an example of the “green” tape before the 
CMFD manufacturing process.  The tape consists of ceramic material and organic 






Figure 5.3.1 Picture of green tape before development process. Figure courtenay of 
Waters Corporation 
     A precision UV micromachining system is used to create a microfluidic channel on a 
single sheet of tape.  The thickness of the tape defines the ultimate height of the 
microfluidic channel, the width of the laser cut determines the channel width.  The 
centre layer is sandwiched by two pairs of sheets closing off the channel creating either 
a square or rectangular cross section.  Vias are placed through the top two layers of 
green tape above the origin and the terminal end of the channel to serve as ports to 
direct fluid into and out of the device. 
      The five-layered stack of green tape is laminated under isostatic pressure and 
elevated temperature ensuring that all layers are in direct contact prior to firing.  The 
firing process occurs in two steps: An initial low-temperature organic burnout is used to 
remove the organic binder.  Following this stage, the furnace temperature is slowly 




ceramic glass particles begin to melt and flow while the structure of the device and 
internal features are maintained.  This process is shown in Figure 5.3.2. The 
densification which accompanies the sintering process results in a monolithic structure 
with an embedded channel able to withstand high pressures.  In this prototype device a 
0.3 mm i.d. channel was capable of 13 kpsi. At this stage the device can be packed with 






















5.3.3 CMFD packing procedure. 
Step 3:
Attach the fritted capillary to the outlet end of tile, then 
connect the transport line from chamber to the inlet end
Step 1
Make Slurry : 25mg of BEH C18 1.7µm 
add to 0.5 ml of acetone 
Step 2:
Pipette in 0.5ml of slurry to the 
chamber and close 
Step 4:
Ramp pump to a max pressure of 10,000 psi in 10 to 15sec . Hold pressure until 
packing material is observed at the inlet end .Once completed decay pressure
Step 6:
Next morning G-shield both inlet and 
outlet via's and let dry under lamp for 1 hr 
Step 5:
Remove fittings and place the tiles 
under lamp to dry overnight
Step 7:
Place tile in oven with 3ml of water and 






























5.3.2 Chromatographic performance and efficiency 
 
       One of the most important factors to be considered when evaluating a new 
separations device format is the chromatographic performance.  The performance of the 
system was tested in both isocratic and gradient mode. This approach would allow for a 
true evaluation of the separation performance of the system across all applications areas. 
The chromatographic performance of the prototype device, Figure 5.3.5 and 5.3.6, was 
compared to that of a 0.3 mm capillary column packed with identical separation media, 
1.7um C18 bonded bridged ethyl-hybrid silica material.  The isocratic performance 
efficiency for a 0.3 mm x 100 mm packed column was determined to average 10,219 
plates for n=6 and that of the prototype microfluidic device was measured to be 9038 






















Figure 5.3.7 Example packing efficiency test for CMFD. 
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    Table 5.3.1 Plate count (N) for multiple standard capillary columns and CMFDs.      
      The reversed-phased gradient performance of the system was investigated using a 
test mix modeled on samples previously developed by Astra Zeneca (AZ) for testing of 
capillary LC performance.  A linear aqueous ammonium acetate pH 3.0 and acetonitrile 
gradient of 5-95% over 6 minutes at a flow rate of 10 µL/min was employed for the 
analysis.  The tile was maintained at 45 ºC. The analyte detection was performed on a 
tandem quadrupole mass spectrometer equipped with a low volume, 75 um internal 
diameter, and stainless-steel capillary to limit chromatographic peak dispersion. The 
result of this test can be seen in Figure 5.3.8. The data  observed for the CMFD showed 
gaussian peak shape for all analytes within the test mixture and a average peak width 
between 4 and 7 seconds, measured at peak base, producing a peak capacity of 55 for 
this separation of six minutes. In addition the chromatographic performance; 
rudimentary four point calibration of each of the components, dissolved in 95:5 
water:ACN, was carried out over a range of 0.1 ng/mL to 100 ng/mL.  The data in 
Figure 5.3.9 shows the calibration line for atenolol. Here we observe good linearity of 
the compound over the previously described concentration range, with a linear, 1/x fit 




Table 5.3.2. for the additional compound in the AZ test mix. Again good linearity was 
obtained for the rest of the compounds with the exception of erythromycin due to the 
detection of multiple peak under the conditions utilized during the test.  
 
 






Figure 5.3.9 Four point calibration line of atenolol solvent standard from 0.1 ng/mL – 
100 ng/mL.  
Compound Curve type  Weighting Correlation coefficient 
    antipyrine linear 1/x 0.991152 
danazol linear 1/x 0.998556 
dextromethorphan linear 1/x 0.999312 
diphenhydramine linear 1/x 0.998637 
erythromycin 
   metoprolol linear 1/x 0.999817 
pentamidine linear 1/x 0.998515 
     
Table 5.3.2 AZ test mix calibration line weighting and correlation coefficients for 




 Compound name: atenolol
Correlation coefficient: r = 0.999688, r^2 = 0.999375
Calibration curve: 7357.4 * x + -112.089
Response type: External Std, Area
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None
ng/mL
















5.3.3 Ceramic microfluidic device reproducibility  
 
    Reproducibility of a bioanalytical separation is a key aspect that must be assessed 
during method development in order for the method to be successfully implemented for 
validation and subsequent use by the analytical laboratory for the analysis of clinical 
samples. Maintenance of chromatographic resolution between parent drugs and their 
associated metabolites is especially important as conversion of drug metabolites may 
convert back to their parent form in the source of the MS [28]. The result of this in-
source conversion process is that the levels of the parent drug may be overestimated 
leading to erroneous results being reported by the analytical team to the clinicians. 
Therefore and evaluation of four prototype 0.3 mm x 100 mm CMFDs was carried out 
utilizing the probe pharmaceutical and the hydroxylated metabolite as a critical 
resolution pair to assess the reproducibility between different ceramic tiles. The 
chromatogram displayed in Figure 5.3.10 illustrates the separation between parent drug 
and metabolite.  
 
Figure 5.3.10 Separation of alprazolam and hydroxyl metabolite utilized to assess 




The separation utilized a fast three minute gradient at a flow rate of 12 µL/min with the 
tile thermostatically controlled at 45 ºC.  1 µL injection volume of the compound 
solvent standards was utilized. Table 5.3.3 shows the data for four different 0.3 x 100 











     Retention time Alprazolam  1.55 1.57 1.56 1.56 
% RSD 0.33 0.00 0.94 0.35 
     Retention time OH 
Alprazolam  1.45 1.48 1.46 1.46 
% RSD 0.28 0.55 0.80 0.27 
     Rs at 5% height 1.50 1.20 1.33 1.17 
 
Table 5.3.3 Reproducibility between four 0.3 x 100 mm CMFDs.  
      The data shown in Table 5.3.3 indicates that the ceramic tiles showed very 
reproducible separations of alprazolam and hydroxyl-alprazolam metabolite for four 
different ceramic tiles. This indicates that the packing procedure is capable and 
sufficient for these types of analyses. The data further indicates that the analytical 
system as a whole, ie  autosampler, gradient delivery pumps, and temperature control  
can provide reproducible results while being run at this scale of chromatography.  
5.3.4 Loading capacity example 
 
     When performing any form of LC/MS analysis the sensitivity of the system is partly 
dependent on the mass of material loaded onto the column.  For a fixed concentration of 




peak intensity.  This will be true as long as the injection volume does not adversely 
affect the chromatographic peak shape.  Change in peak shape manifest itself in one of 
two ways: mass overload, or volume overload [29].  In mass overload conditions the 
retention time of the peak is gradually reduced, and the peak takes on a characteristic 
shark-fin shape. In volume overload conditions the centre of the peak remains 
unchanged and the peak broadens in both directions. Both manifestations of 
chromatographic overload reduce the performance and usability of the system. To 
evaluate the maximum injection volume and loading capacity of the microfluidic 
system, two real situations were mimicked; the first was the loading of a model 
pharmaceutical (alprazolam) in an aqueous solution, the second was a bioanalytical 
analysis.   
     In the second case, a solution of alprazolam was prepared in a 60:40 
acetonitrile:aqueous solution and diluted 1:1 with water.  This organo-aqueous mixture 
replicates the situation encountered in drug discovery and some areas of drug 
development where simple protein precipitation with organic solvent is employed.  The 
injection volume was gradually increased from 0.1 µL to 2 µL and the MS response and 
chromatographic peak shape was monitored (Figures 5.3.11 and 5.3.12). From this data 
we can see that for the aqueous solution the peak shape remained stable and the change 
in MS response with injection volume was linear up to an injection volume of 2 uL, 
whereas with the organo-aqueous solution the maximum loading volume was 1.2 uL 
before the peak became distorted.  As the injection is increased beyond 1.2 uL with the 
organo-aqueous solution we see that there is evidence of severe peak 
fronting/shouldering and even the formation of two peaks.  This is due to the high 




carrying the drug analyte through the column.  Thus for this application the maximum 
usable injection volume for a bioanalysis / DMPK type application would be 1 – 1.2 uL. 
 
Figure 5.3.11 Injection series for alprazolam (1000 ng/mL) dissolved in 95:5 
H2O:CH3CN performed under gradient conditions.  
Figure 5.3.12 Injection series for alprazolam (1000 ng/mL) prepared in 33.3:66.6  H2O: 
CH3CN performed  under gradient conditions. 
      The injection volume of 1-1.2 uL compares favorably with the bed volume of 7uL of 
the micro-fabricated device.  As with any form of compound analyzed by reversed-
























strength required to elute the compound.  Hence for these compounds, if injected in a 
lower strength solvent than the starting conditions of the mobile phase, a greater mass 
can be injected onto the column as they can be focused on the head of the column. 
5.3.5 Tolerance towards plasma derived samples  
 
     The sensitivity increase of the micro–scale separation observed in this is attractive to 
the bioanalyst particularly for low volume samples, such as those from tail bled mice or 
genetically modified rodents.  However in order to be an effective analytical technique 
the system must be robust towards the injection of plasma extract on the 
chromatographic system, allowing for routine day-to-day operation.  The majority of 
bioanalytical assays require the analysis of seventy to one hundred samples in a single 
batch with the majority of bioanalyst expecting to obtain five hundred to one thousand 
injections per column.  In order to evaluate the robustness of the CMFD towards plasma 
derived samples rat plasma was spiked with alprazolam and hydroxyl alprazolam 
metabolite at concentrations of 1000 pg/mL.  The several replicate plasma samples were 
processed by protein precipitation with acetonitrile; the resulting supernatant was 
transferred to glass autosampler vials for analysis.  A 1 µL aliquot of the resulting 
solution was injected onto a CMFD that contained a 0.3 x 100 mm column packed with 
1.7 µm C18 organo-hybrid material.  The sample was eluted with a 5-95% reversed 
phase acetonitrile – 0.1% aqueous formic acid gradient over three minutes at 12 µL/min.   
The samples were injected in batches of 100 injections after which the column 
performance was evaluated with the check standard.  The data displayed in Figure 
5.3.13 shows the overlaid injection of the first and one thousandth injection.  The 















Figure 5.3.13 Overlay of pressure traces and separations of alprazolam and hydroxyl 
alprazolam at injection 1 and injection 1000 prepared in protein precipitated plasma.  
5.3.6 Operation of system under high basic conditions and ESI + MS 
 
     The previous three chapters focused on the utilization and benefits of high pH (> 10 
pH units) mobile phases with ESI + MS detection. Based on the results generated from 
these studies the desire to reproduce these types of conditions and to incorporate them 
with methods utilized with  the ceramic tile and nanoscale LC/MS configuration 
described in this chapter would therefore be highly advantageous. Therefore testing was 
carried out to determine the feasibility of utilizing extremely high pH conditions with 




crude ceramic material utilized in the building of the ceramic separations device. 
Incubation of the material was performed in pH 10.5 environment. This was 
accomplished by the addition of 1 mL of ammonium hydroxide to one liter of water.  
Both of the images show that there appears to be no dissolution of the material and the 
morphology of the material appears to be similar after incubation of the ceramic 
material in pH 10.5 solution. The BEH chromatographic particles were not a concern as 
they have been previously demonstrated to be capability to operate at  basic pH [30]. In 
addition the LC system was modified as described in the experimental section in order 
that the capillary tubing and other fitting would be capable of withstanding prolonged 
exposure to these conditions. 
 
 





Figure 5.3.15 Magnified sonogram of ceramic material after 24 hours of incubation in 
pH 10.5. 
    However the modification of the typical silica-based tubing with high-polished silica 
tubing did not withstand the extreme of pH 10.5. The system resulted in over pressure in 
a time period  of roughly 10 samples, one hour of constant run time. Examination of in 
line frits and filters resulted in the determination that the high-polished silica was 
dissolving  when exposed to pH 10.5. Therefore the system was replumbed with the 
high-polished silica tubing and cleaned througly. High pH mobile phases was then 
remade with a pH of 10 utilizing a buffer of ammonium acetate.  The data produced 
with this mobile phase combination yielded stable system back pressure and 
chromatographic sepersations. Figure 5.3.16 below shows an example of alprazolam 





Figure 5.3.16 Separation of alprazolam under pH 10 on ceramic microfliudic device 
and modified nano LC system.  
The chromatogram produced in Figure 5.3.14 had an average peak width of 7 seconds at 
base  +/- 0.08 seconds over a period of six injections and a peak area of 61 area count 
+/- 2 area counts 
       The system was then run continuously over a 7 day period the pressure trace is 
shown in Figure 5.3.17  is an overlay of the system pressure taken at the beginning of 
the day. As can be seen the system pressure is stable and no plugging of any frits, filters 






Figure 5.3.17 System pressure trace over a seven day period run under pH ten 
conditions. 
 
Figure 5.3.18 Overlay of summed spectra over gradient period of six days.  
Overlay of 7 injections run over ~7 
days
Inj. 21 – Day 0
Inj. 80 – Day 1
Inj. 180 – Day 2
Inj. 240 – Day 3
Inj. 340 – Day 4
Inj. 510 – Day 5




     The MS background was further monitored over a six day period with the CMFD in 
line to determine if any chemical bleed or appearance of new additional ions were 
detected over the test period. This study was carried out to ensure an increase in 
chemical noise would not be produced by these method conditions as any increase could 
be indicative of system degradation and lead to contamination of the MS source. 
However, as the data from Figure 5.3.18 shows there was no data to indicate that there 
was any degradation of the system and CMFD under these conditions and for the 
designated test period.  
5.3.7 MS Source Optimization 
 
5.3.7.1 Open versus closed MS Source(s)  
 
      Nano and capillary scale LC has been predominantly exploited in the field of 
proteomics for the detection and characterization of peptides and intact small molecular 
weight proteins.  The majority of the MS sources employed in for these applications can 
be classified as “open-sources” and are not isolated from the general laboratory 
atmosphere. This is in contrast to the ion-spray sources (electrospray or turbo ion-spray) 
that are employed with conventional scale chromatography where the source is isolated 
from the laboratory environment.  This “open-source” construction allows easy 
adjustment of spray position and optimization of response by the scientist, the higher 
mass-to-charge values monitored in proteomics, typically 600 m/z and above ensures 
that the majority of the chemicals present the laboratory atmosphere do not interfere 
with the experiment being undertaken.  However with small molecule analysis these low 
molecular weight compounds present in the laboratory atmosphere can significantly 




the “open-source” construction and “closed-source” construction are shown in Figure 
5.3.19.   
     These results show that the “open-source” possessed significantly more low m/z 
background signal than the “closed-source” construction.  In the closed source there a 
relatively few ions above m/z = 300 with the m/z = 218 ion being the dominant ion, 
where as with the open source the m/z = 148.9 and m/z = 95 ion show a significant 
response as does the m/z = 354 and m/z = 370.9.  While operation in SRM acquisition 
mode on a tandem quadrupole may eliminate or limit any interfering chemical noise 
from the ions illustrated in Figure 5.3.19 there still exists the possibility of interference 
that could influence overall assay sensitivity via ion suppression.  
     This incidence of interference would be exasperated in full scan or SRM mode. This 
could become very problematic when carrying out full scan type work which is often 
the mode of operation when conducting biomarker discovery or “omics” types of 
experiments.  As a result of this all of the experimentation conducted in this study was 








Figure 5.3.19 Summed spectra from blank chromatographic run on closed an open MS 
source. 
5.3.7.2 Capillary voltage  
 
       In  nano spray LC/MS  the column flow rate is in the two hundred to four hundred 
nanolitres  per minute and  electrospray ionization process is assisted by the application 
of a capillary voltage (usually 3kV) to the capillary or spray tip. However, with 
capillary LC the column flow rate in the order of 3 to 10 µL per minute the column flow 
rate is too high for the column effluent to be nebulised by voltage alone.  Thus for the 
capillary scale analysis a heated nebulising gas was added co-axially to the column 
spray tip to assist in the nebulisation process.  There is an additional beneficial factor 
from the use of a nebulising gas and this is analyte response.  The affect of capillary 
voltage on signal response is illustrated in Figure 5.3.20 for the analysis of alprazolam 
operated at five different capillary voltages.   
m/z


















































Figure 5.3.20 Influence of capillary voltage on alprazolam.  
     It can be clearly seen from this data that the use of a 1.0 kV value produces the 
greatest signal response.  An additional drawback to using just the capillary voltage to 
effect ionization is that at low organic solvent compositions the mobile phase becomes 
increasingly difficult to ionize resulting in poor droplet formation at the end of the spray 
tip.  This deleteriously affects the sensitivity of the system for the more polar analytes, 
1 kV 10 ng/mL alprazolam
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which elute with a low k′ value.   These previous statements suggest that, at the 300 µm 
capillary scale, the use of capillary voltage alone is not ideal to promote ionization and 
nebulisation.  As can be seen in Table 5.3.4 many different molecules behave much like 
the alprazolam example in Figure 5.3.18. Here in this table we see that a vast majority, 
80 percent of the molecules tested ionize best below the 3.0 kV setting. In Figures 
5.3.21 and 5.3.22 the influence on the spray is seen at with a capillary voltage of 3 kV 
(Figure 5.3.22) and with a capillary voltage of 1 kV (Figure 5.3.21).  
 
Compound Class Capillary Voltage (kV) 
   Aldosterone Steroid Biomarker 2.5 
Alprazolam Benzodiazepine Sedative 1.0 
Lidocaine Amide Anesthetic 2.1 
Fluconazole Trazole Antifungal 0.5 
Propranolol Beta Blocker 3.2 
Verapamil Calcium Channel Blocker 2.0 
Danazol Steroid  1.7 
Nortriptyline Tricylic Antidepresent  2.0 
Acetaminophen Aniline Analgesics 0.5 
Desmopressin Peptide Hormone 3.0 
   





Figure 5.3.21 Column effluent exiting MS capillary probe with 1 kV applied. 
 




5.3.8 Development of the Prototype MS Source  
 
     The previously discussed points regarding the need for a closed source to the 
laboratory environment and the desire to run lower than 3.0 kV capillary voltage setting 
for small molecule pharmaceutical compounds was the impetus  for the development of 
an ESI source that could operate with these conditions at flow rates in the range of 9 to 
16 µL/min. Therefore a collaborative effort was made with Michael Tomany, Principal 
Engineer, Instrument Research Group, Waters Corporation to assist in the creation of 
such a device. Figure 5.3.23 below shows iteration on the development of the Prototype 
MS source.   
 
Figure 5.3.23  Prototype MS source utilized on tandem quadrupole MS. 
Ceramic micro fluidic device in insulated jacket 
Stage adjustment
Ceramic micro fluidic device 
Temperature control module
Capillary and voltage lead voltage 
Ceramic micro fluidic device 






     The prototype source consisted on an aluminum block modified from a regular high 
flow source. The introduction of the column effluent was directed from the front 
(horizontal) side of the housing in contrast to the top position (vertical) as is normal for 
analytical scale LC. This was done as a manner to reduce the capillary length and thus 
post column dispersion. Figure 5.3.23 shows the prototype MS source utilized to gather 
all of the data within this chapter. Capillary voltage was applied via the jumper clip 
shown in the previous figure and was controlled via the software. The source contained 
adjustment of the capillary position via a x and y axis stage device with independent 
adjustments for each axis as a means to locate the optimal position with respect to the 
entrance cone of the mass spectrometer. The ceramic microfluidic device was connected 
to the source capillary via highly polished fused silica tubing with standard peek fittings 
and polymer sleeves. A further difference with this source design as compared to 
traditional nano flow sources is the ability to have and control desolvation gas flow and 
temperature, a requirement due to the flow rates required to operate the 0.3 mm i.d. 
ceramic microfluidic device under optimal chromatographic conditions.  
     The following Figure (5.3.24a through 5.3.24d) show the signal intensity as a 
function of both desolvation gas temperature and flow rate for acetaminophen, 
dextromethorphan, alprazolam, and verapamil. These compounds were chosen due to 
their range in elution order and thus hydrophobic nature, under reversed-phase 
conditions. Acetaminophen being the least hydrophobic and verapamil being the most 






Figure 5.3.24a Influence of desolvation gas flow and temperature on MS response for 
acetaminophen.  
                  
 


































Figure 5.3.24c Influence of desolvation gas flow and temperature on MS response for 
dextromethorphan.  




















































These results show the different responses for these four compunds have to the change 
desolvation gas flow and temperature.  It can be seen however that at a temperature of 
340 ºC and gas flow of 600 L/hr or greater high signal intensities were obtained for all 
compounds regardlesss of where they eluted durting the reversed-phase gradient. 
 
Figure 5.3.25 Comparison of signal and background noise for alprazolam on prototype 
MS source and conventional high flow source with narrow bore capillary installed.  
0.25ng/mL alprazolam
Time




























































     Once the optimal position, desolvation temperature and gas flow were determined for 
optimal operation of the prototype source a comparison in overall performance based on 
overall signal response and signal to noise was carried out to compare it to a standard 
high flow source modified with the narrow bore capillary.  The data shown in Figure 
5.3.25 shows the increase in signal that was achievable with the prototype source 
compared to the modified high flow MS source. The high flow source was modified 
replacing the standard 120 µm i.d. capillary with a 75 µm i.d. capillary as a means to 
control post column peak dispersion which is pronounced as the diameter of a column is 
reduced.  An important note to make again is the chromatographic performance of the 
system. Exhibited here is a peak width measured at peak base of 3.6 seconds with a 1 
µL injection. This comparison of the two MS sources for the analyte alprazolam 
produced a result of a 1.7 fold increase in sensitivity and a 3.7 fold  increase in the 
signal to noise for the prototype source as compared to the modified high flow source.   
5.3.9 Sensitivity improvement 
 
     Once the MS source was optimized for operation an investigation into the increase in 
area counts, overall MS signal and signal to noise was carried out using multiple 
injections of standards in solvent on both the ceramic microfluidic/MS platform and a 
standard UPLC/MS run on a 2.1 x 50 mm i.d. column. Figure 5.3.26 shows the 
measurement of these parameters from a single 1 µL injection of the nefazodone 
standard (0.01 ng/mL).  In the data from Figure 5.3.26, shows an increase in area 
counts from 329 to 2066, an increase in MS signal from 1.66e4 to 8.01e4, and an 
increase in signal to noise from 12.8 to 158.1 when analyzed on the ceramic 
microfluidic/MS platform versus the traditional UPLC/MS system. Similar results were 




combined results of these comparisons are shown in Tables 5.3.5 and the individual 
compound results from three consecutive injections are shown in Tables: 5.3.6, 5.3.7, 
5.3.8, and 5.3.10.  
    The interest in peptide and protein drugs has seen an increase in recent years from 
pharmaceutical companies. Therefore the inclusion of a peptide drug desmopressin was 
carried out to evaluate the effect of analyzing this class of molecule on each of the 
analytical platforms. The results of this test can be viewed in Figure 5.3.27. Here we 
observe for a single 1 µL injection of desmopressin solvent standard that the ceramic 
microfluidic/MS system yielding an increase in area counts from 250 to 15201, an 
increase in signal to noise from 40 to 1748, and finally an increase in MS signal from 
1.66 e4 to 5.35 e5 compared to the results generated on the traditional UPLC/MS 















Figure 5.3.26 A) area counts B) signal to noise C) signal for nefazodone separated on a 
conventional 2.1 mm i.d. UPLC/MS configuration. D) area counts E) signal to noise F) 













Figure 5.3.27 A) area counts B) signal to noise C) signal for desmopressin separated on 
a conventional 2.1 mm i.d. UPLC/MS configuration. D) area counts E) signal to noise 
F) signal for desmopressin separated on the  CMFD and prototype MS source 









  Area Signal Signal to noise 
Alprazolam 10.1 4.7 8.3 
Alprazolam OH 16.4 6.3 15.5 
Desmopressin 66.6 38.2 38.6 
Fluconazole 12.1 4.7 10.5 
Nefazodone 6.3 5.2 13.5 
 
Table 5.3.5 Combined average area counts, signal, and signal to noise increases for 
small molecule pharmaceuticals analyzed on the ceramic microfluidic/MS system 




Compound name alprazolam 
 
area counts signal signal to noise 
Configuration UPLC/MS 
 
377 27000 44 
   
372 28300 35 
   
353 28500 42 
      
  
AVG 367 27933 40 
  
STDEV 13 814 5 
  
%RSD 3 3 12 
      Compound name alprazolam 
 
area counts signal signal to noise 
Configuration CMFD/prototype MS 
 
3805 127000 363 
   
3589 125700 330 
   
3641 132000 362 
      
  
AVG 3678 128233 352 
  
STDEV 113 3326 19 
  
%RSD 3 3 5 
 
Table 5.3.6 Area counts, signal and signal to noise increases for ceramic microfluidic 




Compound name alprazolam OH 
 
area counts signal signal to noise 
Configuration UPLC/MS 
 
72 6930 9 
   
74 7910 11 
   
66 7690 11 
      
  
AVG 71 7510 10 
  
STDEV 4 514 1 
  
%RSD 6 7 11 
      Compound name alprazolam OH 
 





1182 44000 223 
   
1260 42800 226 
   
1256 42500 220 
      
  
AVG 1233 43100 223 
  
STDEV 44 794 3 
  
%RSD 4 2 1 
      Table 5.3.7 Area counts, signal and signal to noise increases for ceramic microfluidic 













Compound name nefazodone 
 
area counts signal signal to noise 
Configuration UPLC/MS 
 
337 18600 10 
   
329 16600 13 
   
357 15900 11 
      
  
AVG 341 16250 11 
  
STDEV 14 495 2 
  
%RSD 4 3 13 
      Compound name nefazodone 
 
area counts signal signal to noise 
Configuration CMFD/prototype MS 
 
2231 87100 162 
   
2066 80100 158 
   
2106 88500 140 
      
  
AVG 2134 84300 153 
  
STDEV 86 5940 12 
  
%RSD 4 7 8 
 
Table 5.3.8 Area counts, signal and signal to noise increases for ceramic microfluidic 













Compound name desmopressin 
 
area counts signal signal to noise 
Configuration UPLC/MS 
 
223 14000 40 
   
219 12800 50 
   
250 16600 54 
      
  
AVG 231 14467 48 
  
STDEV 17 1943 7 
  
%RSD 7 13 14 
      Compound name desmopressin 
 
area counts signal signal to noise 
Configuration CMFD/prototype MS 
 
15391 568000 2005 
   
15505 556000 1834 
   
15201 535000 1748 
      
  
AVG 15366 553000 1920 
  
STDEV 154 16703 131 
  
%RSD 1 3 7 
 
Table 5.3.9 Area counts, signal and signal to noise increases for ceramic microfluidic 













Compound name fluconazole 
 
area counts signal signal to noise 
Configuration UPLC/MS 
 
676 31000 39 
   
584 28300 45 
   
615 33500 36 
      
  
AVG 625 30933 40 
  
STDEV 47 2601 5 
  
%RSD 7 8 11 
      Compound name fluconazole 
 





7805 140000 464 
   
7583 145000 430 
   
7241 155000 362 
      
  
AVG 7543 146667 419 
  
STDEV 284 7638 52 
  
%RSD 4 5 12 
       
Table 5.3.10 Area counts, signal and signal to noise increases for the ceramic 














          A 0.3 x 100 mm i.d. CMFD and compatible MS source was successfully designed 
for the analysis of biological samples for use in DMPK laboratories. The device showed 
average chromatographic efficiencies of 9038 plates compared to 10219 plates for 
standard silica capillary columns. Gradient performance utilizing a diverse mix of 
compounds yielded a peak capacity of 55 as the average peak widths for all analytes 
was 0.11 minutes for a 6 minute separation.  
     Resolution of the probe pharmaceutical alprazolam and associated hydroxyl 
metabolite was maintained between 1.2 and 1.5 for four different devices. Testing of the 
device with plasma samples prepared by protein precipitation resulted in over 1000 
injections being carried out over approximately a one week period while maintaining 
resolution of alprazolam and associated hydroxyl metabolite. Furthermore no dramatic 
increase in system back pressure was observed over this test period.  
     Sample volume loading studies resulted in the successful loading of 2 µL of 
alprazolam in a 95:5 H2O:CH3CN solution. This volume was approximately 30 percent 
of the open channel volume, and is equivalent to an injection volume of 98 µL on a 2.1 
mm i.d. column. Loading of the same analyte from acetonitrile protein precipitated 
plasma, yielded a top injection volume of 1.2 µL before significant peak fronting was 
observed. The volume represents a 60 µL injection on a 2.1 mm i.d. column.  
     The system was unable to withstand the high pH (10.5) utilized in the previous 
chapters. This was most likely due to the dissolution of the silica-tubing resulting in line 
plugging and system overpressure.  However the ceramic material appeared stable with 
incubation with the 10.5 pH solution as the morphology and appearance was observed 




     MS source optimization studies indicated the requirements for operation of lower 
capillary voltages for many of the small molecules tested which cannot be achieved with 
conventional nano-spray source which typically requires 3 kV to produce a stable spray. 
Further a closed source resulted in less background noise observed. The resulting MS 
source built to operate under these conditions and with the flow rates required to operate 
the 0.3 x 100 mm CMFD yielded increases in  signal-to-noise in the range of 8.3 to 38.6 
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Applications using a Ceramic Microfluidic Device coupled with Mass 
Spectrometry for DMPK and Metabonomic Studies 
 
This chapter is based partially on the following publication: 
Addressing the challenge of limited sample volumes in in vitro studies with capillary-
scale micro-fluidic LC–MS/MS 
 
Paul D. Rainville, Norman W.  Smith, Ian D. Wilson, Jeremy K. Nicholson, Robert S. 
Plumb 














     Advances in the generation of specific model animals through the use of genetics can 
be used to investigate the potential treatment of a variety of diseases. However, animal 
models, including genetically modified and “knock-out” mice, more traditional 
mutation-derived models such as the Zucker rat [1] (a model for type II diabetes) and 
germ free axenic rats [2]come with a significant economic cost. This, combined with the 
ethical drive to reduce, replace and refine such experimentation so that a minimum 
number of animals are used has resulted in a drive to reduce sample volumes to the 
extent that a complete PK profile is obtained from a single animal, via low volume 
sampling techniques such as dried blood spots (DBS).   
     The ability to acquire meaningful PK information from very small sample volumes 
would allow for serial tail bled sampling [3] and expand the potential of these animal 
models, while also improving the quality of the data, and also reducing the amount of 
drug material needed for the study further lowering costs, thus enabling studies to be 
performed earlier in discovery.  The low sample volumes available from such studies 
require much greater sensitivity from the analytical system compared to those typically 
obtained for conventional LC/MS/MS analysis (ca. 100-200µL of plasma). Furthermore, 
the need to extract the maximum information from the previously described animal 
models biofluids during the drug development process means that multiple assays are 
generally required. These include analysis by a variety of analytical methods such as 
bioassays, NMR, LC,  and GC and hyphenated MS techniques.  
      In this chapter these challenges are addressed by a Ceramic Microfluidic Device 
(CMFD) in both quantitative and qualitative DMPK applications.   The CMFD/MS 




alprazolam and sitamaquine. These samples were prepared by protein precipitation and 
by DBS respectively. Experiments were carried out to determine the feasibility and 
high-throughput capability of the approach for standard bioananalytical studies. This 
technique was also utilized to interrogate human liver microsome incubations of 
propranolol and further in the profiling of axenic rat urine and dog bile for the purposes 
of metabonomic and biomarker discovery studies. Comparative separations carried out 
with traditional 2.1 mm i.d. chromatography columns and the CMFD were  performed 
utilizing axenic rat urine in order to determine any increases in sensitivity and signal to 
noise capability.  The combination of basic mobile phases with the CMFD/MS system 
operating in ESI + was also explored as a strategy for increasing assay sensitivity in 
biomarker profiling studies.  




6.2 Materials and Methods 
6.2.1 Chemicals and Materials 
 
     Propanolol, monobasic sodium phosphate, dibasic sodium phosphate, and bile acids 
were purchased from Sigma Chemical Co. (St. Louis, MO., US).  Ammonium acetate, 
ammonium hydroxide, formic acid, methanol and acetonitrile were all purchased from 
Thermo Fisher Scientific (Pittsburgh, PA, US) Human liver microsomes and co-factors 
were purchased from BD Biosciences (San Jose, CA, USA) Alprazolam, deuterated 
internal standard, and the hydroxyl metabolite were obtained from Cerilliant (Round 
Rock, TX, USA). Rat plasma was obtained from Equitech-Bio (Kerrville, TX, USA). 
Sitamaquine and sitamaquine D10 were supplied by Dr. Chet Bowen from 
GlaxoSmithKline Upper Marion PA USA). Dog bile was supplied by Dr. Ian Wilson 
from Astra Zeneca (Maccelsfield, UK). Axenic rat urine was supplied by Professor 
Jeremy Nicholson, Imperial College (London, UK).   Water was obtained from an in-
house milli Q filtration system. 
6.2.2 Sample Preparation (alprazolam bioanalytical assay) 
 
     Alprazolam, deuterated internal standard (IS), and its hydroxyl metabolite were 
dissolved in 100 % methanol. Stock solutions were then diluted with 95:5 
water:methanol and spiked into rat plasma producing a dilution series ranging from 0.1 
ng/mL to 500 ng/mL. A simple protein precipitation was then performed using a 2:1, 
acetonitrile (with IS): plasma mix. The samples were vortex mixed for one minute and 
centrifuged at 13,000 RCF for 10 minutes. The supernatant was then removed and 





6.2.3 CMFD/MS (alprazolam bioanalytical assay) 
 
      A 1.2 µL injection of the sample was then made onto the nano ACQUITY UPLC 
system. The mobile phase consisted of A: 0.1% formic acid and B: acetonitrile. The 
analytes were eluted under a linear gradient from 5 – 95 % B in 2.0 minutes at a flow 
rate of 12 µL/min on a modified nanoACQUITY system equipped with a prototype 
CMFD with a 0.3 mm x 100 mm channel packed with 1.7 µm BEH C18 which was 
thermostatically controlled at 45.0˚  C. The column effluent from the system was routed 
into a Waters Xevo TQ equipped with a prototype ESI source as described in Chapter 5. 
The mass spectrometer was operated in electrospray positive and in SRM mode.  
Compound SRM m/z 
Cone 
(V) Collision Energy (eV) 
Alprazolam 309.2 > 281.0 40 25 
Alprazolam D5 314.2 > 286.1 40 25 
Alprazolam OH 325.0 > 297.0 40 25 
 
Table 6.2.1 SRM transitions and MS conditions utilized for alprazolam assay. 
6.2.4 Sample Preparation (metabolic profiling) 
     Rat liver microsomes were stored at –80.0˚C. They were thawed and re-suspended in 
a phosphate buffer solution at a ratio of 1:15 (v/v).  The co-factor solution was prepared 
by adding 1.6 mL of cofactor solution A and 0.32 mL of cofactor solution B to 10.9 mL 
of phosphate buffer. Microsomal incubations were carried out as described in reference 
[4].  Briefly, 100 µL p450 substrates + 100 µL test compound + 100 µL cofactor 
solution + 100 µL phosphate buffer were combined and placed into a 2 mL, 96 well 
plate and heated to 37.0 ˚ C for 10 minutes. Rat  liver microsomes were then added in 
100 µL increments and the 96 well plate was then incubated at 37 ˚C while shaking for 




acetonitrile (4˚C). Controls were included consisting of a quenched incubation at time 0 
and an incubation containing no test compounds. 
6.2.5 CMFD/MS (metabolic profiling) 
 
      A 1 µL injection of the sample was then made onto the nanoACQUITY UPLC 
system. The mobile phase consisted of A: 0.1% formic acid and B: acetonitrile. The 
analytes were eluted under a linear gradient from 5 – 95 % B in 10 minutes at a flow 
rate of 10 µL/min on a modified nano ACQUITY system equipped with a CMFD with a 
0.3 mm x 100 mm channel packed with 1.7 µm BEH C18 thermostatically controlled at 
45.0˚ C. The column effluent from the system was routed into a Waters Xevo TQ 
equipped with a prototype ESI source as described in Chapter five. The mass 
spectrometer was operated in electrospray positive and in SRM mode, full scan mode, 
and parent scan mode.  
6.2.6 Sample preparation (bile acid profiling) 
 
     Bile acid stock standards where dissolved in 95:5 water:methanol at a concentration 
of 1 mg/mL Bile acids were then diluted to a concentration of 1 ng/mL. Dog bile was 
prepared by diluting with water 1:10 (bile:water), then centrifuged at 13,000 RCF for 5 
minute. 
6.2.7 CMFD/MS (bile acid profiling) 
 
      A 0.2 µL injection of bile acid standards was made onto the nano ACQUITY UPLC 
system. The mobile phase consisted of A: 10 mM ammonium acetate (pH 5) and B: 
acetonitrile. The analytes were eluted under a linear gradient from 20 – 80 % B in 10 
minutes at a flow rate of 10 µL/min on a CMFD with a 0.3 mm x 100 mm channel 




effluent from the system was routed into a Waters Xevo G2 QTof equipped with a 
prototype ESI source as described in Chapter 5. The mass spectrometer was operated in 
electrospray negative ionization and in full scan mode.  
6.2.8  Sample preparation (sitamiquine dried blood spot assay) 
 
    Sitamaquine is an orally active 8-aminoquinoline analog and is GlaxoSmithKline's 
(GSK) potential new once-a-day oral treatment for visceral leishmaniasis, a disease 
caused by protozoan parasites of the Leishmania genus. This disease is the second-
largest parasitic killer in the world (after malaria), responsible for an estimated 500,000 
infections each year worldwide and is usually fatal if untreated Sitamaquine and 
deuterated internal standard (IS) were dissolved in 100 % methanol. Stock solutions 
were then diluted with 95:5 water:methanol and spiked into rat blood producing a 
dilution series ranging from 1 ng/mL to 10,000 ng/mL. Dried blood spot cards (DBS) 
were prepared as previously described [5]. Briefly, a 20 µL spot of blood was placed on 
the DBS and left to  dry. Spots were then cut out with a 7 mm punch and placed into a 
tube with methanol containing the IS and vortex mixed for 60 minutes. The samples 
were then centrifuged at 13,000 RCF for five minutes, and subsequently diluted with 
water (50:50) 
 
6.2.9 CMFD/MS (sitamiquine dried blood spot assay) 
 
     A 1.2 µL injection of the sample was then made onto the nano ACQUITY UPLC 
system. The mobile phase consisted of A: 0.1% formic acid and B: acetonitrile. The 
analytes were eluted under a linear gradient from 30 – 70 % B in 2.5 minutes at a flow 




CMFD with a 0.3 mm x 100 mm channel packed with 1.7 µm BEH C18 thermostatically 
controlled at 45.0˚  C. The column effluent from the system was routed into a Waters 
Xevo TQ equipped with a prototype ESI source as described in Chapter 5. The mass 
spectrometer was operated in electrospray positive and in SRM mode. These conditions 
are listed in Table 6.2.2. 
Compound SRM Cone (V) Collision Energy (eV) 
Sitamaquine  344.3 > 271.2 35                  27 
Sitamaquine D10 354.2 > 271.2 35 27 
 
Table 6.2.2 SRM transitions and MS conditions utilized for sitamaquine assay. 
6.2.10  Sample preparation (metabonomic study) 
 
     Rat urine was diluted 1:4 (urine:water), vortex mixed and then centrifuged at 13,000 
RCF for five minutes. 
6.2.11 CMFD/MS  (metabonomic study) 
 
     A 2 µL injection of the urine sample was then made onto the nano ACQUITY UPLC 
system. The mobile phase consisted of A: 0.1% formic acid or 10 mM ammonium 
acetate pH 10 and B: acetonitrile. The analytes were eluted under a linear gradient from 
2 –70 % B in 10 minutes at a flow rate of 12 µL/min on a modified nano ACQUITY 
system equipped with a prototype CMFD with a 0.3 mm x 100 mm channel packed with 
1.7 µm BEH C18 thermostatically controlled at 45.0˚ C. The column effluent from the 
system was routed into a Waters Xevo G2 QTof equipped with a prototype ESI source 
as described in Chapter 5. The mass spectrometer was operated in electrospray positive 




6.3 Results and Discussion 
 
6.3.1 Quantitative assay for alprazolam derived from plasma and sitamiquine from 
whole blood.  
       Previous work by Fraser et a.l. and other illustrated the use of capillary scale 
LC/MS for the analysis of biofluids [3, 6].  In this study the CMFD/MS system was 
implemented for the quantitative analysis of alprazolam in rat plasma. The study further 
investigated the compound sitamaquine derived from whole rat blood and prepared from 
DBS.  Figure 6.3.1 shows the structure of alprazolam. Alprazolam is a short acting 
benzodiazepine used for the treatment of moderate to severe anxiety disorders, panic 
attacks, and as an adjunctive treatment for anxiety associated with clinical depression. It 
was previosly described in Chapter 3 of this thesis. 
 
 






Figure 6.3.2 Separation of alprazolam (5 ng/mL) and D5 alprazolam derived from 
protein precipitated rat plasma on CMFD/MS.  
Here we observe good peak shape for both of these analytes with a peak width of 4.2 
seconds measured at the peak base for each of the analytes in the separation. This 
resulting peak width generated by the CMFD is slightly larger than the average peak 
widths of between 2.5 and 3 seconds, measured at peak base, that are normally 
generated  by standard 2.1 mm i.d.,  1.7 µm columns. However this result is still 
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Figure 6.3.3 Limit of detection for alprazolam assay at 0.1 ng/mL level.  
      The limit of detection (LOD) was determined to be at the 0.1 ng/mL where a signal 
to noise value of 6.48 was obtained (Figure 6.3.3). While the lower limit of 
quantification (LLOQ) was determined to be 1 ng/mL at this level, the calibration line 
was created with all deviation (residual)  values below 15 percent. Figure 6.3.4 shows 
the calibration line for alprazolam over the range of 1 ng/mL to 500 ng/mL. The 
correlation coefficient was determined to be greater than 0.99 for the multi replicate 
calibration curve.  
Alprazolam 0_1 ng/mL
Time
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Figure 6.3.4 Calibration line and residuals for alprazolam assay.   
This data shows that the system is capable of generating data of sufficient quality and 
sensitivity with appropriate throughput (<5 minute cycle time), for discovery 
bioanalysis.   
          A further assay was developed on the CMFD/MS system utilizing the DBS 
format. DBS has gained much attention and ongoing research in the bioanalytical 
community and in the literature for the last few years [5, 7, 8]. The purported 
advantages of this technique include: First, the need for remarkably lower blood 
volumes and second, easier shipping and storage, often at ambient temperatures. This 
leads to a simplification of the blood collection process and a reduction in the costs 
involved. Moreover, in preclinical studies the number of animals can be reduced due to 
the need for lower blood volumes which is in accordance with the 3R requirement of 
animal studies (replacement, reduction, refinement). Sitamaquine and D10 deuterated 
Compound name: Alprazolam
Correlation coefficient: r = 0.999346, r^2 = 0.998692
Calibration curve: 0.0949026 * x + -0.0182317
Response type: Internal Std ( Ref 2 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Include, Weighting: 1/x, Axis trans: None
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sitamaquine were obtained from Chet Bowen (GSK Upper Marion PA, USA). Samples 
were prepared onto a Whatman FTA© DMPK card as outlined in section 6.2.8.  
    Sitamaquine (Figure 6.3.5) 8-aminoquinoline analog and is GlaxoSmithKline's 
(GSK) potential new once-a-day oral treatment for visceral leishmaniasis [9]. 
 
Figure 6.3.5 Structure of sitamaquine.  
 
      An example chromatogram produced by the CMFD/MS system for the sitamaquine 
assay is shown in Figure 6.3.6. The peaks for both the sitamaquine and IS both show an 
increase in peak tailing compared to the previous alprazolam example. However, the 
peak width is still rather impressive as the peak width at base generated for both 





Figure 6.3.6 Separation of sitamaquine (50 ng/mL) and D10  sitamaquine derived from 
DBS of whole rat blood on CMFD/MS system.  
      
10 ng/mL sitamaquine DBS 
Time
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Figure 6.3.7 Limit of detection for sitamaquine DBS assay at 10 ng/mL level.  
     The limit of detection (LOD) was determined to be at the 10 ng/mL where a signal to 
noise value of 6.48 was obtained (Figure 6.3.7). While the lower limit of quantification 
(LLOQ) was determined to be 50 ng/mL as at this level, the calibration line was created 
with all deviations (residual) within 15 percent of the theoretical value. Figure 6.3.8 
shows the calibration line for sitamaquine over a range of 50 ng/mL to 10,000 ng/mL. 
The correlation coefficient was determined to be greater than 0.99 for the multi replicate 
calibration curve.  
1ng/mL sitamaquine DBS 
Time
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Figure 6.3.8.Calibration line and residuals for sitamaquine assay.   
As with the previous alprazolam assay the CMFD/MS system is capable of generating 
data of sufficient quality and sensitivity with appropriate throughput i.e. < 5 minute 
cycle time.  This means that the methods are truly fit for purpose from an economic 
point of view.           
     The chromatographic performance of the CMFD/MS device is more than acceptable, 
especially if one considers that the injection volumes utilized in this study, (1.2 µL) is 
equivalent to loading 58.8 µL onto a standard 2.1 column. Also a LLOQ of 1 ng/mL is 
an acceptable value for many LC/MS bioanalytical assays of pharmaceuticals in 
biofluids during discovery DMPK studies.  This injection volume represents 17 percent 
of the volume of the unpacked, open cylinder volume in µLs. As shown by Figure 
5.3.11 in the previous chapter, when using a simple protein precipitation approach, the 
volume that can be loaded onto the system is limited.  Thus the overall detection limit 
may not be improved compared to that of a 2.1mm i.d. column packed with the same 
Compound name: Sitamaquine
Correlation coefficient: r = 0.999582, r^2 = 0.999164
Calibration curve: 0.00106664 * x + 0.0152894
Response type: Internal Std ( Ref 2 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Include, Weighting: 1/x, Axis trans: None
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material and operated at the same mobile phase linear velocity, as a greater volume of 
sample can be therefore loaded onto this i.d. column that may not be feasible with the 
0.3 µm i.d. device utilized in this study.  The CMFD/MS devices thus may have two 
main areas of application; i) when sample volume is limited and ii) when samples 
containing the analyte of interest can be concentrated into a sufficiently small volume. 
However in this case, depending on analyte concentration, a situation of creating a mass 
overload situation could prove detrimental as severe band broadening may occur. This 
situation will be illustrated in section 6.3.3. 
6.3.2 Metabolic profiling of propranolol  
 
      Drug metabolism plays a key role in the drug discovery and development phases, as 
critical sites of metabolism or soft spots are identified [10], and differences in species 
metabolism need to be investigated [11]. The study of the drug metabolism of new 
chemical entities can reveal information not only on the fate of a molecule but also 
changes in the endogenous metabolic profile resulting from drug administration,  
yielding useful potential biomarker information [12, 13].  This information can be used 
to detect the presence of potentially toxic metabolites and monitor the efficacy of a 
treatment [14, 15]. In this section of Chapter 6, the application of the CFMD/MS for the 
analysis of metabolites of the model beta blocker propranolol following incubation with 
rat liver microsomes, is presented.   
     The applicability of the CFMD approach for in vitro drug metabolism analysis was 
evaluated using an incubation of the betablocker propranolol with rat liver microsomes.  
As indicated in the experimental section, MS data were acquired using a combination of 




MRM-Dual Scan mode. In this last mode the tandem quadrupole mass spectrometer is 
able to rapidly switch between MS and MS/MS mode during a single run [16].  
       The positive ESI LC/MS TIC full scan trace for the gradient LC analysis of 1µL 
injection of the 1µMol incubation of propranolol is shown in Figure 6.3.9. 
 
 
Figure 6.3.9 Full MS scan of CMFD/MS separation of propranolol microsomal 
incubation. 
  Herein some thirteen major peaks were detected via this gradient profile. The peak 
widths are somewhat wider than that normally obtained by traditional geometry 
columns packed with sub 2 µm particle materials, where the peak width is typically 2-3 
seconds.  Although the peak capacity is less than that of standard analytical scale sub 
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2µm particle LC it is still sufficient to provide a high quality separation.   The reduction 
in performance may be due to i) high sample load, ii) lower density of the packed 
column bed or iii) the percentage of organic in the sample that was loaded onto the 
column. Thus, considering that with a column length of 10 cm and an internal diameter 
of 300 µm, a 1 µL injection of sample  represents 14 % of the column bed volume the 
resulting peak shapes are quite impressive.  
    
 
Figure 6.3.10 MS/MS spectra of propranolol.  
Propranolol (m/z = 260) eluted with a retention time of 4.2 minutes and gave the 
MS/MS spectrum displayed in Figure 6.3.10.  The fragmentation of propranolol gave 
rise to three major MS spectral peaks at m/z = 183, 157 and 116 and a minor peak at 
m/z 218.  These MS/MS fragmentation results generated here in this study further 
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agreed with data reported from previous research[17]. Therefore these ions were utilized 
as diagnostic fragment ions to search for drug related metabolites in the sample.   
     A 1 µL sample of the 1 µMol incubation of propranolol was injected on to the 
CMFD/MS system operated in survey scan mode thereby collecting both full scan MS 
and MS/MS data dependent upon the intensity of the eluting peaks.  The extracted ion 
chromatogram for the three fragment ions m/z = 183, 157 and 116 are shown in Figure 
6.3.11. This data shows that the m/z = 116 ion detected a greater number of potentially 
drug related metabolites than the others (eight in total).  Hence this was selected as the 
most suitable fragment for detecting possible drug related metabolites for further work.  
As these data were not derived from accurate mass determination the exact origin of the 
peaks cannot be confirmed based on it, nonetheless it remains a useful initial approach 










Figure 6.3.11 Survey scan results from microsomal incubation of propranolol using 
diagnostic fragment ions of  (top) m/z 116, (middle) m/z 157, and (bottom) m/z 183.  
 
     The identification of the drug metabolites was confirmed by a review of the MS/MS 
spectra obtained from the survey scan mode analysis.  In this mode of operation the 
mass spectrometer continuously monitors the LC chromatogram in full scan mode (in 
this case a range of 100 to 650 m/z in positive ESI).  When an eluting peak’s intensity 
exceeded a preset, user defined, threshold the instrument selected the base peak in the 
MS spectrum and switched to acquire an MS/MS spectrum of the base ion.  After a 







MS mode. The peaks eluting at retention times of 1.92, 2.24 and 2.90 mins gave rise to 
a base peak mass of m/z =452 and fragment ions of m/z = 276, 199 and 116, Figures 
6.3.12, 6.3.13 and 6.3.14.   
 
Figure 6.3.12 MS/MS spectra for hydroxyl glucuronide propranolol peak eluting at 
retention time 1.92 minutes.  
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Figure 6.3.13 MS/MS spectra for hydroxyl glucuronide propranolol peak eluting at 























Figure 6.3.14 MS/MS spectra for hydroxyl glucuronide propranolol peak eluting at 
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These peaks can be rationalized as the phase II hydroxyl glucuronide metabolites of 
propranolol.  There is a characteristic loss of 176 Da from 452 ⇒276 relating to the loss 
of the glucuronic acid moiety.  The peak eluting at 2.90 minutes also had the 
characteristic base peak of m/z =452, however, this peak was much weaker than those 
peaks eluting at 1.92 and 2.24 minutes with the most intense peak being the m/z = 276 
ms/ms fragment ion.  This data suggests that this metabolite peak maybe thermally 
labile with the glucuronic acid group dissociating in the MS source as there has been 
past evidence of this phenomenon or has undergone in source fragmentation [18].   
 
Figure 6.3.15 Comparison of the MS/MS spectrum of a hydroxyl propranolol 
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The 276 ion is can be rationalized as resulting from the hydroxylation of the propranolol 
molecule.  The peak eluting with a retention time of 3.53 mins gave rise to a peak with 
an m/z value of 276. A comparison of the MS/MS spectrum obtained for this peak (top) 
with that of the propranolol peak (bottom) is given in Figure 6.3.15. 
      From this it is evident that the ion 276 is +16 to the 260 ion in the propranolol 
spectrum, the 234 ion is +16 to the 218 ion in the propranolol spectrum, the 199 ion is 
+16 to the 183 ion from propranolol and the 173 on is +16 to the 157 ion in the 
propranolol spectrum.  The 116 ion is present in both spectra suggest that the site of 
hydroxylation metabolism may not be on the aliphatic part of the propranolol molecule, 











 The MS/MS spectra derived from the peaks eluting with retention times of 3.67 and 
3.80 minutes are displayed in Figures 6.3.17 and 6.3.18.  The MS/MS analysis of both 
LC peaks (3.67 and 3.80 mins) yielded the product ions m/z =436, 260 and 116.  The 
ions m/z = 260 and 116 were derived from the propranolol molecule whereas the peak 
m/z = 436 can be rationalised as metabolism to a glucuronide, thus these two peaks are 
most probably glucuronide metabolites of the propranolol molecule itself.  Table 6.3.1 
summarizes the potential metabolites of propranolol indentified by diagnostic fragment 
ions and their respective retention times. 
 
      
Figure 6.3.17 MS/MS spectra of glucuronide metabolites of propranolol eluting at 
retention time 3.67 minutes.  
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Figure 6.3.18 MS/MS spectra of glucuronide metabolites of propranolol eluting at 
retention time 3.80 minutes.  
 






Propranolol 4.19 260 183, 157, 116 
Hydroxyl Metabolite 3.53 276 199, 116 
Glucuronide metabolite 3.67 436 436, 260, 116 
Glucuronide metabolite 3.8 436 436, 260, 116 
Hydroxyl Glucuronide metabolite 1.92 452 452, 276, 116 
Hydroxyl Glucuronide metabolite 2.24 452 452, 276, 116 
Hydroxyl Glucuronide metabolite 2.9 452 452, 276, 116 
 
























6.3.3 Application to metabonomic or biomarker discovery studies 
 
     As stated in Chapter 4, metabonomics has been defined as “Quantitative 
measurement of multivariate metabolic responses of multicellular systems to 
pathophysiological stimuli or genetic modification”  and has been primarily utilized to 
provide information for the wide-spread understanding of global metabolic regulation 
and biological system failure [19].  Initial work in the area of metabonomics was 
focused upon understanding the mechanisms of drug toxicity in mammalian systems 
[20-23].    
      Much of the initial metabonomics research employed either NMR or GC-MS as the 
primary platforms to acquire analytical data [24-26].  Although NMR and LC/NMR are 
used in drug metabolism studies, LC/MS is by far the dominant analytical platform for 
the acquisition of qualitative and quantitative data in drug metabolism and 
pharmacokinetics (DMPK) studies because of the inherent sensitivity, speed and 
throughput of the technique.  The application of LC/MS to metabonomics studies has 
provided complementary data to that obtained by NMR, often producing assays of 
greater sensitivity [27-29].   
     The vast majority of the LC/MS metabonomics methodologies employed the use of 
formic acid based organo-aqueous gradient approaches [30-32], on 2.1 mm i.d. 
columns. Previously an investigation utilizing basic mobile phases with ESI positive 
mode MS was presented by Rainville et al. [33]. In this section of Chapter 6 the use of 
the CMFD/MS system with both acidic and basic mobile phases was utilized as a 
strategy to increase the potential information that could be obtained during a 






Figure 6.3.19 Separation of axenic rat urine by conventional 2.1 mm i.d. UPLC and on 
the prototype CMFD/MS system.   
 Figure 6.3.19 illustrates a separation of urine from axenic rat number nineteen on both 
a standard 2.1 mm i.d. UPLC column and the CMFD.  In these chromatograms we 
observe an overall increase in the MS response for the analytes when they were 
separated under the CMFD/MS conditions compared with the conventional LC/MS 
approach. Many of the analytes in the chromatogram run under the CMFD/MS 
conditions show acceptable peak shape with minimal tailing, however there is evidence 
of overload of some of the analytes in particular those that elute between 2.3 and 2.8 
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Figure 6.3.20 XIC of analtye with m/z 146.057 derived from axenic rat urine on 
conventional UPLC/MS and prototype CMFD/MS systems. 
 
     In the example shown in Figure 6.3.20 the area counts, signal and signal to noise 
values are shown for the analyte with m/z of 146.057. Here we observe that the area 
counts have increased from 57 to 517, which is an increase of 9.1 fold. The overall 
signal utilizing the unsmoothed integrated data showed an increase from 1420 to 8370 
i.e. a 5.9 fold increase, and a signal to noise increase from 28.8 to 257.3 or 8.9 fold. This 
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data is in agreement with the acquired results illustrated for the small molecule probe 
pharmaceuticals in Chapter 5. The peak width at base for this particular analyte however 
increased from 4.2 seconds on the UPLC/MS system to 7.8 seconds on the CMFD/MS 
system. While the peak width for this particular analyte is greater than those generated 
by previous analysis, one explanation for this could be related to the chemical structure 
of the analyte, since wider peak widths than the typical 3 second peak widths was also 
generated for this analyte by the UPLC/MS system.  
     The data in Figure 6.3.21 shows the XIC for another analyte found in the sample 
(m/z 182.079). In this example, multiple peaks are present with the same m/z. The 
boxed in area highlights the separation of closely eluting peaks with the same m/z 
separated both by UPLC/MS and the CMFD/MS system.  In this example the 
UPLC/MS separation showed increased resolution of the highlighted peaks compared to 
the CMFS/MS separation. This example illustrates the balance that can exist between 
the desired or required resolution of analytes from each other as well as from other 
matrix components, and the amount that can and or  should be loaded for the desired 
sensitivity increase.  
     The utilization of high pH mobile phases as outlined in the previous chapters was 
again demonstrated with the analysis of the axenic rat urine in conjunction with the 
CMFD/MS system. However, theses separations carried out utilized ammonium acetate 
buffer systems adjusted to a pH value of 10. This modification was a result of the 
inability of the nano ACQUITY LC module to operate at the previously utilized basic 
pH of 10.5 as was described in Chapter 5, due to the dissolution of internal silica 
tubings within the LC system. The data shown in Figure 6.3.22 illustrates the vast 




samples such as urine are separated under both the traditional acidic modified mobile 
phase and the basic modified mobile phase.   
     
 
Figure 6.3.21 XIC of analtye with m/z 182.079 derived from axenic rat urine on 
















5_5_012 1: TOF MS ES+ 
182.079
4.33e3





























Figure 6.3.22 Linked axis display of full MS scan of axenic rat urine separated with 
CMFD/MS system under acidic (top chromatogram) and basic (bottom chromatogram) 

















12MAY_0012 1: TOF MS ES+ 
BPI
3.14e4









Figure 6.3.23 XIC of analyte with m/z of 372.250 analyzed with CMFD/MS system 
under acidic (top chromatogram) and basic (bottom) mobile phase conditions.  
     Again as was shown in Chapters 2 - 4, increases in analyte response can be increased 
when the MS is operating in ESI positive ionization mode with a basic modified mobile 
phase. Here we also observe that the resolution of the two analytes with m/z of 372.250 
maintained baseline resolution.  Also observed in Figure 6.3.23 is the retention time 
shift of the analytes towards the void volume of the separation. This example again 
indicates that increases in MS sensitivity while operating under these basic conditions is 
not related to increased analyte retention and subsequent elution in a higher organic 
composition as the contributing variable responsible for the increase in MS response. 
Therefore these increases in sensitivity obtained with the basic mobile phases could 
result in significant sensitivity increases compare to traditional 2.1 mm i.d. scale 
chromatography analyzed under acidic mobile phase conditions and could therefore be 
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fully capable of obtaining similar information for small sample volumes of biofluids in 




Figure 6.3.24 XIC of analyte with m/z of 174.124 analyzed with CMFD/MS system 
under acidic (top chromatogram) and basic (bottom) mobile phase conditions.  
Figure 6.3.24 illustrates the differences in response of analytes with the same m/z when 
exposed to traditional acidic and basic mobile phase conditions. In this example, vast 
differences are observed in the separation profile for these analytes with a m/z of 
172.124 as was also observed on the full scan data from Figure 6.3.22. These examples 
indicate the potential of these separation conditions to be implemented as a strategy for 
increased analyte detection for studies focused on the profiling of complex samples such 
as biofluid samples.  
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6.3.4 Bile acid profiling in dog   
 
     Bile is a complex biofluid and the source of important cholesterol derivatives such as 
the bile acids which are involved in the emulsification of lipids via the formation of 
micelles to aid in lipid digestion. The dispersion of lipid molecules fat into these 
micelles provides for an increased surface area for the action of lipases, which actually 
digests the triglycerides. As triglycerides are broken down into fatty acids and  
monoglycerides, they are absorbed by the villi on the intestine walls. After being 
transferred across the intestinal membrane, the fatty acids reform into triglycerides, 
before being absorbed into the lymphatic system through lacteals. Without bile salts, 
most of the lipids in food would be excreted in feces, undigested. Therefore without the 
action of bile acids this essential biomolecule would not be to be utilized by humans and 
other mammals.  
      Under normal health circumstances bile acid levels exist in relatively low 
concentrations in both plasma and urine, however in a diseased state the concentration 
and composition of bile acids can become disturbed. Therefore the profiling of bile 
acids provides for a tool into the determination of the liver and intestinal activity[34] .  
In earlier published work with rats, the utilization of UPLC coupled with ToF mass 
spectrometry was presented for the purpose of  profiling  bile acids from both dogs and 
rat samples [35]. In this section of  Chapter 6, the use of the CMFD/MS system for the 
purposes of  profiling  bile acids from dog bile is presented. Table 6.3.2 shows common 






Bile acid  m/z ESI- Structure 
Cholic acid 407.5635 
 
Deoxycholic acid 401.5158 
 
Glycocholic acid 464.6148 
 





Taurocholic acid 514.6951 
 
Taurodeoxycholic acid 497.6877 
 
Taurochenodeoxycholic acid  498.6957 
  
















































Figure 6.3.26 Deoxyholic acid standard, XIC of deoxycholic acid from dog bile, and 
dog bile separation.  
 
Figure 6.3.27 Glycocholic acid standard, XIC of glycocholic acid from dog bile, and 
dog bile separation.  
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Figure 6.3.28 Glycochenodeoxycholic acid standard, XIC of glycochenodeoxycholic 
acid from dog bile, and dog bile separation.  
 
Figure 6.3.29  Taurocholic acid standard, XIC of taurocholic acid from dog bile, and 
dog bile separation.  
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Figure 6.2.30 Taurodeoxycholic acid standard, XIC of taurodeoxycholic acid from dog 
bile, and dog bile separation.  
Figure 6.2.31 Taurochenodeoxycholic acid standard, XIC of taurochenodeoxycholic 
acid from dog bile, and dog bile separation.  
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     The data shown in Figures 6.3.25 through 6.3.31 illustrates the ability of the 
CMFD/MS system to successfully operate in ESI negative ionization mode. The data 
further shows the ability of the system for the separation of bile acids and in the 
profiling of bile acids from diluted dog bile. The peak shifts for the bile acids 
taurocholic, taurodeoxycholic and taurochenodeoxycholic acids are likely due to the 
high concentration of these bile acids in the dog bile sample. Each of these bile acids 
exhibit a shark fin like appearance whereby the tail end of the peaks are at the same 
retention time as the standard, however the overall retention time of the peak has shifted 
towards the void volume [36]. The lack of MS signal produced by the bile acids 
deoxycholic acid and glychochenodeoxycholic acid could be due to two possibilities. 
The first is that the relative levels of these two bile acids in the diluted dog bile are 
below the detection limits of the MS. The second possibility for the lack of detection 
could be related to ion suppression as both of the analytes co-elute with 
taurodeoxycholic and taurochenodeoxycholic acid, both of which are present at large 












        The utilization of the CMFD/MS system for the analysis of biofluid samples was 
shown in both ESI positive and ESI negative ionization modes. The use of the 
CMFD/MS system was shown to allow for the analysis of small sample injection 
volumes from plasma prepared by protein precipitation and from dried blood spots. 
Peak widths generated for these two analytes were in the order of between three to five 
seconds at base. Limits of detection for alprazolam and sitamaquine prepared as 
previously stated respectively were 0.1 ng/mL and 10 ng/mL. Both assays proved linear 
for three orders of magnitude and residual values for a multipoint calibration line proved 
to within the criteria as set forward by the US FDA for bioanalytical validation criteria. 
Cycle times produced for both of the assays were within five minutes therefore 
illustrating the  high-throughput potential of the device. 
    This device was successfully utilized for the profiling of metabolites from the beta 
blocker drug, propranolol. The CMFD/MS system was shown capable of separating 
some thirteen related metabolites from the parent drug. The device was coupled with 
tandem quadrupole MS operating in survey scan lead to the detection of hydroxyl and 
glucuronide metabolites utilizing diagnostic fragment m/z of 116, 157 and 183. This  
data indicated the potential for high sensitivity, high resolution drug metabolism studies 
where sample volumes may be limited.  
    Further separation of complex biofluid samples derived from axenic rats and bile 
from dogs again indicated the separation and sensitivity capabilities offered by the 
CMFD/MS system. Comparisons of analyte response derived from axenic rat urine 
showed an increase in signal of almost six fold and an increase in signal to noise of nine 




shown to be possible with the CMFD. This combination of basic mobile phase and 
CMFD/MS operating in ESI + mode showed the differences in separation profile that 
could be obtained by implementing these conditions. Increases in sensitivity where 
again shown for analytes under the basic conditions compared to traditional acidic 
conditions for analytes detected in the axenic rat urine.  This data would indicate that 
the coupling of the CMFD/MS system with basic mobile phases would be a viable 
strategy for metabonomics studies. Furthermore,  in the case where only small sample 
volumes are available, this strategy of pH profiling on the CMFD/MS system with its 
increased sensitivity capabilities over traditional 2.1 mm i.d. columns, may lead to a 
significant increase in the ions detected over the traditional utilized LC/MS 
methodology.  
    The CMFD/MS device was also shown to be capable of operating in ESI – mode. The 
successful separation of analytes from dog bile was carried out. Chromatographic peaks 
identified as bile acids were shown to be of gaussian peak shape unless in a state of 
mass overload. The most concentrated bile acids identified by accurate mass MS and by 
authentic standards were found to be taurocholic, taurodeoxycholic and 
taurochenodeoxycholic acids. The peak shape and decrease in retention of these 
analytes was indicative of a mass overload condition with the concentration and 
injection volume that was utilized for the bile separation.  
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Chapter 7  
 












But now my task is smoothly done, 













7.1 Final Conclusions      
 
     The direction of this research project was derived from two distinct approaches as a 
means to increase the sensitivity and information obtained from the analysis of biofluid 
samples under electrospray positive mode LC/MS.  The first approach demonstrated the 
benefits of  using basic solutions such as ammonium hydroxide and ammonium acetate 
to modify the aqueous mobile phase in LC/MS analysis operating in electrospray 
positive ionization mode. Both small molecule pharmaceuticals and endogenous 
compounds in biofluids showed increases in signal, signal-to-noise, and retention in 
comparison to traditional acidic modified mobile phase LC/MS.  
     An increase in the chromatographic retention of poorly retained small molecule 
pharmaceuticals such as ranitidine was observed compared to identical LC/MS 
separations carried out under traditional acidic modified aqueous mobile phases. This 
increase in retention time could therefore be incorporated as a strategy to reduce any 
potential matrix interferences that could occur near the void volume of a LC/MS 
separation. The study did not however show a significant increase in retention for the 
predominant analytes that were detected in the column void volume found in urine 
samples under basic mobile phase conditions compared to the same analysis acquired 
with the acidic mobile phase. Therefore although the strategy of utilizing basic mobile 
phases increased the retention of many of the pharmaceutical compounds in the study it 
was not successful with the highly polar compounds detected in the void volume of the 
urine samples tested.  
      The base modified mobile phase further made it possible to resolve endogenous 
compounds found in urine that had previously co-eluted under traditional acidic aqueous 




not primarily related to the late elution of analytes in a higher organic composition 
under basic conditions which is often the interpretation for the increase in MS response 
under these conditions. This was shown with compounds such as alprazolam and 
fluticasone which maintained identical retention times under both pH conditions and 
still showed increased MS signal when chromatographed under the basic conditions. 
Moreover analytes found in rat urine that exhibited a shorter retention time under basic 
versus acidic mobile phase conditions also showed increases in MS response.  
     The effect of the mobile phase pH on the choline-containing phospholipid fraction 
present in protein precipitated rat plasma from four different sources, was grossly 
unaffected by the change in mobile phase pH. However, the basic modified aqueous 
mobile phase in combination with methanol yielded the highest response for the 
choline-containing lipid fraction of the prepared plasma sample. Therefore, although 
there was an increase in MS response for many of the pharmaceuticals tested in Chapter 
2, as well as increased retention, careful assessment to ensure co-elution of 
pharmaceuticals with the choline containing phospholipids should be assessed if 
implementing the use of basic mobile phases as matrix interferences could exists.  
       These high pH conditions were then utilized in combination with a 1.7 µm C18 
chromatographic column to produce a simple, sensitive, and specific LC/MS assay for 
alprazolam in rat plasma The limit of quantification using protein precipitation was 
determined to 0.01 ng/mL. The variability of the assay was determined to be less than 
6% calculated via multiple QC sample levels. The assay was shown to be linear over a 
range of 0.01 to 10 ng/mL. The system and column was also shown to be robust as the 
system was operated under these conditions continuously over a 4 day period and 1000 
injections of protein precipitated plasma samples without any deterioration of 




further utilized in the DMPK laboratory at Waters to produce high sensitive assays for 
other compounds such as fluticasone, and clopidogrel.   
     Moreover the application of basic mobile phases in LC/MS operating in electrospray 
positive ionization mode in metabonomic studies showed great promise. The technique 
provided complementary data to that obtained with traditional acidic based mobile 
phases and resulted in an increased in the overall number of ions detected during the 
study.  The analysis of a real sample set of control rats and rats dosed with hydrazine 
revealed that both the acidic and basic system were capable of differentiating between 
the 0-hr and 48-hr time points.   
     The second approach was the development and implementation of a 0.3 x 100 mm 
i.d. ceramic microfluidic device packed with 1.7 µm C18 BEH chromatographic particles 
and coupled to a compatible ESI MS source for the analysis of biological samples for 
use in DMPK laboratories. The device showed average chromatographic efficiencies of 
9038 plates compared to 10219 plates for  standard silica capillary columns packed with 
the identical sorbent. Gradient performance utilizing a diverse mix of compounds 
yielded a peak capacity of 55 as the average peak widths for all analytes was 0.11 
minutes for a 6 minute separation.  
     Resolution of the probe pharmaceutical alprazolam and associated hydroxyl 
metabolite was maintained between 1.2 and 1.5 for four different devices. Testing of the 
device with plasma samples prepared by protein precipitation resulted in over 1000 
injections being carried out over approximately a one week period while maintaining 
resolution of alprazolam and its associated hydroxyl metabolite. Furthermore no 




     The nano-scale system utilized in this work was unable to withstand the high pH 
(10.5) utilized in Chapters 2 through 4. This was most likely due to the dissolution of 
the silica-tubing resulting in line plugging and subsequent system overpressure.  
However, the ceramic material appeared stable following incubation with the pH 10.5 
solution as the morphology and appearance was observed to be similar before and after 
incubation at this elevated pH. Prolonged operation of the system at a pH of 10 was 
obtainable and these conditions were utilized to analyze the small molecule 
pharmaceutical alprazolam during a continuous six day period without incidence or 
failure of the system. These mobile phase conditions were further utilized in the 
separation of endogenous components found in rat urine.  
     MS source optimization studies indicated the need for operation of lower capillary 
voltages as many of the small molecules tested ionized best under condition of less than 
3.0 kV applied to the capillary. Further a closed source resulted in less background 
noise observed and therefore was implemented during the course of the work carried out 
in Chapter 6. The resulting MS source built to operate under these conditions and with 
the flow rates required to operate the 0.3 x 100 mm ceramic microfluidic device yielded 
an increase in signal-to-noise for many small molecule pharmaceuticals when compared 
to the traditional  high-flow source fitted with a narrow-bore (75 µm i.d.) capillary.  
     This LC/MS configuration was then successfully utilized in the analysis of small 
molecule pharmaceuticals in rat plasma prepared by protein precipitation. The 
configuration was further utilized in the separation of metabolites from microsomal 
incubation of propranolol. Operation of the system under negative electrospray 
ionization mode was demonstrated utilizing bile acids as the test molecules. 
Furthermore, the profiling of bile acids was successfully carried out with diluted dog 




low pH mobile phase combinations for the analysis of urine derived from rats dosed 
with the model toxin hydrazine as an example of the utility of such a device for 
metabonomics or biomarker discovery studies.  
     
7.2 Future Research 
 
 Future research should focus on several areas to further explore the utilization of both 
of the approaches investigated within this body of work. These could include: 
1. The influence on the stability, and increase, or decrease in MS signal obtained 
from phase I and phase II small molecule drug metabolites when utilizing high 
pH mobile phases compared to tradition acidic mobile phases analyzed under 
ESI + LC/MS.  
 
2. While the investigation of the use of the high pH mobile phase showed that there 
was no retention time shift for the choline-containing phospholipids found in 
protein-precipitated plasma, an investigation on the use of this technique as a 
means to either reduce or increase matrix effects could prove useful. 
 
 
3.  Basic mobile phase pH has been shown as a means to increase the loading 
capability of basic pharmaceuticals for preparative chromatography. A similar 
investigation carried out on capillary or nanoscale chromatography may prove 
useful as a means to further increase bioanalytical assay sensitivity by increasing 





4. Further investigation into the mechanism of small molecule ionisation in basic 
solutions under electrospray positive mode conditions.  
 
5. Investigation into other ceramic microfluidic i.d. dimensions and channel shapes 
on chromatographic performance, robustness and LC/MS assay sensitivity. 
 
6. As previous “chip” based devices utilize a trap and analytical column 
configuration in one device, a comparison on the advantages of this approach 
versus a separate trap and analytical configuration would be useful. The later 
approach would provide for a disposable guard column type format as well as 
the ability to have multiple chromatographic sorbent configurations that could 
prove useful during method development as this configuration would be more 
flexible for method development compared to the traditional approach of both 
trap and analytical media on the same chip.   
 
7. Packing of the ceramic microfluidic device with “fused-core” or “poroshell” 
type particles and a comparison of the chromatographic separation capability, 
influence on system pressure and analyte loading capacity compared to the 1.7 
µm porous particles utilized in this could shape the future of capillary and lower 
scale chromatography. Further packing the ceramic microfluidic device with 
other packing materials such those utilized in hydrophilic interaction 
chromatography  could be carried out and may prove useful.  
 
